

NIOSH

CRITERIA FOR A
RECOMMENDED STANDARD....

OCCUPATIONAL
EXPOSURE TO

ANTIMONY

U. S. DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE
Public Health Service
Center for Disease Control
National Institute for Occupational Safety and Health



criteria for a recommended standard....

OCCUPATIONAL EXPOSURE TO ANTIMONY



U.S. DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE

Public Health Service

Center for Disease Control

National Institute for Occupational Safety and Health

September 1978

For sale by the Superintendent of Documents, U.S. Government
Printing Office, Washington, D.C. 20402

DISCLAIMER

Mention of company names or product does not constitute endorsement by the National Institute for Occupational Safety and Health.

DHEW (NIOSH) Publication No. 78-216


PREFACE

The Occupational Safety and Health Act of 1970 emphasizes the need for standards to protect the health and provide for the safety of workers occupationally exposed to an ever-increasing number of potential hazards. The National Institute for Occupational Safety and Health (NIOSH) evaluates all available research data and criteria and recommends standards for occupational exposure. The Secretary of Labor will weigh these recommendations along with other considerations, such as feasibility and means of implementation, in promulgating regulatory standards.

NIOSH will periodically review the recommended standards to ensure continuing protection of workers and will make successive reports as new research and epidemiologic studies are completed and as sampling and analytical methods are developed.

The contributions to this document on antimony by NIOSH staff, other Federal agencies or departments, the review consultants, the reviewers selected by the American Industrial Hygiene Association and the American Medical Association, and Robert B. O'Connor, M.D., NIOSH consultant in occupational medicine, are gratefully acknowledged.

The views and conclusions expressed in this document, together with the recommendations for a standard, are those of NIOSH. They are not necessarily those of the consultants, the reviewers selected by professional societies, or other Federal agencies. However, all comments, whether or not incorporated, were considered carefully and were sent with the criteria document to the Occupational Safety and Health Administration for consideration in setting the standard. The review consultants and the Federal agencies which received the document for review appear on pages v, vi, and vii.



J. Michael Lane, M.D.
Acting Director, National Institute
for Occupational Safety and Health

The Division of Criteria Documentation and Standards Development (DCDSD), National Institute for Occupational Safety and Health, had primary responsibility for development of the criteria and recommended standard for antimony. Allan S. Susten, Ph.D., served as criteria manager during the initial development and Barbara L. Wilkes during the final development of this criteria document. The DCDSD review was provided by Douglas L. Smith, Ph.D. (Chairman), Paul E. Caplan, and Keith H. Jacobson, Ph.D., with Carl Zenz, M.D.

Personnel from other NIOSH divisions who assisted in developing the basic information for this document were Harry M. Donaldson (Division of Surveillance, Hazard Evaluation, and Field Studies); David H. Groth, M.D., and Harry B. Plotnick, Ph.D. (Division of Biomedical and Behavioral Science); Peter M. Eller, Ph.D., James A. Gideon, R. DeLon Hull, and William F. Todd (Division of Physical Sciences and Engineering).

REVIEW CONSULTANTS

Albert L. Belcher
Industrial Hygienist
National Lead Industries
Hightstown, New Jersey 08520

Donald Birmingham, M.D.
Chairman, Department of Dermatology
Wayne State University School of Medicine
Detroit, Michigan 40239

David K. Detweiler, D.V.M.
Professor of Physiology
University of Pennsylvania School of Veterinary Medicine
Philadelphia, Pennsylvania 19104

Sharon W. Felicetti
Lovelace Biomedical & Environmental Research Institute
Albuquerque, New Mexico 87115

Harold Halbedel, Ph.D.
Technical Director
Harshaw Chemical Company
Cleveland, Ohio 44106

JD Mortensen, M.D.
Director, Surgical Research
Utah Biomedical Test Laboratory
Salt Lake City, Utah 84102

Eugene P. Pendergrass, M.D.
Emeritus Professor of Radiology
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania 19104

S. Anderson Peoples, M.D.
Emeritus Professor of Pharmacology and Toxicology
University of California School of Veterinary Medicine
Davis, California 95616

Lucien E. Renes
Fallbrook, California 92028

R. Craig Schnell, Ph.D.
Associate Professor of Pharmacology
Purdue University School of Pharmacy
West Lafayette, Indiana 47907

REVIEW CONSULTANTS (CONTINUED)

William F. Sunderman Jr., M.D.
Chairman, Department of Laboratory Medicine
University of Connecticut School of Medicine
Farmington, Connecticut 06032

Michael Wright
Industrial Hygienist
U.S. Steelworkers of America
Pittsburgh, Pennsylvania 15222

Morton M. Ziskind, M.D.
Professor of Medicine
Tulane University School of Medicine
New Orleans, Louisiana 70112

FEDERAL AGENCIES

Department of Defense

Office of the Deputy Assistant Secretary for
Energy, Environment, and Safety

Department of the Army

Army Environmental Hygiene Agency

Department of the Navy

Bureau of Medicine and Surgery
Navy Environmental Health Center

Department of the Air Force

Office of the Surgeon General

Department of Energy

Division of Operational and Environmental Safety

Department of Health, Education, and Welfare

Food and Drug Administration
National Institutes of Health
National Cancer Institute
National Heart, Lung, and Blood Institute
National Institute of Environmental Health Sciences
National Institute of Neurological and
Communicative Disorders and Stroke

Department of the Interior

Mining Enforcement and Safety Administration

Department of Labor

Mine Safety and Health Administration

Department of Transportation

Office of Hazardous Materials

Consumer Product Safety Commission

Bureau of Biomedical Science

Environmental Protection Agency

Office of Assistant Administrator for Research
and Development
National Environmental Research Center
Health Effects Research Laboratory

CONTENTS

	<u>Page</u>
PREFACE	111
REVIEW CONSULTANTS	v
FEDERAL AGENCIES	vii
I. RECOMMENDATIONS FOR AN ANTIMONY STANDARD	1
Section 1 - Environmental (Workplace air)	1
Section 2 - Medical	2
Section 3 - Labeling and Posting	2
Section 4 - Personal Protective Clothing and Equipment	4
Section 5 - Informing Employees of Hazards from Antimony	6
Section 6 - Work Practices	7
Section 7 - Sanitation Practices	8
Section 8 - Environmental Monitoring and Recordkeeping	8
II. INTRODUCTION	10
III. BIOLOGIC EFFECTS OF EXPOSURE	11
Extent of Exposure	11
Historical Reports	12
Effects on Humans	15
Epidemiologic Studies	30
Animal Toxicity	43
Correlation of Exposure and Effect	52
Carcinogenicity, Mutagenicity, Teratogenicity, and Effects on Reproduction	57
Summary Tables of Exposure and Effect	58
IV. ENVIRONMENTAL DATA	65
Environmental Concentrations	65
Sampling and Analytical Methods for Antimony in Air	70
V. ENGINEERING CONTROLS, WORK PRACTICES, AND PERSONAL PROTECTION	74
VI. DEVELOPMENT OF STANDARD	79
Basis for Previous Standards	79
Basis for the Recommended Standard	81
VII. RESEARCH NEEDS	86

CONTENTS (CONTINUED)

	<u>Page</u>
VIII. REFERENCES	87
IX. APPENDIX I - Methods for Sampling Antimony in Air	103
X. APPENDIX II - Analytical Methods for Antimony	106
XI. APPENDIX III - Material Safety Data Sheet	111
XII. TABLES	119

I. RECOMMENDATIONS FOR AN ANTIMONY STANDARD

NIOSH recommends that employee exposure to antimony and its compounds in the workplace be controlled by compliance with the following sections. The recommended standard is designed to protect the health and provide for the safety of employees for up to a 10-hour workshift, 40-hour workweek, over a working lifetime. Compliance with all sections of the recommended standard should prevent adverse effects of antimony or antimony compounds on the health of employees and provide for their safety. The standard is measurable by techniques that are reproducible and available to industry and government agencies. Sufficient technology exists to permit compliance with the recommended standard. Although NIOSH considers the workplace environmental limit to be safe based on current information, employers should regard it as the upper boundary of exposure and make every effort to maintain exposure as low as is technically feasible. The criteria and recommended standard will be reviewed and revised as necessary.

"Antimony" refers to elemental antimony and all antimony compounds except the gas stibine (SbH_3). Stibine is excluded from the standard because it evolves as a byproduct of operations involving other sources of antimony. The "action level" is defined as one-half the appropriate recommended time-weighted average (TWA) concentration limit. "Occupational exposure to antimony" is defined as exposure to antimony at a concentration greater than one-half the recommended environmental limit. Exposures to airborne antimony concentrations equal to or less than one-half the TWA workplace environmental limit, as determined in accordance with Section 8(a), will require adherence to all sections of the recommended standard except Sections 2(b), 4(c), 8(b), and the monitoring provisions of 8(c). If exposure to other chemicals occurs (for example, from contamination of antimony with arsenic or free silica), provisions of any applicable standards for the other chemicals shall also be followed.

The recommended environmental limit is based on data which indicate that exposure to antimony may cause cardiac and respiratory changes and irritation of the skin and mucous membranes. Compliance with the following sections should provide worker protection from these hazards. Some data on antimony workers raise the possibilities of reproductive and carcinogenic effects; however, these hazards ascribed to antimony have not been confirmed.

Section 1 - Environmental (Workplace Air)

(a) Concentrations

Exposure to antimony shall be controlled so that employees are not exposed to antimony at a concentration greater than 0.5 milligram per cubic meter of air (0.5 mg/cu m), determined as a time-weighted average concentration limit for up to a 10-hour workshift in a 40-hour workweek.

(b) Sampling and Analysis

Environmental samples shall be collected and analyzed for antimony as described in Appendices I and II or by any methods at least equivalent in accuracy, precision, and sensitivity.

Section 2 - Medical

Medical surveillance as outlined below shall be made available to workers subject to exposure to antimony.

(a) Preplacement examinations shall include at least:

(1) Comprehensive medical and work histories, with special emphasis directed to skin, respiratory, cardiac, and reproductive systems.

(2) Comprehensive physical examinations, with particular attention to the skin, mucous membranes, and pulmonary and cardiac systems.

(3) Clinical tests including a 14- x 17-inch postero-anterior chest roentgenogram, electrocardiogram, and pulmonary function tests including forced vital capacity (FVC) and forced expiratory volume in 1 second (FEV1).

(4) A judgment of the employee's ability to use positive and negative pressure respirators.

(b) Periodic examinations shall be made available at least annually. These examinations shall include at least:

(1) Interim medical and work histories.

(2) A physical examination and tests as outlined in paragraphs (a)(2) and (a)(3) of this section.

(c) During or after examinations, applicants or employees having medical conditions such as dermatitis or pulmonary disease that would be directly or indirectly aggravated by exposure to antimony shall be counseled on the increased risk of impairment of their health from working with these materials. In addition, employees shall be advised that one report has indicated possible hazards to reproduction in both humans and animals due to antimony exposure.

(d) Pertinent medical records shall be maintained for all employees exposed to antimony and shall be kept for at least 30 years after the last work-related exposure to antimony. Records of environmental exposures applicable to an employee shall be included in that employee's medical records. These records and copies, if requested, shall be made available to the designated medical representatives of the Secretary of Health, Education, and Welfare, of the Secretary of Labor, of the employer, and of the employee or former employee.

Section 3 - Labeling and Posting

All warning signs shall be printed both in English and in the predominant language of non-English-reading workers. Workers unable to read the labels and signs provided shall receive information regarding hazardous areas and shall be informed of the instructions printed on labels and signs.

(a) Labeling

Containers of antimony compounds shall carry labels that bear the trade names of the products, the chemical name(s) of the compound(s) contained therein, and information on the effects of the particular product(s) on human health. The trade names and pertinent information shall be arranged as in the following examples.

For Antimony Oxides and Sulfides:

TRADE NAME
(CHEMICAL NAME)
MAY BE HARMFUL IF INHALED OR SWALLOWED
MAY CAUSE SKIN AND RESPIRATORY TRACT IRRITATION

Do not get in eyes, on skin, on clothing.
Avoid breathing dust, fume, vapor.

For Antimony Halides:

TRADE NAME
(CHEMICAL NAME)
DANGER
CAUSES SEVERE BURNS
VAPOR HAZARDOUS

Do not get in eyes, on skin, on clothing.
Do not breathe vapor.
Keep container closed.

Immediately flush with copious amounts of water and remove contaminated clothing. For eyes, get medical attention. Wash contaminated clothing before reuse.

(b) Posting

Readily visible signs containing information on the effects of antimony on human health shall be posted in work areas and at entrances to work areas or building enclosures where antimony is present. Warnings shall follow these examples:

For Antimony Oxides and Sulfides:

TRADE NAME
(CHEMICAL NAME)
MAY BE HARMFUL IF INHALED OR SWALLOWED
MAY CAUSE SKIN AND RESPIRATORY TRACT IRRITATION

Avoid breathing or swallowing dust.
Work with adequate ventilation.
Wash hands thoroughly after handling, and before eating or smoking.
Keep skin clean to avoid irritation.

For Antimony Halides:

TRADE NAME
(CHEMICAL NAME)
DANGER
SEVERE INHALATION, SKIN, AND EYE HAZARD
CAUSES BURNS
DO NOT BREATHE DUST, FUME, OR VAPOR
DO NOT GET IN EYES, ON SKIN, OR ON CLOTHING

In case of contact, immediately flush skin or eyes with copious amounts of water and remove contaminated clothing. For eyes, get medical attention. Wash clothing before reuse.

Section 4 - Personal Protective Clothing and Equipment

(a) Protective Clothing

(1) Work and protective clothing appropriate for the work situation shall be provided by the employer. This may include underwear, cloth or calfskin gloves, coveralls or long-sleeved shirts and trousers, and head and neck protection. When antimony halides are being processed in a manner that may result in skin contact, gloves with gauntlets and aprons made of rubber or other material resistant to penetration by antimony halides shall be used. The employer shall ensure that appropriate clothing is worn by every employee.

(2) The employer shall ensure that a change of clothing is immediately available to any employee whose clothes become grossly contaminated or lose their protective quality.

(3) If protective clothing becomes grossly contaminated, or in the case of halides, if the resistant material is penetrated, this clothing must be removed immediately and not be reworn until the antimony compound is removed.

(4) Protective clothing shall be changed at least daily at the end of the shift.

(5) Contaminated clothing must be stored in closed containers until washed or discarded.

(6) The employer shall inform persons involved in laundering or handling the contaminated clothing of the hazardous properties of the contaminant.

(b) Eye and Face Protection

(1) Chemical safety goggles meeting the requirements listed in 29 CFR 1910.133 and ANSI Z87.1-1968 shall be provided by the employer and shall be worn during any operation in which there is a reasonable possibility of antimony entering the eyes.

(2) Where antimony halides may contact the eyes, employers shall provide an eye wash fountain or other source of water within the immediate work area for flushing the eyes in an emergency.

(c) Respiratory Protection

(1) Engineering controls shall be used when needed to keep concentrations of airborne antimony at or below the environmental limit. Compliance with this standard by the use of respirators is permitted only during installation and testing of engineering controls, during performance of nonroutine maintenance or repair, or during emergencies.

(2) When a respirator is permitted, it shall be selected and used in accordance with the following requirements:

(A) The employer shall establish and enforce a respiratory protective program meeting the requirements of 29 CFR 1910.134.

(B) The employer shall provide respirators in accordance with Table I-1 and shall ensure that, when needed, employees use the respirators provided. The respiratory protective devices provided shall be those approved by NIOSH and the Mine Safety and Health Administration (MSHA). Initial selection and assignment of negative pressure respirators shall be made on the basis of qualitative or quantitative facepiece fit tests. The employer shall ensure that respirators are properly cleaned, maintained, and stored when not in use.

(3) Respirators specified for use in higher airborne concentrations of antimony may be used in atmospheres of lower concentrations.

(4) The employer shall ensure that employees are properly instructed in the use of respirators assigned to them and in ways to test for leakage, proper fit, and proper operation.

(d) The employer shall perform a routine periodic check of all personal protective equipment to maintain it in a safe state of repair and shall store it properly to prevent damage by heat, degrading chemicals, or other harmful agents.

TABLE I-1

RESPIRATOR SELECTION GUIDE FOR PROTECTION AGAINST ANTIMONY

Dust Concentration	Respirator Type Approved Under 30 CFR 11
Less than or equal to 5 mg/cu m	(1) Half-mask respirator with replaceable high efficiency filter(s)* (2) Type C supplied-air respirator, demand type (negative pressure) with half-mask facepiece**
Less than or equal to 25 mg/cu m	(1) Full facepiece respirator with replaceable high efficiency filter(s) (2) Type C supplied-air respirator, demand type (negative pressure) with full facepiece (3) Self-contained breathing apparatus in demand mode (negative pressure) with full facepiece
Less than or equal to 500 mg/cu m	Powered air-purifying (positive pressure) respirator with high efficiency filter(s)
Greater than 500 mg/ cu m	(1) Self-contained breathing apparatus with positive pressure in full facepiece (2) Combination supplied-air respirator, pressure demand type with auxiliary self-contained air supply
For antimony halides:	
No concentration limit	(1) Self-contained breathing apparatus with positive pressure in full facepiece (2) Combination supplied-air respirator, pressure demand type with auxiliary self-contained air supply

*A high-efficiency filter is a filter having an efficiency of at least 99.97% against 0.3 μ m dioctyl phthalate.

**If eye irritation occurs with half-mask, a full facepiece respirator should be worn.

Section 5 - Informing Employees of Hazards from Antimony

(a) All new and current employees working with antimony shall be informed of the hazards, relevant signs and symptoms of overexposure, appropriate emergency procedures (including first aid), and proper conditions and precautions concerning safe use and handling of the hazardous material(s). Employees shall be informed, preferably by medical personnel, that antimony can irritate the skin and mucous membranes, cause respiratory and cardiac changes, and possibly cause reproductive problems.

(b) The employer shall institute a continuing education program, conducted by persons qualified by experience or training, to ensure that all employees have current knowledge of job hazards, preventive sanitation and work practices, proper maintenance and cleanup methods, and proper use of personal protective equipment. The instructional program shall include a description of the general nature of the environmental and medical surveillance procedures and of the advantage to the employee of participating in these surveillance procedures. Educational programs for employees engaged in maintenance and repair shall include instruction on those work situations in which they will be exposed to antimony.

(c) Instructional material in written or published form shall be kept on file at each establishment or department where employees are exposed to antimony. Each employee shall be informed of the availability of the required information, which shall include, as a minimum, that prescribed in Appendix III.

(d) Required information shall be recorded on the "Material Safety Data Sheet" shown in Appendix III or on a similar form approved by the Occupational Safety and Health Administration, US Department of Labor, and shall be kept on file, readily accessible to employees.

Section 6 - Work Practices

(a) Engineering controls shall be used wherever needed to keep concentrations of airborne antimony within the recommended environmental limit. Ventilation systems shall be designed to prevent the entry, accumulation, or recirculation of these materials in the breathing zones of employees.

(b) Exhaust ventilation systems discharging to the outside air shall conform to applicable local, state, and Federal air pollution regulations.

(c) Ventilation systems shall be subject to regular preventive maintenance and cleaning to ensure their continuing effectiveness. Continuous airflow indicators, such as appropriately mounted and calibrated water or oil manometers (marked to indicate acceptable airflow), are recommended and should be checked frequently and recorded at least quarterly. If such indicators are not used, the efficiency of the ventilation system should be verified by airflow measurements taken at intervals determined by the documented maintenance history of the system.

(d) Procedures for emergencies shall be established. Necessary emergency equipment, including appropriate respiratory protective devices, shall be kept in readily accessible locations.

(e) Where there is possibility of skin contact with antimony halides, employers shall provide facilities for quick drenching of the body within the immediate work area. Eye wash facilities shall also be conveniently located.

(f) Where antimony dust accumulates on work surfaces, it shall be removed by vacuum cleaning or wet methods. Cleaning may be performed by washing down

with a hose, provided that a fine spray of water has first been laid down. Sweeping or other methods which can stir the dust into the air shall not be used.

(g) Waste materials contaminated with antimony shall be disposed of in a safe manner. The disposal method must conform to applicable local, state, and Federal regulations.

(h) Antimony compounds shall be stored so as to minimize exposures due to accidental leaks and spills. Storage areas must be cool, dry, well ventilated, and protected from sunlight. Antimony halides must be stored in glass carboys protected by wooden frames. Storage areas for halides must be isolated from manufacturing or production areas.

Section 7 - Sanitation Practices

(a) The pertinent requirements for plant sanitation, stated in 29 CFR 1910.141, shall be complied with. The subsections entitled General (a), Toilet Facilities (c), Washing Facilities (d), Change Rooms (e), and Consumption of Food and Beverages on the Premises (g) are especially relevant to antimony.

(b) Employees exposed to antimony shall be provided with separate lockers or other storage facilities for street clothes and for work clothes.

(c) Employees exposed to antimony shall not wear work clothing away from the plant.

(d) Showers shall be provided for employees exposed to antimony. Workers shall shower before changing into street clothes.

(e) If accidental skin contact with antimony halides occurs, the exposed worker shall shower immediately.

(f) Employees shall wash their hands and mouths before eating or smoking during the workshift.

(g) No smoking or food shall be permitted in areas where antimony is present.

Section 8 - Environmental Monitoring and Recordkeeping

(a) Industrial Hygiene Surveys

After the promulgation of a standard based on these recommendations, employers shall determine by an industrial hygiene survey whether exposure to airborne antimony is in excess of the action level. Records of these surveys shall be retained until the next survey has been completed. If an employer concludes that there is no occupational exposure to antimony, the records shall show the basis for this conclusion. Surveys shall be repeated at least annually and within 14 days after any process change likely to result in occupational exposure to antimony.

(b) Personal Monitoring

If it has been determined that occupational exposure to antimony occurs, the employer shall institute environmental monitoring.

(1) A program of personal monitoring shall be instituted to identify and measure, or to permit calculation of, the exposure of each employee. Source and area monitoring may be used to supplement personal monitoring.

(2) In all personal monitoring, samples representative of exposure in breathing zones of the employees shall be collected.

(3) For each determination of the concentration of antimony, a sufficient number of samples shall be taken to characterize the employee's work and production schedules, location, and duties. Changes in production schedules shall be considered in deciding when samples are to be collected.

(4) Each operation shall be sampled at least once every 6 months. For intermittent operations, ie, those lasting less than 6 months, at least one monitoring regimen shall be conducted during each operation period, and monitoring should coincide with the periods of maximum potential exposure to antimony during these intermittent operations.

(5) If an employee is found to be exposed to antimony at concentrations exceeding the recommended TWA concentration limit, control measures shall be initiated, the exposure of that employee shall be measured at least once every week, and the employee shall be notified of the exposure and of the control measures being implemented. Such monitoring shall continue until two consecutive determinations, at least 1 week apart, indicate that the control measures have been effective and that the employee's exposure no longer exceeds the recommended exposure limit; routine semiannual monitoring may then be resumed.

(c) Recordkeeping

Records of environmental monitoring and other pertinent records shall be kept for at least 30 years after the employee's last work-related exposure to antimony. Records of environmental monitoring shall include an identification of the employee being monitored, duties and job locations within the worksite, time and dates of sampling and analysis, sampling and analytical methods used and available evidence of their precision and accuracy, the number, duration, and results of samples taken, TWA concentrations determined from these samples, and the type of personal protective equipment used by the employee. Employees shall have access to data on their environmental exposures and be permitted to obtain copies of the data. Records shall be made available to the designated representatives of the Secretary of Labor, of the Secretary of Health, Education, and Welfare, of the employer, and of the employee or former employee.

II. INTRODUCTION

This report presents the criteria and the recommended standard based thereon that were prepared to meet the need for preventing occupational disease or injury arising from exposure to antimony, excluding stibine. The criteria document fulfills the responsibility of the Secretary of Health, Education, and Welfare, under Section 20(a)(3) of the Occupational Safety and Health Act of 1970, to "develop criteria dealing with toxic materials and harmful physical agents and substances which will describe...exposure levels at which no employee will suffer impaired health or functional capacities or diminished life expectancy as a result of his work experience."

After reviewing data and consulting with others, NIOSH formalized a system for the development of criteria on which standards can be established to protect the health and provide for the safety of workers from exposure to hazardous chemical and physical agents. The criteria and recommended standard should enable management and labor to develop better engineering controls and more healthful work practices, and simply complying with the recommended environmental limit should not be the final goal.

These criteria for a recommended standard for antimony are part of a continuing series of documents developed by NIOSH. The proposed standard applies only to workplace exposure to antimony arising from the processing, manufacture, handling, and use of antimony. The standard is not designed for the population-at-large, and any extrapolation beyond the occupational environment is not warranted. It is intended to (1) protect workers against the adverse effects of exposure to antimony especially on the heart, lungs, and skin, (2) be measurable by techniques that are valid, reproducible, and available to industry and government agencies, and (3) be attainable with existing technology.

The major hazards associated with occupational exposure to antimony are cardiac changes, respiratory changes including pneumoconiosis, and irritation of the skin and mucous membranes. One study suggested that antimony exposure may exert an adverse effect on reproductive capacity. The possibility also has been raised that antimony exposure may increase the risk of lung cancer. The carcinogenic, mutagenic, and teratogenic potentials of antimony compounds, along with possible effects of antimony on reproduction, remain to be determined.

III. BIOLOGIC EFFECTS OF EXPOSURE

Extent of Exposure

Antimony (Sb) is a metal obtained chiefly as a byproduct or coproduct of base metal and silver ores, and is used in a variety of industries [1]. At standard temperature and pressure, antimony and most of its compounds are solid; hence, they are usually encountered as dusts in the industrial environment. Most occupational exposures are to antimony trioxide, a soft, flowing powder. Antimony pentachloride is the only compound occurring as a liquid at standard temperature and pressure. The antimony halides, unlike the oxides and sulfides, can severely burn the skin, eyes, and mucous membranes. Table XII-1 lists physical and chemical properties of antimony and some common antimony compounds.

Antimony is brittle and hard with a Mohs rating of 3-3.5. It alloys readily with many metals. When alloyed with antimony, lead is harder and more resistant to chemical corrosion than when unalloyed [1]. Until recently, the major use of antimonial lead has been for production of grids and terminals for storage batteries. This use is now declining because the automotive battery industry is adopting calcium-tin and low antimony alloys [2].

The specific heat and electrical resistance of antimony make it useful in electronic semiconductors and thermoelectric devices [1,3]. The peculiar light-transmitting qualities of antimony trioxide and the various colors of antimony compounds make them outstanding pigments for ceramics, glass, metalware, and enamels. Plastics and flame-retardant chemicals are also major end-products. Tables XII-2 and XII-3 show additional uses, originating forms, and production tonnages of antimony.

About 25 countries throughout the world are involved in antimony production [1]. In 1976, the US imported almost 24,000 tons of antimony metal, oxide, and ore for consumption; predominant sources were the Republic of South Africa, Bolivia, the United Kingdom, and France. US production totaled almost 35,000 tons, of which 42% (over 14,900 tons) came from primary sources (283 tons from ore, 14,618 tons from primary smelters), and 58% (almost 20,000 tons) was secondary (recycled) metal [2]. Secondary antimony is recovered chiefly from battery scrap.

Domestic mine production totaled 283 tons during 1976, down 68% from 1975, the result of a long strike at one mine and the continued development of another. The two mining operations producing antimony metal in the US are in Idaho and Montana. A new smelter is expected to open in Texas [2].

Domestic consumption of primary antimony in 1976 was up over 1975 consumption despite a loss of tonnage in metal products; the loss was more than offset by gains in nonmetal and flame retardant applications. Antimony trioxide, often referred to as antimony oxide, is in increasing demand as a fire retardant, and represents the largest class of primary antimony material produced in the US (about 10,600 out of 14,900 tons). In 1976, there were five major producers of antimony trioxide [2]. Most other antimony compounds are derived from the trioxide. Of these, antimony pentoxide, antimony tri- and pentasulfide, antimony tri- and pentachloride, and antimony potassium

tartrate (tartar emetic) are materials of commercial significance in the United States. Table XII-3 shows the end uses of these materials.

NIOSH estimates that 1.4 million US workers are potentially exposed to antimony in their occupational environment. Exposures are largely to metal alloys and to the metal oxide and sulfide. Table XII-5 lists occupations that have the potential for antimony exposure.

Health problems associated with occupational exposure to antimony have been reported from textile dyeing [4]; antimony mining, smelting, and refining [5-14]; the abrasives industries [15]; and glass manufacturing [16]. Exposure problems associated with minor uses of the metal, such as in the chemical industry, in metal polishing and decorating, and in the pharmaceutical industry, have not been reported. Antimonial drugs are not known to be manufactured in the US at this time.

Historical Reports

Antimony was probably first used industrially by the Chaldeans around 4000 BC to manufacture vases and vessels, according to a comment by Bradley and Fredrick [17]. Reference to the use of the element as an eye cosmetic can be found in the Bible, and both Dioscorides and Pliny discussed its use as a medicine [18]. The Romans knew of antimony's emetic properties. When they allowed wine to stand in goblets made of antimony-rich alloys, sufficient antimony leached from the cup to induce vomiting [19].

(a) Occupational Exposures

The first known accounts of occupational hazards ascribed to antimony were written in 1713 by Ramazzini [20]. In his description of diseases of chemists, Ramazzini recorded the case of a chemist who had inhaled fumes of antimony and sulfur after an accident that occurred while he was making a preparation. For 4 weeks after the accident, the chemist was described as being tormented by a cough and could think of no reason other than the acid fumes that had roughened his respiratory organs. Ramazzini [20] also reported that workmen who pulverized stibium (Sb_2S_3) to make glass suffered from vertigo and that their lungs were affected. Wright's translation of Ramazzini's account of the maladies occurring in glass workers is vivid:

But a far worse fate awaits those who make colored glass for bracelets and other ornaments for women of the lower class and for other uses. In order to color the crystal, they use calcinated borax, antimony, and a certain amount of gold; these they pound together to an impalpable powder and mix it with glass to make the paste needed for this process, and however much they cover and avert their faces while they do this they cannot help breathing in the noxious fumes. Hence it often happens that some of them fall senseless, and sometimes they are suffocated; or in the course of time they suffer from ulcers in the mouth, oesophagus, and trachea. In the end they join the ranks of consumptives, since their lungs become ulcerated, as has been clearly shown by the dissection of their corpses.

Ramazzini pointed out that such symptoms were not observed among glass workers in a factory that did not make colored glass [20].

In 1910, McWalter [21] suggested that many of the obscure and characteristic disorders of printers were due to antimony rather than lead. He reported observing a number of printers with a form of neuritis similar to arsenic neuritis. He described the disorder as being nonfatal, characterized by languor, intense depression, pallor, a tremor-like writer's palsy but more painful and confined to the ulnar side of the hand, pain in the region of the bladder and urethra, temporary impotence, dyspnea without physical signs of lung disease, irritable hyperactivity of the heart, and gastric irritation. The author [21] recognized that many of the symptoms described could be produced by arsenic, a contaminant of the type metal. Lead was also thought to be a possible cause of some of the symptoms, although McWalter [21] noted that the men had few if any of the classic signs of plumbism.

Schrumpf and Zabel [22], also in 1910, described a chronic malady, similar to that observed by McWalter [21], occurring among 15-20% of young typesetters. In addition, Schrumpf and Zabel noted a somewhat lower blood pressure, and found antimony in the feces. The arsenic content of the feces was not given although trace amounts of arsenic were stated to have been found in the metallic antimony used to make the type metal. The authors [22] did not explain what "traces of arsenic" meant. Examination of the workers' blood samples showed leukopenia with concomitant eosinophilia. The symptoms disappeared after suspension of work for 2-3 weeks. The results of experiments with rabbits, though poorly controlled, led Schrumpf and Zabel to conclude that antimony, and to some extent arsenic, caused the illnesses in the workers. The authors [22] were convinced that lead did not cause the observed symptoms.

In 1913, Rambousek [23] expressed doubt that industrial poisoning was traceable to antimony or its compounds and that arsenic, usually present as a contaminant, was more likely the cause. No supporting data or information were presented.

Seitz, in 1923 [24] and again in 1924 [25], reported that workers in a type foundry were found to have abnormal blood profiles. The factory workers were exposed to metallic dusts containing lead and antimony and to vapors that contained, according to Seitz, antimony in barely measurable concentrations. The method of analysis was not given. The most consistent blood changes among the workers included more than a 50% reduction in the normal thrombocyte (platelet) count and a 50% increase over the normal eosinophil count. A slight lymphocytosis was also reported. Seitz [24,25] related the results of experimental studies in cats, rabbits, and guinea pigs that tended to suggest that antimony and not lead was responsible for the blood changes observed in the foundry workers.

Shirley [26] suggested in 1927 that antimony pentasulfide, present in rubber-compounding ingredients, was responsible for skin irritation leading to eczema or dermatitis, irritation of mucous membranes, ulcerations around the mouth, and a variety of gastrointestinal disturbances including anorexia, cramps, and diarrhea. The author [26] thought it doubtful that absorption of antimony caused any central nervous system disorders.

In a reply to Shirley's article, Shirk [27] refuted the charges against antimony and stated that he knew of no cases of antimonial poisoning among 25-50 workmen engaged over a 12-year period in the manufacture of about 15 million pounds of precipitated antimony sulfide (pentasulfide). Furthermore, no case had come to his attention from six other plants producing antimony sulfide, nor from rubber factories using the product. Shirk, however, did not refer to any medical reports to back up his assertion that the workers suffered no symptoms.

In 1928, Selisky [4] reported 200 cases of skin lesions ascribed to solutions containing antimony potassium tartrate that were being used as mordants in cloth dyeing operations. He described the condition as a pustular necrotic dermatitis commencing as a folliculitis and eventually resulting in atrophic scarring. Acid intermediate products, resulting from the addition of priming colors to the dye solutions, were thought responsible for the dermatitis. The addition of chalk as a neutralizer drastically reduced the number of cases [4].

In 1939, Feil [28] described adverse dermal and mucous membrane effects among workers engaged in the production of antimony metal, antimony trioxide, and crude or pure antimony sulfide. The antimony ore used in the foundry was reported to contain only small amounts of arsenic; the maximum concentration in the ore was 10 mg/kg (0.001%). Of 15 foundry workers studied, 14 had skin eruptions or histories of eruptions. At the time of examination, seven cases of active rash were noted. The eruptions, described as being itchy and resembling chickenpox or smallpox, were usually found on the neck, forearms, and lower extremities. Feil noted that the lesions disappeared with time (about 3 weeks), especially if the workers quit their jobs. Heat, perspiration, and scratching maintained the rash, according to the author. The rash was more prevalent in the summer. Other frequent diagnoses among the 15 workers included conjunctivitis (7) and tracheitis, pharyngitis, and headache (5). Six anemias were also reported but details were not provided. Three workers had a decrease in sexual potency which seemed to be associated with high exposures at the foundry's furnaces.

Feil [28] also related that workers engaged in the production of yellow sulfur and antimony vermillion (antimony oxysulfide) had no signs of antimony toxicity even though they were "absolutely" covered with powder. The powders were described as amorphous antimony sulfides formed either by the reaction of antimony chloride and a hyposulfite or by the decomposition of a sulfoantimonate by an acid. The sulfides produced ranged from golden yellow to deep violet and were used as coloring agents or in the vulcanization of rubber [28].

(b) Therapeutic Use

The therapeutic use of antimony became widespread after it was discovered in 1906 that antimony, combined with an organic molecule, could be administered intravenously (iv) in doses much larger than those tolerated orally. This represented a significant advance in the treatment of tropical diseases [29]. Organic antimonial compounds became, and in many cases remain, the drugs of choice for the treatment of the different forms of schistosomiasis or bilharziasis (caused by parasitic flukes of the genus Schistosoma) and leishmaniasis (caused by parasitic protozoa of the genus Leishmania) [30]. The trivalent antimonial compounds generally have been most

effective against schistosomiasis; the pentavalent drugs have been used primarily against leishmaniasis and as drugs of second choice against schistosomiasis [18,30]. The effects of antimonial drugs are discussed in the subsection on therapeutic exposures under Effects on Humans.

Effects on Humans

Most information on the biologic effects of antimony on humans is derived from clinical studies in which organic forms of antimony were used therapeutically and administered parenterally. Occupational exposures occur primarily by inhalation and skin contact with inorganic forms of antimony (metallic, inorganic salts, and hydrides). Though caution must be exercised in drawing strict parallels between occupational and therapeutic data, the latter may be valuable in assessing the occupational hazards of antimony. For this reason, information from therapeutic and from accidental exposures is reviewed in this document.

(a) Nonoccupational Exposures

(1) Accidental

Acute poisoning following the ingestion of antimony is characterized by a burning sensation in the stomach or other abdominal pain, nausea, intense vomiting, diarrhea, and possibly collapse [31,32]. Dunn [33] and Monier-Williams [31] recounted a 1928 incident of accidental antimony poisoning at a company picnic. Lemonade made from fruit crystals was prepared in new white enamelware buckets for the firm's employees and was allowed to stand overnight. Approximately 70 of the 500 employees drank the lemonade, and practically all of these people became rapidly ill. Fifty-six employees were hospitalized for burning stomach pains, colic, nausea and vomiting, and collapse. Diarrhea was not observed. The severity of illness seemed to vary with intake, though in some cases hysteria may have added to the degree of distress and period of incapacity. Most patients returned to work within 3 hours and some were able to eat dinner shortly after the incident. Two of the patients remained in the hospital overnight but were released without sequelae the next morning [31].

Analysis of the bucket enamel that had not been touched by the lemonade indicated 2.88% antimony trioxide [33]. The acid lemonade solution had dissolved the antimony from the enamel, and analysis found the lemonade to contain 0.013% metallic antimony. Each person who consumed a 300-ml tumblerful of the solution would have ingested 36 mg of antimony, or if expressed as tartar emetic, 100 mg of the drug. The British Pharmacopoeia listed the emetic dose of tartar emetic as 30-65 mg [33].

Werrin [32] recounted a similar incident that occurred in 1959. About 150 children became ill at a church picnic after drinking pink lemonade. The drink had been prepared the preceding day, and antimony had leached from the agate lining of the pot. Each child had probably consumed 7.5 mg of antimony, equivalent to 20 mg of tartar emetic. The principal symptoms were nausea, intense vomiting, abdominal pain, and some diarrhea. Most children recovered within a few hours [32].

Although antimonial compounds, usually tartar emetic, have reportedly been used as agents for suicide or homicide, the emetic properties of the tartrate generally make its use for these purposes of questionable effectiveness. A number of such cases were summarized by Polson and Tattersall [34].

Chronic antimony toxicity of nonoccupational origin is not commonly reported. In a discussion of clinical toxicology, Polson and Tattersall [34] described chronic antimony intoxication as resembling natural illness, with nausea, vomiting, loss of appetite, thirst, and diarrhea. Muscular cramps, sometimes severe, were considered to be an outstanding feature. Death was reported to follow chronic antimony intoxication [34], but no details were given.

(2) Therapeutic

(A) Effects on the Heart

The sudden death of a patient during a routine course of therapy for schistosomiasis was described by Khalil [35] in 1931. The patient had collapsed and died while seemingly well, 6 hours after an injection of antimony potassium tartrate. Death was ascribed to sudden heart failure although an autopsy was not performed. The death was typical of other cases Khalil had observed that rarely occurred before the sixth dose and usually a few hours after the injection [35]. Khalil suggested that the drug exerted a toxic effect on the heart and that strenuous muscular effort contributed to the deaths.

Mainzer and Krause [36] reported in 1940 that 9 of 12 bilharziac patients receiving routine therapeutic administration of antimony potassium tartrate had altered electrocardiograms (ECG's). The ECG changes were primarily in the T wave. Of the nine ECG's showing changes, three were considered pathological, four suspicious, and two were judged insignificant. Bradycardia, which the authors [36] considered significant and related to cardiotoxic effects of antimony, was also noted.

Numerous authors using many antimonial drugs have attempted to elucidate the action of antimony on the heart. A complete description of the ECG changes seen following antimonial therapy was provided by Honey [37] in 1960. Although Honey's patients had received antimony sodium tartrate, the effects observed have been seen regularly after administration of antimony potassium tartrate [36,38-40], antimony sodium gluconate [41-43], antimony dimercaptosuccinate [41,44-49], stibophen [38,39,41,50], and antimonate of n-methyl glucamine [41]. Not all drugs produced the full range of effects described by Honey [37].

In all but one of Honey's 59 patients, ECG changes were seen toward the end of the course of therapy [37]. In the single case, the changes were seen very early. Changes varied from very slight (within normal limits) to severe changes that, in the absence of a history of antimony sodium tartrate administration, would have been interpreted as indicating severe myocardial disease [37].

ECG leads consisted of three standard and three augmented unipolar limb leads and the precordial leads V1 to V6. The following changes were considered to be characteristic. The P wave became tall and broad in some

leads, while R wave voltage became significantly lowered. In some patients, minor changes in the QRS axis were noted. No changes in PR or QRS intervals were found. The QT interval increased in most cases [37].

The most characteristic abnormalities seen were in the ST segment and T waves. The earliest change was a reduction in amplitude of the T wave in all leads. As this progressed, the T waves in the left precordial leads became unmistakably abnormal with decreased voltage; both the upstroke and downstroke became more gradual and prolonged. This accounted for much of the QT prolongation. Later on in therapy, the T wave became flat or diphasic in the three standard bipolar limb leads, and, in V5 and V6, the outermost precordial leads. At this time, the ST segment became straight, especially in the precordial leads V2 to V4, located over the heart. Characteristically, the terminal portion of the T wave dipped progressively further below the isoelectric line. This terminal negative phase of the T wave was accentuated by a prominent upright U wave in some instances. Later, in severely affected cases, the T wave became completely inverted, sometimes very deeply, especially in V2 and V4. Inversion of the T wave tended to appear later in V5 and V6. In many patients, the U wave became exaggerated, either interrupting the downslope of a broad low T or following an inverted T or the terminal portion of a diphasic T. No consistent change in pulse rate was seen, though there was one case of serious ventricular arrhythmia. Honey [37] theorized that the longest intervals were associated with sinus arrest or sinoatrial block.

The ECG changes described above have been associated with both trivalent and pentavalent antimonial therapy, though more commonly with the more widely used trivalent compounds, especially those given iv [38,39,51]. Unfortunately, the most effective drugs in the treatment of schistosomiasis also cause the greatest disturbance to the heart. The percentage of patients having altered ECG's has often approached 100% after iv administration of the trivalent antimony potassium or sodium tartrate [37-39]. The percentage of patients with altered ECG's usually has been less than 80% for those receiving trivalent antimonials intramuscularly (im), probably because im administration allows more dilution of the antimony compound in the blood before the drug reaches the heart (DK Detweiller, written communication, May 1978).

ECG changes following treatment with pentavalent compounds have been infrequently observed. Germiniani et al [41] studied the ECG's of 30 patients under treatment for schistosomiasis or leishmaniasis. Both trivalent and pentavalent antimonials were used; however, only five patients received the pentavalent compound. Administration of trivalent and pentavalent drugs both resulted in flattened T waves, anomalous QT intervals, and myocardial ischemia of the subepicardial layer [41].

In contrast, Lopez and da Cunha [52] failed to see ECG alterations in patients treated with the pentavalent drug despite the much larger doses given of pentavalent than trivalent antimony in a study comparing the two drugs. The total dose of pentavalent antimony ranged from 4.95 to 19.35 g given iv over 5-10 days, whereas the total dose of trivalent antimony ranged from 214 to 510 mg given iv over 2-9 days. All patients given trivalent antimony sodium gluconate showed diffuse alterations in ventricular repolarization, seen primarily in the T wave, accompanied by a sinus tachycardia in one case. In the group receiving the pentavalent drug n-methyl glucamine antimoniate,

only one patient showed ECG changes; the authors [52] attributed the arrhythmia to the patient's advanced case of kala-azar.

Tarr [39] was similarly unable to find ECG alterations in three patients treated with the pentavalent drugs ethylstibamine or glucostibamine sodium. However, he did find the typical changes in the T wave of patients given either of two trivalent compounds, antimony potassium tartrate or stibophen.

The mechanism of myocardial toxicity due to antimonial drugs is not completely understood. According to one opinion, antimony becomes fixed to the cardiac cellular membrane and interferes with sodium permeability, thus slowing repolarization and causing ECG alteration until the antimony is excreted (DK Detweiller, written communication, May 1978). Pentavalent antimony compounds are generally excreted more quickly than trivalent, a fact which may help explain the apparent differences in myocardial toxicity between the two valence forms. Excretion is discussed further in this section under Distribution and Fate.

Honey [37] noted that the action of antimony on the myocardium appeared to be cumulative on an individual basis; ECG changes became progressively more severe during the course of therapy. However, taking the group of patients as a whole, there was no relation between total dose per unit of body weight and the degree of ECG change. Individual patient susceptibility apparently played a great part in the observed ECG changes. Honey believed that Asians and Africans (from Nigeria, Ghana, Sudan, Uganda, Mauritius, Iraq, and Kuwait) were more susceptible than Europeans to the cardiotoxic effects of antimony. Of 15 African or Asian patients, 11 had severe ECG changes; 7 of 45 European patients had changes classified as severe [37].

Others have noted that women may be more susceptible than men to the cardiotoxic effects of antimonial drugs [44,53,54]. Huang et al [53] reported that among Chinese, severe cardiac arrhythmia was more frequently encountered in female patients, especially during menstruation or lactation. The authors [53] were, however, not aware of any severe arrhythmia episodes occurring in pregnant women receiving antimony therapy. Lu and Liu [54] referred to a government report of the People's Republic of China which stated that the female death rate due to antimonial drug intoxication was much higher than the male death rate. Neither group of investigators presented specific data.

Waye et al [44] noted that although only about 25% of their 38 US patients receiving antimony dimercaptosuccinate were women, the 3 patients who showed severe ECG changes were all women. No explanations were offered.

The cardiotoxic effects of antimony therapy occasionally have been severe enough to elicit the Stokes-Adams syndrome (periodic weakness, dizziness, or loss of consciousness from lack of cerebral blood flow due to recurring atrioventricular heart block). Dancaster et al [42], in 1966, reported such a case in a 26-year-old female bilharziac patient receiving antimony sodium gluconate. Twenty-four hours after her fourth daily injection (totaling 760 mg of the drug), the woman suddenly lost consciousness. There was no pulse and her blood pressure could not be recorded. She stopped breathing temporarily and became cyanotic but recovered after external cardiac massage. During the next 24 hours, she lost consciousness six times, about 90 seconds in each case, all preceded by a ringing in the ears and blurring of vision. The first ECG taken showed changes compatible with hypokalemia, with

flattening of the T wave, and a prominent U wave. An ECG taken 24 hours later showed changes suggesting an inferior myocardial infarction. The authors [42] thought that the myocardial injury, possibly including patchy necrosis or infarction, could be due either to a direct effect of antimony on the myocardium or to coronary spasm caused by the antimony. The woman's ECG gradually returned to normal in 6 weeks. Similar case histories with other organic antimonial drugs and drug regimens have been reported [43-45,50].

Khalil [55], in 1936, estimated 0.2% mortality following antimony potassium tartrate administration in Egypt. This estimate probably involved under-reporting [55]. Huang et al [53] indicated that mortality following antimony therapy in China had dropped from 0.4% in 1950 to 0.005% in 1958 due to improved methods of treatment.

According to Lu and Liu [54], cardiac intoxication caused 70-97% of reported antimony drug-related deaths, followed by hepatic or acute generalized intoxication, though no data were given. An autopsy on a person who died after 12 injections of antimony sodium tartrate, totaling 1.5 g of the drug, showed cardiac edema and fragmentation of myocardial fibrillar structures [37]. The heart gave appearances of a very recent moderate-sized myocardial infarction. Analyses for antimony showed: blood, 0.017 mg/100 g; liver, 0.020 mg/100 g; skeletal muscle, 0.30 mg/100 g; and heart muscle, 0.20 mg/100 g. The apparent affinity of antimony for muscle tissue was not discussed.

In 1947, Tarr [39] looked for trends in heart rate in the records of 181 courses of antimony therapy. The investigation revealed an increase averaging 10-15 beats/minute (range, 6-30) in 48 courses, a decrease in rate averaging 10-15 beats/minute in 77 cases, and no change in the remaining 56. Tarr [39] was unable to draw any relationship between the T wave and heart rate changes. Other investigators [37,38,40,44,46] generally have failed to observe significant changes in heart rate in their patients receiving antimonial drugs.

(B) Effects on Blood

Hematologic disorders associated with antimony therapy have only rarely been reported and then only with the treatment of schistosomiasis [56-59]. The blood conditions observed could have been caused or contributed to by factors other than antimony, particularly the cases of hemolytic anemia and eosinophilia.

De Torregrosa et al [56] described two cases of hemolytic anemia and referred to six others, all of which occurred in schistosomiasis patients receiving stibophen. Five of the eight patients died of hemolytic reactions with anaphylactic shock. The authors [56], however, were not convinced that antimony had caused the reactions. They suggested that the anemias may have resulted from an immunological response to the organic portion of the stibophen molecule.

Eosinophilia in 24 of 36 patients receiving antimony dimercaptosuccinate was reported by Spingarn et al [57] in 1963. In six of these patients, the percentage of eosinophils rose to 55-60%. The authors [57] reported that the eosinophilia was usually noted at the completion of therapy, implying that the

eosinophilia was a response to the antimony drug, but it is also possible that histamine release in tissues damaged by the parasites caused the condition [60].

Kahn and Brod [58], in 1961, described a case of thrombocytopenic purpura that occurred in a 55-year-old woman being treated with stibophen for schistosomiasis. Both ecchymoses and petechiae were present. Ecchymoses were noted on the left buttock at the injection site and on the left shoulder. Petechiae were present on the face, all extremities, the back, the buccal mucosa, the hard palate, and the bulbar conjunctiva of both eyes. One retinal hemorrhage was noted. Initial laboratory findings were virtually normal except for a very low platelet count of 34,000/cu mm. The plasma prothrombin and whole blood clotting times were normal. Following several in vitro and in vivo challenge studies, Kahn and Brod [58] concluded that the stibophen-related thrombocytopenic purpura was an immunologic phenomenon involving antibodies and complement.

Rivera et al [59] reported another case of immune thrombocytopenic purpura due to stibophen in a 33-year-old man. Following the fourth injection of the third course of treatment, numerous petechiae and ecchymoses developed over the patient's entire body. Extensive subconjunctival hemorrhages were present, but the retinas were normal. There was marked periorbital swelling and purple discoloration. Submucosal ecchymoses were present in the oral cavity, fauces, tonsils, and vocal cords. All laboratory and clinical tests, including an ECG, were normal. Administration of plasma from this patient to another who also received stibophen produced thrombocytopenia without purpura. It was postulated that this case of thrombocytopenic purpura was due to the occurrence of a drug-antibody complex capable of destroying or agglutinating platelets and depressing megakaryocyte activity [59].

(C) Hepatic and Renal Effects

The therapeutic use of antimony has been associated with hepatic damage. O'Brien [50] stated in 1959 that acute fatal liver necrosis had occurred among a small proportion of West African soldiers treated during World War II with antimony potassium tartrate for schistosomiasis. The number treated and proportion affected were not given.

Elevated serum transaminase levels, indicative of cardiotoxic or hepatotoxic effects, have been reported following the administration of several antimonial compounds [44,57,61,62]. The enzyme glutamic-oxalacetic transaminase, found in various tissues, primarily the heart and liver, is released into the serum as the result of tissue damage; hence, serum glutamic-oxalacetic transaminase (SGOT) levels may increase following heart or liver damage. A value of 4-44 units is normal. Glutamic-pyruvic transaminase is another enzyme found in the serum (SGPT) that concentrates in the liver. A normal blood value is 3-36 units. Hepatic disease, such as parasitic infection, or insult, such as the toxic action of a drug, can result in increased concentrations of both enzymes in the blood.

Abdalla et al [61] determined SGOT and SGPT levels in 55 Egyptians before, during, and after antimony potassium tartrate therapy. Increases in SGOT and SGPT before treatment were seen in all cases, though the increases were moderate and more pronounced in hepatosplenic infections than in urinary or intestinal ones. SGOT and SGPT levels in all patients rose throughout

treatment and reached 182 units/ml for SGOT and 178 units/ml for SGPT in the hepatosplenic group, which had consistently higher values than the urinary or intestinal groups. Fifteen days after treatment ended, serum levels of both enzymes had declined gradually in cases of urinary and intestinal schistosomiasis, but were still high in hepatosplenic cases [61].

Asshauer [62] found that rises in SGOT and SGPT occurred simultaneously in 38 patients given antimony potassium tartrate or stibophen for schistosomiasis. SGOT was normal in all cases before antimony therapy. Following treatment, 59% of the cases had abnormally high values, the highest being 510 units. No relation to dose was found. SGPT was elevated in one case prior to treatment and in 57% of the cases after treatment. The maximum level found was 349 units. The increase in SGPT level also was not related to dose [62].

Waye et al [44], however, found a somewhat positive correlation between SGOT elevation and total dose of antimony dimercaptosuccinate. The highest value, 320 units, was found in a patient who had received 65 mg of the drug/kg. Waye et al believed that SGOT could not be used as an index of cardiotoxicity during antimony therapy. Forty percent of their patients without significant ECG changes had SGOT elevations, but only one of three patients with severe ECG changes had a rise in SGOT. They [44] concluded that SGOT was a measure of hepatic, not cardiac, necrosis during antimony treatment. The authors [44] admitted, however, that more frequent SGOT determinations might have revealed a greater incidence of elevated levels in patients with altered ECG's.

Spingarn et al [57] noted considerable SGOT elevations in 17 of 23 patients receiving antimony dimercaptosuccinate. Three patients had high levels (up to 86 units) before therapy, indicating that some heart or liver damage could have occurred due to the parasitic disease. Following antimony therapy, increases of up to 360 units over pretreatment values were seen. SGOT elevation was generally proportional to the dose administered. Of the 17 patients with abnormal SGOT levels, 12 also had abnormal ECG's. These studies [44,57,61,62] indicate that antimony therapy was the major cause of the reported SGOT and SGPT elevations, but whether they indicated hepatic or cardiac intoxication is unclear.

Renal complications following antimonial therapy have been reported. Charlas and Benabadji [63] reported in 1962 that a 4-year-old girl being treated for kala-azar had developed azotemic nephritis 1 week after a second course of therapy with n-methyl glucamine antimoniate, a pentavalent compound. The nephritis, not known to be a complication of kala-azar, suggested metal poisoning to the authors [63] because it was characterized by an initial anuria followed by a polyuria. Based on the nature of the azotemic nephritis, the recent antimony therapy, and the lack of any other evident cause, the authors [63] concluded that the nephritis was caused by the antimonial drug.

Two cases of lupus erythematosus aggravated by the therapeutic use of anthiolimine, a trivalent antimonial drug, were described by Rollier et al [64]. In one case the drug was thought to be responsible for transforming edematous lupus erythematosus into severe systemic lupus erythematosus. The authors [64] viewed this response as exceptional since several patients had previously received anthiolimine without aggravation of their lupus.

(D) Other Effects

The most common side effects of antimony therapy have been mentioned in articles that emphasized other, more severe, effects. More or less in passing, it was stated [35,37,43,47,56,58] that some patients experience some or all of the following symptoms: nausea, anorexia, vomiting, dizziness, joint or muscle pains, headache, diarrhea, fever, and coughing. Reports have generally not given estimates of how widespread these effects are among patients. Khalil [35] found that the numbers of affected patients differed according to the drug administered. He estimated that in patients receiving antimony potassium tartrate, 10% experienced coughing in varying degrees of intensity. Nausea without vomiting occurred in about 1.6% of the cases, and with vomiting in 3.8%. After administration of stibophen, no cases of coughing occurred, nor was there nausea without vomiting. Vomiting was reported in 0.36% of these patients, and dizziness in 0.018%. The percentages were based on at least 2,000 patients [35].

An association between antimony therapy and the occurrence of herpes zoster infections has been noted by several investigators [64-66]. Aslamazov et al [65] observed herpes zoster (shingles) in 2 of 28 bilharzic patients under treatment with antimony sodium tartrate and in 1 of 42 patients treated with stibophen. Most et al [66] reported that herpes zoster infections had developed in 6 of 600 patients being treated with tartar emetic or stibophen. Rollier et al [64] reported shingles in the same patient whose lupus erythematosus had become systemic after treatment with anthiolimine.

(b) Distribution and Fate

Distribution and excretion profiles for man have been determined largely from therapeutic studies. In general, the studies show that trivalent antimony has a greater affinity for red blood cells [67] and is eliminated more slowly than are pentavalent compounds [68]. Antimony is primarily eliminated via the urine following parenteral administration.

Boyd and Roy [68] investigated excretion of a pentavalent compound, ethylstibamine, and compared it with a trivalent compound, antimony sodium tartrate. Estimates of antimony in the urine were made by the Gutzeit method of Sanger and Reigel [69].

Two patients each received a single 300-mg iv dose of ethylstibamine containing 123 mg of pentavalent antimony [68]. Antimony in the urine was determined at frequent intervals for the first 3 days and then every 24 hours for several days. The authors [68] reported that about 19% of the antimony injected was excreted in the first 2.5 hours, 41% during the first 24 hours, 6% during the second 24 hours, and 1.25% during the third 24 hours. Thereafter, daily excretion remained low (1% or less) and was measureable for as long as the two patients were followed (11 and 13 days). An average of 49% of the antimony was excreted in the first 3 days. Reducing the dose to 150 mg did not alter the excretion rate.

A trivalent compound, antimony sodium tartrate, was given in single iv doses of 50 or 60 mg to two patients [68]. These doses represented about 20 and 24 mg of trivalent antimony. The resulting excretion pattern was distinctly different from that observed with the pentavalent compound. The data showed that about 2.5% of the antimony was excreted during the first 24

hours and 2% in the second 24 hours; it decreased very gradually to about 1% or less during the next 24 hours. Total excretion after 3 days was estimated to be about 5% (see Table III-1). Concentrations in the blood were not reported.

TABLE III-1

URINARY EXCRETION OF TRIVALENT AND PENTAVALENT ANTIMONIAL DRUGS

Compound	Ref. No.	Total Dose of Sb (mg)	Route	Excretion, Cumulative Percent Days		
				1	2	3
Trivalent Compounds						
Antimony potassium tartrate (Tartar emetic)	[70]	19-120	iv	12	17	20*
Antimony sodium tartrate	[68]	20-24	iv	2.5	3.5	4.3
Lithium antimony thiomalate	[67]	34.5	im	11.4		
Sodium antimony dimercaptosuccinate (Astiban)	[71]	75-125	im	25**		
		320-619	im	36	38	
Monosodium antimony thioglycollate	[67]	31	im	8.1		
Pentavalent Compounds						
Ethylstibamine (Neostibosan)	[68]	123	iv	41	47	49
		123	im	34	37	38
		61.5	iv	39	43	44
	[67]	127.5	iv	19		
Antimony sodium gluconate	[67]	195	iv	43		
Urea stibamine	[72]		iv	35	41	

*31% after 1 week; 73% after 4 weeks

**50% after 2 weeks

Following the same experimental design, a single dose of 300 mg of ethylstibamine was administered im to two patients [68]. Averaging the

results from the patients, 34% of the antimony was excreted during the first 24 hours, 3% during the second 24 hours, and 1.5% during the third 24 hours. Thereafter, daily excretion rates were low (1% or less) and constant.

The work by Boyd and Roy [68] indicated that dose and route of administration of antimony drugs exerted little effect on the rate of excretion. Intramuscular administration produced a slightly slower excretion rate, a predictable finding in view of the slower absorption expected from im administration. The excretion patterns of a trivalent drug and a pentavalent drug were found to be different.

Otto et al [67] also compared the distribution and excretion patterns of trivalent and pentavalent compounds in a 1947 report. A total of 497 determinations for antimony were made by Maren's colorimetric method on blood cells, blood plasma, feces, and urine of 14 patients being treated with antimony compounds. Two trivalent compounds, anthiolumine and monosodium antimony thioglycollate, and two pentavalent compounds, antimony sodium gluconate and ethylstibamine, were studied.

Distribution of the trivalent compounds in blood was characterized by rapid movement of antimony to the blood cells and continued higher concentrations in blood cells than in surrounding plasma. On the other hand, pentavalent antimony showed little or no affinity for blood cells, but concentrations in plasma were high (see Table III-2).

TABLE III-2

AVERAGE 24-HOUR ANTIMONY LEVELS IN ERYTHROCYTES, PLASMA, AND URINE
AFTER INTRAMUSCULAR INJECTIONS OF TRIVALENT AND PENTAVALENT ANTIMONIALS

	<u>Concentration of Antimony</u>				
	Average Dose of Sb given (mg)	Cells ($\mu\text{g/g}$)	Plasma ($\mu\text{g/g}$)	Ratio Cells/Plasma	Sb Excreted (% dose)
<hr/>					
	Trivalent Compounds				
Anthiolimine	34.5	0.15	0.03	5.0	11.4
Monosodium antimony thioglycollate	31	0.35	0.07	5.0	8.1
	Pentavalent Compounds				
Antimony sodium gluconate	195	0.6	0.32	1.9	43.0
Ethylstibamine	127.5	0.25	0.8	0.31	17.0

Adapted from Otto et al [67]

Even after repeated heavy doses of the pentavalent drugs, the amounts of antimony recovered from blood cells were scarcely more than could be accounted for in light of known contamination of the cell fraction with plasma [67]. The high plasma concentration of pentavalent antimony and its corresponding low affinity for blood cells apparently enabled quick excretion. Trivalent antimony, on the other hand, became bound to blood cells and remained in circulation for a considerable time.

Some variation in excretion rates was seen by Otto et al with the two pentavalent compounds they studied. They theorized that rate of excretion may to some extent be inversely proportional to the toxicity of the compound [67]. Valency seems to be the primary determinant of excretion rate, but the configuration of the organic molecule also seems to play a role.

Khalil [35], in 1931, reported on the analysis of urine, feces, sweat, milk, and sputum as potential routes of antimony excretion. The subjects were undergoing routine treatment with antimony potassium tartrate or stibophen. Antimony was reported to be excreted only in the feces following im or iv administration of either drug. During the 45 days of observation, 45-50% of administered antimony was excreted in the urine and 3.5% was excreted in the feces.

Baseline values of antimony concentrations in blood, urine, and feces of normal healthy Japanese city dwellers were measured by Hirayama [73] in 1959. The study participants had no known history of occupational or therapeutic exposure to antimony. Analysis for antimony was performed by a procedure that combined the microcolorimetric methods of McChesney [74] and Elkind et al [75].

Antimony concentrations in the whole blood of 104 subjects (79 men and 25 women) ranged from undetectable to 13.5 μg of antimony/100 g of whole blood [73]. The overall median value was 2.4 μg /100 g. Medians for men and women were 2.5 and 2.1 μg /100 g, respectively. Twenty-four-hour urine values were determined for 80 men and 55 women. Urine values ranged from undetectable to 18.5 μg /day. The overall median value was 5.3 μg /day; for men and women the medians were 5.4 and 5.1, respectively. Antimony excreted in the feces of 85 men and 41 women ranged from a trace to 56 μg /day. Half of all the cases measured were 13 μg /day or less, and 95% were 35 μg /day or less. There were no statistically significant differences due to sex in blood, urine, or fecal concentrations of antimony.

Hirayama [73] speculated that the baseline levels were probably common to industrial cities, resulting from factory soot containing antimony and factory waste fluid that had emptied into river and irrigation water. Ingestion of various plants and animals containing antimony had probably occurred, which could explain the high antimony concentrations in the feces. The author [73] thought it unlikely that enamel on eating utensils was a source of antimony. The influence of cultural factors, including diet, in affecting biologic antimony levels is not known.

The concentration and distribution of antimony in the human lung and other organs were studied by Molokhia and Smith [76] in 1967. Radioactive analysis of 45 samples of lung tissue obtained from men and women 40-70 years of age who were killed in accidents in Glasgow, Scotland, showed a mean wet-weight

antimony concentration of 0.095 ppm, a range of 0.007-0.45 ppm, and a median concentration of 0.056 ppm.

Results of distribution studies from 15 lung pairs are shown in Table III-3; distribution of antimony was log-normal [76]. Antimony concentrations were more than twice as high at the apex of each lung than at the base, which led the authors [76] to conclude that the source of the accumulated antimony was airborne dust. No information was provided about occupations, smoking habits, places of residence, or disease states of the victims.

TABLE III-3

DISTRIBUTION OF ANTIMONY IN LUNG AND OTHER TISSUES*

Tissue	Mean Concentration (ppm Wet Weight)
Right lung, Apex	0.084
Middle	0.038
Base	0.033
Left lung, Apex	0.087
Base	0.035
Lymph glands	0.258
Right paratracheal hilar	0.429
Left paratracheal hilar	0.339
Visceral pleura	0.037
Trachea	0.007
Pulmonary artery	0.006
Pulmonary vein	0.007
Tongue	0.007

*Data determined from 15 lung pairs

Adapted from Molokhia and Smith [76]

(c) Occupational Exposures

Numerous authors [4-9,15,16,77-80] have stated that antimony causes occupational health problems. This has been questioned by several other authors [18,81,82], some of whom have noted that many of the reported symptoms and signs of occupational "antimony toxicity" are similar to those of arsenic. Arsenic is a common contaminant of antimony ore and is often found with industrial grades of antimony [83]. Arsenic lies just above antimony in the periodic table [84], and its chemical, physical, and toxicologic properties are similar in several respects to those of antimony [5,85,86]. Arsenic, like antimony, is caustic to skin and mucous membranes and can cause eczema and other forms of dermatitis [87,88], congestion of the upper respiratory tract, and cardiovascular changes [87-93]. These similarities have caused

considerable doubt in some investigators about the actual cause of the occupational toxicity ascribed to antimony, especially that related to mucous membrane and skin effects [77,81].

(1) Effects on the Heart

Reports of altered ECG's in workers occupationally exposed to antimony trioxide and trisulfide have been made by Brieger et al [15] and Klucik and Ulrich [11]. Brieger et al found altered ECG's in 37 of 75 workers exposed to antimony trisulfide who were engaged in the manufacture of resinoid grinding wheels. Klucik and Ulrich found T wave depression, borderline normal QT waves, a prolonged atrio-ventricular transmission, prolonged QRS complexes, and ST segment changes in metal workers exposed to antimony trisulfide and trioxide. Details of these key studies are presented in this chapter under Epidemiologic Studies. They [11,15] are the only reports of altered ECG's in workers, and the only reports implicating inorganic antimony.

(2) Skin and Mucous Membrane Effects

Skin irritation and rashes resulting from occupational exposure to antimony compounds, which often contain arsenic as a contaminant, have been well documented [4-6,10,12,77,78]. These effects have most often been observed following exposure to antimony trioxide [5,77,81] and have been usually associated with hot environments such as might occur during smelting operations or in the summer months [5,12,77,81]. Antimony oxychloride, pentachloride, and trisulfide have not been reported to cause dermatitis.

Rothman [94] suggested in 1943 that antimony salts, as with salts of other heavy metals, form compounds with fatty acid radicals of the sebum and other fats of the skin surface and are absorbed in these forms. No data were presented.

Stevenson [78] gave a different opinion in 1965 on the cause of "antimony spots." After finding dermatitis in 23 of 150 workers exposed to antimony trioxide at the antimony works at Newcastle-upon-Tyne, England, Stevenson noted that all affected workers were exposed to hot environments; 17 worked at the furnaces. Workers in cooler but equally dusty parts of the factory had no spots. The antecubital area, where sweat and flexing occurred, was most often involved. The dermatitis subsided in 3-14 days when the worker was transferred to a cooler part of the factory. Microscopic examination of the lesions showed epidermal cellular necrosis with associated acute dermal inflammatory cellular reaction. The lesions were found close to sweat ducts. A questionnaire survey disclosed that 6 men who bathed relatively infrequently did not have more severe or extensive lesions than the remaining 17. There were no positive reactions in patch tests conducted with dry antimony trioxide or with antimony trioxide suspended in water. Stevenson noted that antimony trioxide is soluble in lactic acid, which is present in sweat in increased amounts following heavy exercise. From these findings, Stevenson concluded that the lesions arose from the irritant properties of antimony trioxide on the dermis after dissolving in sweat and penetrating the sweat ducts [78].

Dermatitis in a worker engaged in the manufacture of fireproof packing material was reported by Paschoud [77] in 1964. A series of cutaneous contact tests of materials going into the final product gave negative results except with antimony trioxide. A positive test for arsenic was noted even though

arsenic was not one of the ingredients in the mixture. Paschoud indicated that other workers exposed to antimony in the same plant also showed positive reactions to both antimony and arsenic. On the other hand, eczemas caused by arsenic in other workers showed negative tests for antimony. The author [77] concluded that the antimony trioxide powder contained impurities of arsenic and that sensitization to both occurred. Double sensitization was thought to be a more plausible explanation than cross-sensitization. Though the process was considered allergic, friction was emphasized as a causative factor [77].

Dermatitis, occurring in two workers producing an antimony trioxide-based powder for treating internal parasites in chickens, was reported by Thivolet et al [81] in 1971. The dermatitis was periodic, usually appearing in the warmer months and disappearing over holidays and during the winter. The lesions were in areas of friction and sweating, such as inside of elbows, popliteal hollows, inguinal folds, and scrotum, and were described as itchy varioliform or necrotic papular pustules.

Chemical analysis of the powder by an undefined method failed to show any traces of arsenic trioxide, and the concentration of the antimony trioxide was not given [81]. A series of skin tests with and without scarification was conducted on the two workers with the commercial antimony trioxide powder and its constituents to determine the cause of the rash. Pure antimony trioxide, pure arsenic trioxide, and Fowler's solution (a solution containing 1% arsenic anhydride) were also tested. Fourteen controls had the same tests. The concentrations used were not reported.

Results of the patch tests without scarification were negative with pure antimony trioxide in 10 controls and in both workers. The results were positive with pure arsenic trioxide in 9 of 10 control subjects and in 1 of 2 workers, and were positive with Fowler's solution in 6 of 10 controls and in the same worker who had responded to arsenic trioxide [81].

With scarification, patch test results were positive with the commercial antimony trioxide powder and arsenic trioxide in both workers, and were positive with pure arsenic anhydride or the commercial antimony trioxide powder in four control subjects [81].

Thivolet et al concluded that the antimony trioxide in industrial or commercial preparations does not appear to play any role in the observed dermatitides, and that an arsenic contaminant was the causative agent. They [81] also concluded that the dermatitides were not due to an allergic process but were caused by the irritant properties of arsenic, the severity of which depended on the degree of individual perspiration.

Linch and Sigmund [82] reported in 1976 the results of laboratory patch tests on 45 women and 7 men who ranged from 17 to 35 years old. A blend of powdered antimony trioxide containing 0.29% arsenic was used. Adhesive patches with moistened gauze centers covered with test material were applied nine times, 24 hours each, over 3 weeks. This series was followed 2 weeks later by a single challenge patch to detect skin sensitization. Because no skin reaction was noted in any subject, the authors [82] did not consider the test material a primary skin irritant or a skin sensitizer. The effects of friction, heat, and sweating as contributing factors to irritation were not studied.

Antimony pentachloride, leaking from a reactor (undefined), was cited by Cordasco [95] as the agent responsible for respiratory distress in a man acutely exposed to an undetermined concentration of the chemical. The patient had received second and third degree burns over most of his body as a result of the accident. The temperature of the material and the worker's protective clothing and equipment were not reported. Almost immediately following exposure, severe coughing, wheezing, dyspnea, and chest tightness developed. Moist rales were found in both base and midlung fields. Pulmonary edema developed which was treated successfully. Antimony pentachloride was also cited by the author [95] as the cause of two fatalities, but no details were provided.

(3) Effects on the Lungs

Exposure by inhalation to dusts and fumes of antimony or antimony compounds has resulted in respiratory illnesses, including pneumoconiosis [5-7,12,95,96]. The amount of functional impairment resulting from most of these exposures is unclear. These reports will be discussed under Epidemiologic Studies.

(4) Effects on Blood

Occupational exposure to antimony has been linked to blood profile alterations, although reported changes have not been frequent. Seitz [24], in 1923, reported thrombocytopenia and relative lymphocytosis in type foundry workers. Anisocytosis was reported by Oliver [10] in 1933 in one of six antimony oxide workers he studied, but he stated that differential white cell counts were generally average, and that the men appeared healthy and apparently had lost little if any time at work because of illness. Gallina and Luvoni [16] found blood profile alterations in workers exposed to antimony pentasulfide (see Epidemiologic Studies).

The most severe cases of blood changes following occupational exposure to an antimony compound were described by Nau et al [97] in 1944. Three metal refinery workers were poisoned by a gaseous mixture containing stibine, arsine, and hydrogen sulfide. The workers suffered severe hemolysis as evidenced by bloody urine and blackened vomitus. Blood bilirubin was elevated. Blood transfusions and fluid replacements were required. These severe symptoms have not been reported following exposure to other antimony compounds.

(5) Other Effects

To elucidate a relationship between induction of chromosome abnormalities and carcinogenesis, Paton and Allison [85] investigated effects of a variety of metal compounds on chromosomes in vitro. Human leukocytes were treated with 2.3 nM concentration of antimony sodium tartrate. One hundred metaphases were examined; 12% of the cells displayed chromatid breaks. This amount of chromosome damage in human cells was reported to be significant at the 0.05 level; controls were not discussed, however. Only salts of antimony, arsenic, and tellurium produced chromosome damage. Although this type of work is used as a screen for mutagenic agents, the results offer limited information and cannot be regarded as conclusive. Nishioka [98] reported no indication of mutagenic activity for antimony tri- and pentachloride in recombination assay experiments using bacterial strains.

Epidemiologic Studies

In 1954, Brieger et al [15] recounted an unexplained increase in the number of sudden deaths among factory workers engaged in the manufacture of resinoid grinding wheels. The workers involved were all from one department and worked in air-conditioned rooms where machines mixed, molded, and pressed materials together. Following the replacement of lead with antimony trisulfide for safety reasons, six sudden deaths and two deaths due to chronic heart disease occurred among 125 workers exposed for 8-24 months. Four of the dead persons were less than 45 years old. In the 16 years before the switch to antimony trisulfide, only one death, from coronary thrombosis, had occurred among the workers in that department. Brieger et al reported that heart disease was suspected in all but one of the sudden deaths. Since autopsies were not performed, confirmation of the suspected heart disease was not possible. An occupational hazard was suspected, which led to a survey of the plant.

Antimony trisulfide in concentrations usually exceeding 3.0 mg/cu m (range, 0.58-5.5 mg/cu m) was found in the air [15]. Phenol formaldehyde resin was also used in the process, but concentrations of this compound in the workroom environment were not reported.

A clinical survey of the employees of that department revealed ECG changes in 37 of 75 workers examined. Alteration of the ECG's was mainly of the T wave. Brieger et al [15] did not define qualitatively or quantitatively the T wave changes but indicated that a cardiologist considered the alterations significant. Apparently, no control ECG's for the 75 workmen studied were available. Alterations in rate and rhythm were not observed. Following cessation of the use of antimony trisulfide in the process, presumably after 2 years, no additional deaths or abnormal cardiac effects were noted. Reexamination of 56 of the workers showed that altered ECG's persisted in 12. Duration of followup was not specified, but it was probably several years.

Of the 113 men examined in the survey, 14 had blood pressures exceeding 150/90 mm and 24 had pressures under 110/70 mm. The ages and weights of these men were not given. X-ray examination revealed that 7 of 111 (63 per 1,000) workers had gastrointestinal ulcers; there were 59 known cases of ulcer in the total plant population of 3,912 (15 per 1,000). These figures are not comparable; more cases of ulcer in the total plant population could have been detected if X-ray screening had been conducted. Irritation of the skin, mucous membranes, and respiratory tract was not found [15].

Urine samples collected at random from the workers contained 0.8-9.6 mg antimony/liter [15]. Antimony content of the urine was analyzed according to a modification of the colorimetric method of Fredrick [99]. Brieger et al [15] did not mention smoking, drinking, or medical histories of the workers. Experiments on rats, rabbits, and dogs conducted by these researchers (discussed under Animal Toxicity) tended to corroborate their occupational findings.

In 1960, Klucik and Ulrich [11] studied 42 metal workers exposed to antimony trisulfide and trioxide at concentrations ranging from 1.3 to 237 g/cu m of inhaled air (sic). The concentrations reported could possibly be 1000-fold in error and may actually have been 1.3-237 mg/cu m. The workers were often reassigned within the plant, making it difficult to establish

exposure groups. Instead, the workers were divided according to the intensity and kind of complaints they expressed. Fourteen had frequent complaints that the authors [11] considered to be related to the heart, including hard breathing, weakness, sweating, stabbing pains or pressure in the chest, and a nonproductive cough. ECG's of these workers were compared with ECG's of the 28 workers who had fewer subjective complaints that might be related to heart problems.

Abnormal ECG's were found in 8 of the 14 workers with frequent subjective complaints. T wave depression, borderline normal QT waves, a prolonged atrio-ventricular transmission, prolonged QRS complexes, and changes in the ST segment were noted [11]. In three workers, the positive ECG findings were unequivocal; in five, symptoms of disturbance were only probable and judged positive in light of the subjective complaints. Three QRS complex changes were noted in the group of 28 workers who complained less, but were thought equivocal. The average age of both groups was in the middle to late 40's.

Klucik and Ulrich's attempt to correlate antimony exposure and heart problems raises some doubts. The authors [11] admitted that some other factor, particularly arsenic, could have caused or contributed to the observed ECG changes. Second, their evaluation of the ECG's does not seem to have been made independently of the workers' complaints. Thus, ECG abnormalities and subjective complaints were positively correlated, but antimony was not proven to be the cause.

The ECG's of a number of workers taken before and after their workshifts were also examined. No significant changes were reported. The ECG of an individual experimentally exposed to the plant dust at 35 mg/cu m remained unchanged for an observation period totaling 26.5 hours. Procedures used to expose the individual were not given.

Renes [5] in 1953 reported a survey, conducted with the plant physician, of employees of a company engaged in mining, concentrating, and smelting antimony sulfide ore. Illnesses had been reported among the workers in the smelting operations and among maintenance workers who spent a substantial part of their time in the smelter building. According to Renes, the illnesses had begun soon after the initial operation of the smelter and had continued for more than 1.5 years.

During the first 5 months of operation, 69 of the 78 workers employed longer than 2 weeks made a total of 218 visits to the plant physician. Dermatitis and mucous membrane irritation were among the most common complaints, but most cases of dermatitis were seen during a 1-week period of heavy exposure. The dermatitis was usually found in sweaty, hairy friction areas such as the axillae, groin, and back of the neck. The lesions were described as nodular and ulcerative. More than 70% of the workers had experienced soreness or bleeding from the nose. In those complaining of laryngitis, erosions or ulcerations of the vocal cords were always observed. An unspecified number of workers complained of shortness of breath. Chest X-rays of six men acutely ill from "heavy" exposure to smelter fumes showed definite pneumonitis extending like a fan from each hilus. However, no evidence of peripheral parenchymal pulmonary damage was found. Table III-4 summarizes the illnesses reported by Renes [5].

TABLE III-4

EFFECTS OF OCCUPATIONAL EXPOSURE TO ANTIMONY TRIOXIDE

Diagnoses	% Workers*
Dermatitis	20
Rhinitis	20
Laryngitis	11
Tracheitis	10
Pharyngitis	8
Bronchitis	7
Pneumonitis	5.5
Conjunctivitis	4
Septal perforations	3.5
Secondary sinusitis	1.5

*From a total of 69 examined

Adapted from Renes [5]

Undefined "heavy" exposure to smelter fumes was also said to have caused systemic effects such as abdominal cramps, diarrhea, vomiting, dizziness, nerve tingling, severe headaches, and prostration [5]. Antimony concentrations in the urine of seven of the nine heavily exposed men ranged from traces to 60 mg/100 ml. It is assumed that these were spot samples although no information was given. The urine containing 60 mg/100 ml was described as heavily discolored with albumin and was obtained from a worker who was severely ill. Another patient had an unspecified amount of arsenic in the urine. According to Renes [5], symptomatic treatment and removal from exposure for several days provided relief. Antimony or arsenic levels in the urine of the other workers were not reported.

The percentage concentrations of the hygienically important constituents present in the materials handled and produced by the workers are shown in Table III-5.

A study of the smelter environment 6 months after the operation began showed gross contamination of the air with dusts and fumes [5]. Renes divided the smelter into two zones for comparison: the electric furnace area, and the cupel area. Breathing zone and general air samples for antimony and arsenic were taken from each area. Table III-6 shows the results.

An average antimony content of about 11 mg/cu m and an average arsenic content of about 0.73 mg/cu m were found in the overall smelter environment. At the cupel operation that used caustic soda to refine the antimony metal, 12, 60, and 64 mg of sodium hydroxide/cu m of air were also found. Microscopic examination showed most of the particulate material to be less than 1 μ m.

One year later, according to Renes [5], engineering controls had lowered the average content of the air to approximately 6.8 mg antimony/cu m and 0.54

mg arsenic/cu m. Table III-7 shows concentrations by area on the second survey. Renes noted that work-related illnesses were still occurring even though engineering controls had been installed.

TABLE III-5

METAL CONSTITUENTS OF HYGIENIC SIGNIFICANCE IN SMELTER MATERIALS

Material or Substance	Concentration of Constituent Elements (%)						
	Antimony	Arsenic	Selenium	Tellurium	Lead	Beryllium	Copper
Dross, iron refining cupel	67.6	4.1	0.04	0	0.28	0	0.4
Dross, arsenic refining cupel	56.9	2.1	0.03	0	0.30	0	0.4
Ore concentrate	21.5	3.6	0.01	0	0.04	0	0.1
Settled fume	35.1	5.3	0.02	0	0.15	0	0.2

Adapted from Renes [5]

TABLE III-6

ANTIMONY AND ARSENIC CONCENTRATIONS IN SMELTER BUILDING (FIRST SURVEY)

Type of Sample	No. of Samples	Antimony (mg/cu m)		No. of Samples	Arsenic (mg/cu m)	
		Concentration Range	Average		Concentration Range	Average
Electric Furnace Area						
Breathing zone	12	0.92-70.7	10.07	12	0.04-4.66	1.10
General room	4	0.40-3.43		3	0.13-1.93	
Cupel Area						
Breathing zone	7	1.19-42.40	11.81	7	0.05-1.45	0.36
General room	8	0.91-22.90		8	0.02-1.59	

Adapted from Renes [5]

TABLE III-7

ANTIMONY AND ARSENIC CONCENTRATIONS IN SMELTER BUILDING (SECOND SURVEY)

Type of Sample	Antimony (mg/cu m)			Arsenic (mg/cu m)		
	No. of Samples	Concentration Range	Average	No. of Samples	Concentration Range	Average
<hr/>						
Electric Furnace Area						
Breathing zone	2	5.0-16.90	4.96	2	1.20-2.90	0.76
General room	4	0.29-3.90		4	0.01-0.33	
Cupel Area						
Breathing zone	3	3.30-17.60	8.23	3	0.08-8.10*	0.39
General room	6	0.23-37.00		6	0.01-2.10	

*The value of 8.10 was not included in the zone average because it resulted from an unusual and noncontinuous step in the process.

Adapted from Renes [5]

Renes recognized that the symptoms observed among the workers were characteristic of both antimony and arsenic intoxication. However, antimony concentrations greatly exceeded the arsenic concentrations both in individual and average values (see Table III-8). The author [5] thought it significant that none of the most common early signs of arsenic intoxication, such as increased pigmentation of certain skin areas, keratoses of the palms and soles, loss of hair and nails, garlic-like odor of the breath and perspiration, or swelling of ankles, were reported among these workers. In addition, higher arsenic exposures, found in the electric furnace area, were not reflected by more intense or larger numbers of illnesses in that area. Therefore, Renes concluded that antimony trioxide, the predominant air contaminant, was responsible for the illnesses [5].

TABLE III-8

PERCENT DISTRIBUTION OF ANTIMONY AND ARSENIC CONCENTRATIONS IN SMELTER AIR

Substance	Concentration Range (mg/cu m of air)		
	0.01-0.49	0.5-4.9	5.0 and above
Antimony	7%	54%	39%
Arsenic	71%	27%	2%

Adapted from Renes [5]

Belyaeva's [13] 1967 report is the only recent investigation into the effects of antimony on reproduction. She noted that Feil [28] had earlier found reduced sexual potency among some men workers in an antimony foundry (discussed under Historical Reports).

Belyaeva compared the reproductive experience of women working in an antimony metallurgical plant, located in the USSR, with that of a group of similar working women not exposed to antimony [13]. Conditions and jobs were not defined. Workers in the metallurgical plant were exposed to unspecified concentrations of metallic antimony dust, antimony trioxide, and antimony pentasulfide. Belyaeva conducted extensive gynecologic examinations twice each year from 1962 through 1964 and reported that the exposed group had higher incidences than the control group of late-occurring spontaneous abortions (12.5% vs 4.1%), premature births (3.4% vs 1.2%), and gynecologic problems (77.5% vs 56%). Gynecologic problems included menstrual cycle disorders (61.2% vs 35.7%), inflammatory disease (30.4% vs 55.3%), and other diseases of the reproductive apparatus (8.4% of antimony-exposed women). No percentage was reported for controls in this last category. The author [13] also observed that the weights of children born to antimony-exposed women were not different at birth from those of control babies, but began to lag behind the controls at 3 months and were significantly less at 1 year of age. Table III-9 gives additional details.

TABLE III-9

WEIGHT OF NEWBORN INFANTS AND DEVELOPMENT OF CHILDREN UP TO 1 YEAR OLD

	No. of Children	Weight of Children (g)			
		At Birth	At 3 months	At 6 Months	At 1 Year
Experimental	70	3,360 \pm 60	6,300 \pm 110	7,460 \pm 120	8,960 \pm 155
Control	20	3,350 \pm 7	6,410 \pm 100	7,950 \pm 80	10,050 \pm 90

Modified from Belyaeva [13]

Antimony concentrations in the blood of exposed workers were more than 10 times greater than in the control group. Average urine levels of antimony for exposed workers ranged from 2.1 to 2.9 mg/100 ml. The highest value found was 18.2 mg/100 ml, and the lowest, 0.5 mg/100 ml. Low levels of antimony were found in the urine of several persons in the control group, according to the report [13], but concentrations were not given (see Table III-10).

Analysis of the antimony workers' biologic fluids by an undefined method detected antimony in breast milk (3.3 \pm 2 mg/liter), in placental tissue (3.2-12.6 mg/100 ml), in amniotic fluid (6.2 \pm 2.8 mg/100 ml), and in umbilical cord blood (6.3 \pm 3 mg/100 ml). Belyaeva [13] also conducted a study of the reproductive effects of antimony on rats (discussed under Animal Toxicity).

Oliver [10] was the first of several investigators to study the health and working conditions of antimony workers at the antimony processing plant at Newcastle-upon-Tyne, England. At the time of Oliver's study (1933), six men were engaged in oxide manufacture, four of whom had worked at this for 13 years, but had been antimony smelters for many years before oxide production began [10]. The two other men had worked with antimony for 2 and 3 years, although they had been with the company for many years.

Observation within the smelter indicated that no special hygienic precautions were taken, and according to Oliver, none appeared necessary. Respirators were provided for workers packing the final product, antimony trioxide, but they were not regularly worn. Despite considerable skin exposure, only a few cases of mild skin irritation were observed. Microscopic examination of the blood showed slight anisocytosis in one man. Differential white cell counts were average except for slightly elevated eosinophils. Chemical examination of the urine (method unspecified) did not detect antimony.

TABLE III-10
LEVELS OF ANTIMONY IN BLOOD AND URINE OF
ANTIMONY METALLURGICAL WORKERS

Group of Subjects	Sb in Blood (mg/100 ml)				Sb in Urine (mg/100 ml)			
	No. Sub- jects	Min	Max	Mean +SE*	No. Sub- jects	Min	Max	Mean +SE*
Workers in dustiest shops (melting, pentasulfide, bene- fication plant)	161	0.5	20.0	5.3 +0.6	133	0.5	18.2	2.9 +0.5
Workers in less dusty shops (chemical laboratory, quality control)	157	0.5	18.2	4.0 +0.5	139	0.5	16.2	2.1 +0.4
Control group	115	0	3.3	0.3 +0.06	-	-	-	-

*Author did not state that these values were standard errors of the mean.

Adapted from Belyaeva [13]

Examination of the feces by an undefined method indicated that intake of antimony had occurred. Levels of antimony in the feces ranged from 10.3 to 97.8 mg, but these amounts were not given per unit weight of feces. Because antimony was excreted in feces rather than in urine, Oliver concluded that antimony was poorly absorbed from the gut [10].

A subsequent examination comparing fecal antimony content before and after more strict enforcement of hygienic work practices was conducted in three of the six men. The average fecal antimony level was 76 mg without strict hygienic supervision, and ranged from 5.1 to 35.7 mg with strict supervision [10].

Oliver [10] stated that the men in the study appeared to have blood pressures below average for their ages, a situation he considered unusual among men engaged in heavy work. Weights of the six men ranged from 112 to 159 pounds. Only one man was over 136 pounds. Three men were less than 63 inches tall. Oliver concluded that the men were healthy and lost very little working time because of illness. He did not consider antimony to be a hazardous substance, but a nuisance to the occasional worker who suffered dermatitis.

In 1963, McCallum [12] reported the results of a survey of the same antimony processing plant at Newcastle-upon-Tyne. Air samples taken at various locations and over several weeks showed that antimony concentrations in the work environment generally exceeded 0.5 mg/cu m. The trioxide powder averaged less than 1 μ m in diameter. The concentrations of antimony were particularly high during the relatively short periods when tapping operations (pouring molten metal) at the furnace were underway; the mean value at these times was estimated to be about 37 mg/cu m. Other parts of the factory had concentrations up to 5 mg/cu m.

Clinical and radiographic examinations of the workers (number not specified) revealed dermatitis and pneumoconiosis. McCallum [12] found situations of severe discomfort due to skin irritation in warm weather and occasional loss of work due to itching and subsequent secondary infections. The rashes consisted of papules and pustules around sweat and sebaceous glands and resembled lesions associated with chickenpox or smallpox. The rashes were found particularly on the forearms and thighs and the flexures where chafing from clothing was likely. Rashes were not observed on the face, hands, or feet. The "antimony spots" were reported to be transient, disappearing over a weekend or holiday and reappearing upon return to work. The author [12] noted that men with the cleanest personal habits were less likely to develop severe dermatitis, if at all.

Pneumoconiosis, resembling that of coal workers (classified by an international group [100] as a simple pneumoconiosis), was diagnosed by radiographic examination in an unreported number of the antimony process workers [12]. The lung changes appeared to be symptomless in nearly all cases. Two of the men subsequently developed tuberculosis which responded to chemotherapy and a third worker, the only one with respiratory symptoms, had chronic bronchitis and respiratory obstruction. Pulmonary function tests suggested that the latter subject had emphysema but no pulmonary fibrosis.

Spot samples of urine taken from three of the antimony process workers with pneumoconiosis had antimony concentrations of 425, 480, and 680 μ g/liter [12]. The case of a retired furnace worker suggested that antimony excretion may continue for some time after exposure ceases. In this subject, urinary antimony concentrations were 55 μ g/liter after 7 months of retirement and 28 μ g/liter after 4 years. Information on urinary levels while working, blood levels, and other possible exposure sources was not given. Even after 4 years of retirement, the furnace worker's urine antimony level was still higher than

the peak background level found by Hirayama [73] among unexposed Japanese (discussed under Effects on Humans).

McCallum [79] reported in 1967 that improved radiological techniques had led to discovery of 26 cases of antimony pneumoconiosis. Eighteen cases were already under clinical observation following the 1963 study [12]. All told, 44 of 262 men employed at the Newcastle-upon-Tyne antimony works had pneumoconiosis ascribed to antimony. Another form of radiologically-discovered pneumoconiosis due to zirconium (processed in an adjacent factory) was present in eight men; eight others had shadows thought to result from mixed dusts. All pneumoconioses were of the simple type. Preliminary results of a new method [8] enabled improved distinction of different dusts in the lung.

Results of microscopic examination of a lung section from an antimony worker who had died from carcinoma of the lung also were reported [79]. Accumulations of dust particles and dust-laden macrophages lying in alveolar septa and in perivascular tissues were described. No fibrosis or inflammation was seen, suggesting that there was little or no reaction to antimony dust in the lung [79].

McCallum et al [8], in 1971, described the method for the detection and measurement of inhaled antimony trioxide dust retained in workers' intact lungs. The method depended on the dust absorbing monochromatic X-rays having two alternative wavelengths which lie on either side of the k critical wavelength of antimony. The antimony content of the lung was deduced from the differential attenuation of these two beams, using a scintillation counter as the detector.

One hundred and thirteen antimony process workers were screened by this method [8]. Most workers had been employed at the Newcastle-upon-Tyne factory for less than 20 years and had worked at different operations for varying periods. The amount of antimony in the lungs of these men ranged from undetectable levels to just over 11 mg/sq cm of lung area. The method of measuring lung area was not described. Although individual lungs varied a great deal, the authors [8] felt that an association could be made, particularly if only the first 20 years of employment were considered. An increase in radiographic category [100] of pneumoconiosis was associated with a rise in the mean period of employment [8]. The man with the highest level of antimony in his lungs (11.2 mg/sq cm) was employed at the factory for 35 years, 16 of which he packed antimony trioxide. Higher median concentrations of an unspecified type of antimony were found in the lungs of the foremen and baghouse workers than in furnace workers; laborers and other workers had the least antimony in their lungs [8].

A continuing investigation into reports of lung cancer deaths among antimony process workers was reviewed in 1973 in a two-page abstract-type statement by Davies [14], then Chief Medical Advisor for the Employment Medical Advisory Service of England. The study was begun in 1962 after it was learned that a man engaged in the processing of antimony had died of lung cancer. Retrospective study found seven other deaths from lung cancer among antimony workers in the previous 8 years. Four of these men had worked at the antimony works at Newcastle-upon-Tyne, which had been studied by Oliver [10] in 1933 and by McCallum in 1963 [12] and 1971 [8]. The other three men had worked in an antimony processing plant that had discontinued operations.

For the period of 1961-1971, 1,081 men and women employees who had been working or had subsequently joined the workforce after 1961 were studied. At the end of 1971, 937 people were known to be alive and living in England, 20 had emigrated and were lost to the study, 56 had died, and 68 were still being traced. Of the 56 deaths, 10 were ascribed to lung cancer. According to Davies [14], the number of lung cancer deaths in persons of all ages was higher among the antimony factory employees than might be expected according to the local community statistics (10 vs 8.0). Nine of the ten had worked solely at antimony smelting and related activities. Among this group of workers, the expected number of deaths from lung cancer was 5.7. It was also observed that 8 of 9 lung cancer deaths were from the 45-64 age group, where the expected rate was 4.5. Deaths from all causes among the antimony factory workers (including office personnel and others not exposed to antimony) were less than expected, 56 vs 65.8. Smoking habits were not reported nor was information on the exact procedures used for computing the reported death rates.

Additional data (KP Duncan, written communication, June 1978) followed the trends seen in the 1973 data, but also did not supply the needed information. Deaths from all causes remained lower than expected for the whole factory (95 vs 108.11) and for the subgroup working in smelting and related activities (64 vs 74.30). The number of deaths from all cancers was slightly greater than expected for the whole factory (31 vs 29.11) and for the smelter subgroup (25 vs 19.93). There was a disparity between observed and expected deaths due to lung cancer for the whole factory (21 vs 14.03), but most of the excess occurred in the smelter subgroup (18 vs 10.25). The disparity was especially prominent in the 45-64 age group (13 vs 7.22). This recent communication, like the earlier report, was brief. Essential information was absent, including control (community) and factory population descriptions, data analysis, medical data, and environmental, blood, and urine antimony concentrations.

In 1958, Karajovic [6] reported on the working conditions and clinical status of 101 men employed at an antimony smelter in Yugoslavia. Common complaints included shortness of breath, muscle pains, mild cough, dyspepsia, diarrhea, and a feeling of tiredness at work. Of the 101 men examined, 51 had catarrhal symptoms of the upper respiratory tract, 12 had conjunctivitis, and 16 had ulcerated nasal septa. Roentgenography of the lung was performed on 62 workers and revealed 31 cases without pathological findings, 17 cases designated only as type X, and 14 cases of simple pneumoconiosis. Emphysema with bronchitis was found in 22 workers, 8 of whom were less than 40 years old. There were four cases of tuberculosis. Karajovic [6] noted that there were no symptoms of damage to the gastrointestinal tract, liver, cardiovascular system, and central and peripheral nervous systems.

Sixteen cases of dermatitis were found among the workers studied, 13 of whom worked at blast furnaces. The skin rashes and itch were reported to have been most prevalent during the summer. The dermatitis was described as vesicular, varioliform, and efflorescent. The efflorescence underwent necrosis in the center and left scars that were hyperpigmented [6].

Roentgenographic examinations of 20 selected workers, 20-50 years old who had worked 3-15 years at the smelter, yielded 8 cases of simple pneumoconiosis, all among men who had spent most of their working hours at the blast furnaces and in the filtering plants. Tests of the workers with

pneumoconiosis showed ventilatory function to be normal in three cases and slightly reduced in four. It was not tested in the remaining individual. Karajovic [6] also reported that blood pressure values were somewhat lower in five of the eight workers with pneumoconiosis, although no data were given. ECG's and hepatograms were normal. Data on the blood pressure determinations and ECG's for the other 12 workers were not provided.

Analysis of blood and urine with Gutzeit's test did not detect antimony [6]. A polarographic method detected 25 μg antimony/liter of urine in three unidentified workers. Antimony was not reported to have been determined in feces.

A survey of the work environment showed that clouds of production dust were often visible. Gravimetric analysis showed dust loads to be 16-248 mg/cu m consisting of 2,150-12,800 particles/cu m. The vast majority of the particles were $<0.5 \mu\text{m}$ in diameter, according to Karajovic [6]. The mixed dust to which the workers were exposed contained antimony trioxide (36-90%), antimony pentoxide (1-6%), arsenic trioxide (0.3-9.0%), ferric oxide (2-4%), and total silica 1-12%, in addition to 1-7% free silicon dioxide [6] (the crystalline form of silica, which, unlike amorphous silica, can cause silicosis).

Karajovic did not doubt that the lung changes observed were contracted as a result of working in the antimony smelter; some workers with lung changes had no other work experience. There was some doubt, however, about whether the changes were attributable to antimony, silica, or both. The author [6] stated that radiographic changes in the lungs of miners with mixed silicosis differed from the changes seen among the smelter workers, a finding that implicated antimony oxides. The influence of arsenic trioxide in causing the observed effects was similarly unclear.

Cooper et al [9] presented data in 1968 on 28 persons who had worked at antimony smelting or ore processing operations for 1-15 years. Pneumoconiosis, determined roentgenographically, was demonstrated positively in three cases and was regarded as suspicious in five others. Cooper et al noted that the 28 employees had lost little if any worktime because of sickness.

Pulmonary function tests were conducted on 14 of the subjects [9]. The tests included vital capacity, lung volume, maximum midexpiratory flowrate, forced 1-second expiratory volume, minute ventilation, mixing efficiency as measured by closed helium circuit technique, tidal volume, maximum breathing capacity, and diffusing capacity. The authors [9] did not present specific data, but they reported that some isolated findings formed no consistent pattern of functional deficit. There were, however, several radiographic changes. One worker had definite small opacities, one had very early unspecified changes, and two had negative chest roentgenograms. Three remaining subjects with either suspicious or definite roentgenographic abnormalities had normal pulmonary function tests.

Cooper et al [9] had monitored the smelter environment in 1966 and found that air concentrations of antimony ranged from 0.081 to 138 mg/cu m. The highest concentration was associated with the bagging operation. Only in that operation did antimony concentrations exceed 75 mg/cu m. In the majority of

cases, concentrations did not exceed 10 mg/cu m. Particle diameters were not given.

ECG's from seven of the workers, three of whom had pneumoconiosis, showed six with normal tracings and one with a slight bradycardia. No other data were provided [9].

The antimony concentrations in urine of these workers were determined in 1962, 1965, and 1968 [9]. The number of subjects sampled varied. The antimony levels in the urine ranged from 7 to 1,020 $\mu\text{g/liter}$, with most between 70 and 800 $\mu\text{g/liter}$. No correlations between urine antimony levels, roentgenographic abnormalities, and pulmonary function tests could be established. Cooper et al [9] also conducted a limited experimental study of the effects of antimony on animals, which is described under Animal Toxicity.

Le Gall [7] reported in 1969 that pneumoconiosis was diagnosed in 10 of 40 workers who operated or worked near furnaces used to produce antimony oxide. Though the cases were labeled as silicosis, Le Gall believed that the pneumoconiosis was caused by antimony. Concentrations of antimony trioxide in the factory ranged from 0.3 to 14.7 mg/cu m, and most particles were reported to be smaller than 3 μm in diameter. The extent of exposure to silica is unclear; the article stated that the presence of silica in dust of the foundry could not be proved, but at another point, it stated that the ore being used contained 1-20% silica. Sulfur dioxide was also found in the air [7].

Urine samples from a few workers did not show the presence of antimony [7]. The workers had been employed at the foundry for 6-40 years, and, except in one case, the pneumoconiosis could not have resulted from other occupations. One affected worker had no work experience except his present job at the oxide furnace, where antimony exposure could be assumed to be relatively high, and silica exposure low or nonexistent. Clinical signs included shortness of breath, coughing, some expectoration, prolonged expiration, and sparse adventitious sounds. The tests used were not specified. The radiographs were described as showing moderate, dense reticulonodular formations scattered through the pulmonary fields. There was no overt illness.

Gallina and Luvoni [16] reported in 1958 on their investigation into a series of illnesses among six workers in a Milan glass manufacturing plant. The affected workers were engaged in preparing a mixture used to produce yellow glass. The disturbances began 15-20 days after the introduction of a new mixture that was intended to produce a more satisfactory color than the old mixture [16]. The previous mixture contained carbon, sulfur, and sodium sulfate. In addition to these ingredients, analysis of the new mixture showed 1.04-1.74% antimony pentasulfide. The affected men were reported to have been exposed to unspecified large amounts of dust when they filled the mixer by shoveling and emptied it by pouring the mixture into trolleys. A worker's only respiratory protection was a single handkerchief applied over the mouth [16].

Case histories indicated that the workers began to feel ill 1-2 hours after their workshifts began. Vomiting was a usual occurrence. Malaise, nausea, abundant salivation, a pasty metallic taste, and diarrhea were common. Most workers felt better after vomiting [16].

Clinical examination of the men yielded evidence of systemic toxicity [16]. Analysis of the urine samples showed that antimony had reached the circulation. Urinary levels of antimony (determined by the colorimetric method of Maren [101]) ranged from 3 to 21 $\mu\text{g}/100\text{ ml}$ and were virtually unchanged 8 days later [16]. Exactly when the dust exposures were first determined was not stated.

In all the men they studied, Gallina and Luvoni [16] found metamyelocytes in the blood. Metamyelocytes constituted 2-6% of the total white cell count. Monocyte counts tended to be elevated, in one case to 15%. Hemoglobin values were generally found to be 90-100% of normal except for two cases that were 66% and 82%. A decreased percentage of lymphocytes was seen in cases 5 and 6, although case 5 had 14,000 total leukocytes/ml of blood. Gallina and Luvoni suggested that these changes indicated a slight modification in the secondary leukopoiesis under the toxic stimulus of antimony.

The investigators [16] also reported rapid and very evident hepatic involvement. Clinical examination of the six employees exposed to antimony pentasulfide revealed enlarged livers with rounded edges that were painful upon palpation in several cases. Urobilinuria was present in all cases. Hepatic function tests were apparently not conducted, and no evidence of any renal involvement was observed.

Upper respiratory tract irritation was reported in 1966 by Taylor [96] following the exposure of seven men to antimony trichloride fume. Antimony trichloride as a 98% solution in concentrated hydrochloric acid was being used as a chemical catalyst in an unexplained enclosed process in which it was circulated at a high temperature (100 C) and pressure (about 7-14 atmospheres). Such a corrosive mixture occasionally produced leaks in the two nickel alloy reciprocating pumps. The men had complete protective clothing (neoprene suits, boots, gloves, and plastic eye shields or airline helmets), but six of the exposed men had removed the helmets or did not wear respirators, and the seventh had taken no precautions at all. Exposure to the fume ranged from several minutes to 8 hours. Three men were exposed briefly to both fume and spray. Environmental measurements suggested that the workmen were exposed to air containing up to 146 mg/cu m of hydrochloric acid and 73 mg/cu m of antimony. Taylor suggested that the transient (1-2 days) irritation of the upper respiratory tract were due primarily to the HCl vapor. Dyspnea and nasal ulceration were not seen in these workers.

Taylor [96] also noted slightly delayed gastrointestinal symptoms experienced by five of the seven men exposed to the antimony trichloride. Nausea, abdominal pain, and anorexia were the most common complaints; vomiting also occurred. The symptoms were somewhat delayed, usually occurring toward the latter part of the workday or on the following day. Anorexia persisted in one case for 10 days. Because antimony was found in excess of 1.0 mg/liter in the urine of five workers, Taylor concluded that the gastrointestinal symptoms were due to systemic action of antimony, not to local action as a result of ingestion.

Linch and Sigmund [82] attempted in 1976 to measure the health status of workers in a plant that manufactured antimony trioxide. Personal samples taken between 1971 and 1975 indicated antimony dust concentrations in the range of 0.3-56 mg/cu m. Of 61 samples, 59 exceeded 0.5 mg/cu m of antimony.

In the breathing zone samples, 25-40% of the dust was respirable as measured by a cyclone separator.

No acute reactions (ie, dermatitis, eye irritation, or pulmonary, gastrointestinal, or upper respiratory tract effects) were reported in the 37 permanent workers then employed, or in any of the 499 workers employed since the plant began operations 24 years earlier [82]. However, information was not available regarding cause of death or the current health status of most of the 499 former employees. Further, no information was available from medical examinations performed before employment or after it ended. The limited medical records available (140 X-rays and reports for 52 workers) disclosed two cases of arteriosclerotic changes, one case of pericardial calcification, one lung cancer, two heart cases (undefined), and a death from cirrhosis of the liver. The authors [82] did not consider the observed medical episodes unusual in a total work population of that size.

Animal Toxicity

Short- and long-term animal exposures to antimony or antimony compounds have been reported to cause lung damage [9,102-105], myocardial damage [15,17,106,107], liver degeneration [17,102,103], splenic damage [102], and changes in the blood [17,102]. Skin effects following cutaneous contact were not observed in the animals studied [104,108]. LD50's of antimony compounds following oral, intraperitoneal (ip) and subcutaneous (sc) administration are listed in Table III-11.

TABLE III-11
LD50's OF ANTIMONY AND COMPOUNDS

Compound	Species	Route	LD50 mg/kg	Ref. No.
Tartar emetic	Rat	oral	300	[17]
"	"	ip	11	[17]
Antimony trifluoride	Mouse	oral	804	[17]
"	"	sc	22.9	[106]
Antimony	Rat	ip	100	[17]
"	Guinea pig	"	150	[17]
Antimony trisulfide	Rat	"	1,000	[17]
Antimony pentasulfide	"	"	1,500	[17]
Antimony trioxide	"	"	2,250	[17]
Antimony pentoxide	"	"	4,000	[17]

Bradley and Fredrick [17] conducted chronic feeding studies in rats in addition to LD50 tests. The animals were fed daily doses of antimony potassium tartrate and antimony metal up to 100 mg/kg and 1000 mg/kg, respectively, for up to 12 months. No tolerance was found to antimony at any dose level. Antimony potassium tartrate produced consistent and reproducible

injury to the heart, indicated by what was described as an increase in the connective and fibrous tissues of the myocardium. There was a marked variation in the staining of myocardial fibers. These changes were similar to the cardiomyopathies observed in the hearts of the animals surviving the acute tests, which are described later in this section.

Levina and Chekunova [103] investigated the acute and chronic toxic effects of antimony trifluoride. Parallel experiments were conducted with other antimony compounds including antimony trioxide, trisulfide, and pentasulfide. To assess the toxic influence of the fluoride, experiments with sodium fluoride were conducted simultaneously with the antimony studies.

The LD50 for antimony trifluoride following a single sc injection in mice was found to be 22.9 mg/kg [103]. Subcutaneous administration of antimony trioxide, trisulfide, and pentasulfide at 50 mg Sb/kg did not kill the animals or cause any significant toxic effects during the 10-30 days of observation. Doses of 500 mg/kg of antimony trioxide or 100 mg/kg of sodium fluoride killed all the animals.

Levina and Chekunova [103] also reported that single intratracheal administrations to rats of antimony trifluoride, ranging from 2.5 to 20 mg, always resulted in death accompanied by labored breathing and convulsions attributed to asphyxia. Rats survived doses of 1.0-1.5 mg and appeared to be normal again after a severe loss of weight. Introduction of 20 mg of antimony trioxide or trisulfide produced an unspecified weight loss in the treated animals; no other signs of toxicity were reported. Rats survived administration of 5 mg of sodium fluoride in the trachea but not 10 mg. The authors [103] did not give the volume or acidity of the solutions used in these experiments. They noted that antimony trifluoride readily hydrolyzes, producing hydrogen fluoride. The marked local action of antimony trifluoride on lungs (described below) was believed to be due to the formation of the irritant hydrogen fluoride.

Levina and Chekunova also described the results of a 1-month study in which 25 sc injections of antimony trifluoride or trioxide were given to rats, in each case at a dose of 89 μ g Sb/kg. Antimony trifluoride produced a severe local reaction that limited the study to 1 month. Compared with controls, antimony trifluoride produced a significant reduction of weight and, near the end of the month, a tendency toward hyperglycemia. Average blood sugar values expressed in mg/100 ml were 141 \pm 29 for antimony trifluoride, 115 \pm 16 for antimony trioxide, and 92 \pm 4 for controls. No differences were found in oxygen consumption or central nervous system integration, though the tests used were not explained. At the end of the study, the rats were killed and various organs were taken for examination. Weights of the lungs, adrenals, and kidneys as compared with those of controls were significantly increased in the antimony trifluoride-treated animals. Less severe changes were observed in the antimony trioxide-treated animals, described only as vascular distensions and small hemorrhages in parenchymatous organs [103].

Gross et al [108] reviewed their findings in 1955 on the effects of antimony trioxide in rats by several routes of administration. A single oral administration of 2.5 g of antimony trioxide, approximately 16 g/kg of body weight, produced no ill effects. No deviation from controls was observed in growth rate or food consumption during 30 days after oral antimony administration. A single intraperitoneal injection of 200 mg of antimony

trioxide produced some peritoneal adhesions seen at examination 2 months later in all three rats tested. The dust deposits were attached to the peritoneal wall as capsules, confined by a thin connective tissue. One year after the injection, no adhesions and only very small foci of dust deposition were found. No significant alterations were observed in the liver, kidney, spleen, or intestinal walls.

No abnormalities were noted in the organs of rabbits receiving one iv 20-mg dose of antimony trioxide nor in rabbits receiving repeated iv injections totaling 200 mg (53 mg/kg) at 2-day intervals. The animals were observed for up to 1 year. In an extended study, 2% antimony trioxide added to a basal diet caused animals to gain weight at a slower rate than controls. No gross or microscopic abnormalities of organs or tissues were noted after 7.5 months at the end of the feeding experiment [108].

Felicetti et al [109] studied clearance of inhaled trivalent and pentavalent radio-labeled antimony aerosols. In a tartrate complex, ^{124}Sb was used as the tracer. Twenty hamsters were exposed to the trivalent and 34 to the pentavalent aerosols. The median aerodynamic diameters determined from radioactive distribution of both aerosols was $1.6\ \mu\text{m}$; therefore, differences observed in the biologic behavior of the aerosols were attributed to valence state.

Whole-body clearance of both aerosols occurred in two phases; the initial clearance, which was rapid, eliminated 90% of the day 1 body burden by the 7th day after exposure. The average body burden on the first day after exposure for the trivalent and pentavalent aerosols was 65% and 60%, respectively, of that found in animals killed on the day of exposure. This indication of rapid 24-hour clearance was followed by a slower clearance phase during which the remaining antimony was eliminated with a biologic half-life of about 16 days. No statistically significant differences in excretion patterns were observed between the two aerosol groups [109].

Distribution of blood antimony between red blood cells (RBC), and plasma differed with the two valence states. Uptake of trivalent antimony by the RBC was more rapid than with pentavalent antimony, but at 24 hours the ratios of antimony in the RBC to the serum were similar regardless of the valence [109].

Tissue concentration and retention data, corrected for physical decay, indicated the solubility of both aerosols by their rapid loss from the lungs [109]. Two hours after exposure, when the first animals were killed, less than 1% of the body burden of either aerosol remained in the lungs. High gastrointestinal tract content in animals killed early in the experiment probably resulted from considerable upper respiratory tract clearance. Tissue deposition patterns in the two aerosol groups were similar, with greatest antimony concentrations in the liver, skeleton, and pelt. However, a significant difference was the greater deposition of trivalent antimony in the liver. This indicated to the authors [109] that extensive reduction of pentavalent to trivalent antimony had not occurred. Apparently, deposition in the heart did not differ from that in other muscle tissue, because the heart was not discussed. Trivalent antimony was consistently found in higher concentrations in muscle than was pentavalent, but these concentrations were not among the higher levels found.

The degree of uptake of inhaled antimony probably depends on particle size and solubility [104,110]. According to Thomas et al [111], both of these factors can be influenced by the temperature at which antimony aerosols are generated. They [111] found that particles formed at 100 C were more soluble and had a greater aerodynamic diameter (1.6 μ m) than particles generated at 500 C (0.7 μ m) and at 1,000 C (0.3 μ m). It was speculated that the tartrate became an oxide at the two higher temperatures. Larger particles resulted in greater deposition in the upper respiratory tracts of dogs and mice and were cleared more rapidly from the lungs [111].

(a) Effects on the Heart

Death was attributed to myocardial failure in experiments conducted by Bradley and Fredrick [17], reviewed in part earlier (Table III-11). Rats dying a few days after injection showed labored breathing, weight loss, general weakness, hair loss, and evidence of myocardial insufficiency. Myocardial congestion with engorgement of cardiac blood vessels and dilation of the right heart were noted. Experiments with guinea pigs showed similar changes [17].

Microscopic changes in the hearts of animals surviving the LD50 tests were also found by Bradley and Fredrick. They [17] observed a marked variation in the staining of myocardial fibers. Intensely red staining cells showed indistinct fibrillar structures. The changes appeared more numerous in the subendocardial and epicardial zones. A fine stippling of dark staining pigment was present within numerous muscle fibers and was more noticeable in animals receiving antimony metal. In the hearts of the group receiving antimony potassium tartrate there was an increase in "connective and fibrous tissues of the myocardium" [17].

Brieger et al [15], in 1954, exposed rats, rabbits, and dogs to dusts containing concentrations of antimony trisulfide ranging from 3.07 to 5.6 mg/cu m for 7 hours/day, 5 days/week for at least 6 weeks. Most inhaled particles measured 2 μ m or less. Parenchymatous degeneration of the myocardium was found in rats and rabbits. Definite and consistent functional disorders of the heart were manifested by ECG changes, primarily a flattened T wave.

Bromberger-Barnea and Stephens [106] reported in 1965 that antimony sodium and potassium tartrates produced a progressive decrease in myocardial contractile force when injected as a single dose of 10-15 mg/kg body weight into the coronary circulation of isolated canine hearts. This decrease was not reversible. The same dose injected iv was fatal in intact open-chested dogs; death resulted within 120 minutes. ST segment changes were seen in the ECG's of both isolated and intact hearts.

(b) Effects on the Lungs

In 1945, Dernehl et al [102] reported pathologic changes produced in guinea pigs that inhaled antimony trioxide at concentrations averaging 45.4 mg/cu m. Exposures were for 2 hours daily, 7 days/week for the first 3 weeks, and then increased to 3 hours daily. The total hours of exposure ranged from 33 to 609. The authors [102] assumed that the maximal retention was 50%, from which they estimated a theoretical daily retention of 1.6 mg. Of 24 guinea

pigs retaining amounts varying from 13 to 424 mg, all showed extensive pneumonitis; all those retaining 50 mg or more showed scattered subpleural hemorrhages [102].

Lipoid pneumonia developed in rats after inhalation of antimony trioxide for 25 hours/week over 14.5 months, according to a 1952 report by Gross et al [105]. Fifty rats were exposed at 100-125 mg/cu m; particles averaged 0.5 μ m. Antimony trioxide induced cellular proliferation, swelling, and desquamation of alveolar lining cells. Fatty degeneration became increasingly evident in the alveolar macrophages and led to subsequent necrosis and rupture of the cells. Lipids from these cells were demonstrable as sudanophilic droplets and crystals, were soluble in fat solvents, and gave a positive reaction for steroid. The authors [105] stated that pulmonary fibrosis appeared to be secondary to the irritant action of the liberated lipids. The absence of fibrosis in lymph nodes, where antimony was heavily deposited, was considered evidence that antimony did not directly cause pulmonary fibrosis. Similar but less severe lesions were produced after intratracheal injection [105].

Gross et al [104] further studied the effects of antimony trioxide on the lungs and reported the results in 1955. Fifty rats were exposed at concentrations ranging from 100 to 125 mg/cu m for 25 hours/week over 14.5 months. Twenty rabbits were exposed at 89 mg/cu m, 25 hours/week for 10 months. There were numerous spontaneous deaths due to pneumonia, especially among the rabbits. Of the experimental animals, 85% of the rabbits and 18% of the rats died. The difference between species was thought to be due to unlike clearance mechanisms, greater sensitivity of rabbit lung tissue, and the occurrence of more bacterial infections among rabbits. Microscopically, lungs of both species resembled the 1952 findings except there was a more pronounced interstitial pneumonia in rabbits, and less diffuse fibrosis. Lymph node deposits of antimony in rabbits were small and few. Despite considerable antimony trioxide in rat lymph nodes, there was no indication of fibrosis, a finding that Gross et al thought remarkable. Both species exhibited the pneumonitis considered secondary to lipid accumulation [104].

Cooper et al [9], in 1968, presented the results of exposure studies of rats to powdered antimony ore or antimony trioxide at an aerosol concentration of 1,700 mg/cu m. The exposed animals consisted of two groups, each composed of 10 male and 10 female Sprague-Dawley albino rats. Use of control groups was not reported. Animals received from one to six exposures, 1 hour each, every 2 months, for 66 to 311 days with the trioxide and for 66 to 366 days for the powdered ore. Some animals from each group were killed and examined periodically during the experiment. Immediately after exposure to antimony ore, the lungs of some rats exhibited a generalized pulmonary congestion with mild edema, which the investigators [9] thought was the result of an acute chemical pneumonitis. This was predominantly a transitory response and was not seen in the group exposed to the trioxide. Exposure to the trioxide or the ore produced similar effects except for the acute response to the ore. At 66 days after exposure to either antimony compound, dust-laden phagocytes were seen lying free within the alveolar spaces or intermingled with cells of the septa. In some rats there was a tendency for the cells to form small focalized deposits throughout the lung. With subsequent exposures, these focalized deposits became increasingly prominent. The phagocytic response persisted 311 days after trioxide exposure and 366 days after exposure to antimony ore without any appreciable chronic pneumonitis [9].

Levina and Chekunova [103] reported in 1964 that a single dose of 2.5-20 mg of antimony trifluoride in the rat trachea invariably proved to be fatal, with labored breathing and convulsions attributed to asphyxia. Post-mortem examination revealed acute serous or serohemorrhagic edema; the lungs were about three times their normal weight. Only with doses of 1.0-1.5 mg did the rats survive. Pulmonary edema apparently had occurred in the latter rats also, but it was reported that their lung weights had returned to normal after a month. Cellular infiltrations of interalveolar septa, areas of atelectasis, and areas where the bronchial epithelium had separated were evident. It is not clear whether the effects seen in these rats were due to antimony or to fluoride, or were agonal.

The only overt change produced by the introduction of 20 mg of antimony trioxide, trisulfide, or pentasulfide into the trachea was a reduction in animal weight for a few days. At inspection a month after the compounds were given, the lungs exhibited signs of macrophage reaction, collections of lymphoid elements around vessels and bronchi, and atelectatic areas showing accumulations of epithelioid cells [103].

(c) Effects on Blood

Dernehl et al [102] recorded blood changes in six guinea pigs that had inhaled antimony trioxide at concentrations averaging 45.4 mg/cu m. The affected guinea pigs had probably retained at least 293 mg of antimony trioxide in their lungs. White cell counts of the treated animals were lower than in controls. A decrease in polymorphonuclear leukocytes and a relative increase in lymphocytes were the most outstanding feature of the differential cell counts. Red blood cell counts and hemoglobin values remained normal.

The blood of Bradley and Fredrick's [17] rats showed eosinophilia after LD50 doses of all compounds tested but was apparently otherwise normal.

(d) Effects on the Liver, Kidneys, Spleen, and Adrenal Glands

Dernehl et al [102] found that 11 of 15 rats retaining at least 77 mg of antimony trioxide in their lungs had fatty degeneration of the liver. Hyperplasia of the lymph follicles of the spleen was also observed, as were phagocytes filled with antimony trioxide. Fifty percent of the spleens examined showed decreased numbers of polymorphonuclear leukocytes. There was also an abnormal amount of blood pigment in 62% of the spleens examined [102].

During their determinations of ip LD50's of antimony compounds, Bradley and Fredrick [17] found that the livers of nearly all experimental rats showed moderate periportal congestion and in some instances pigmentation by blood. A mild hepatotoxemia was seen, characterized by functional hypertrophy with many of the hepatic cells appearing cloudy with finely reticulated cytoplasm. Numerous plasma cells were found in the liver. In animals given antimony potassium tartrate, there was slight periportal connective tissue increase with capillary congestion and infiltration of a few lymphocytes into the livers. Antimony oxides produced no changes in the spleen, but in animals that received antimony metal or tartrate, there was a slight congestion and a moderate diffuse hyperplasia. Glomerular congestion with coagulated material in the tubules was seen in the kidneys of the animals given antimony metal or tartrate.

Levina and Chekunova [103] found that 25 sc injections (each 15 mg/kg over a 1-month period) of antimony trifluoride produced liver and kidney changes in rats. The liver showed a moderate degree of cloudy swelling, fatty infiltration, and areas of edema. The most marked degenerative changes were seen in the kidneys, including cloudy swelling of the epithelial cells lining the convoluted tubules, nuclear pyknosis, karyolysis and desquamation of epithelium, hemorrhages, protein masses in the lumina of tubules, accumulations of cell elements between tubules, and occasional shriveled glomeruli [103].

Minkina et al [107] investigated the effects of antimony trioxide and lead acetate on the adrenals and on biologic amines in rats and reported the results in 1973. Antimony trioxide was administered sc five times a week for 3 months, for a total dose of 165 mg (1/20 the LD50). No changes were observed after four injections of the antimony compound, but, after 20 injections, a broadening of the cortical layer was found, due primarily to growth of the fascicular and retriulate zones. The cell size in these zones was increased, as were the nucleus diameter and monoamine oxidase activity. The authors [107] indicated that these were signs of increased adrenocortical functional activity, which virtually disappeared after 35 injections and were completely gone after 47 injections. Minkina et al considered this finding an example of what was translated as habituation to a toxin but did not explain the phenomenon.

(e) Effects on Skin and Eyes

Gross et al [108] described the irritant properties of antimony trioxide on rabbits and rats in a 1955 report. Acute tests of the eye and skin were performed, and an extended study investigated the effect of antimony trioxide on the healing of open wounds. The antimony trioxide used in these experiments had an average particle size of 1.3 μ m and contained up to 0.2% arsenic as a contaminant.

The eye irritation tests were conducted by Gross et al in three groups of 10 rabbits each according to the method of Carpenter and Smyth [112]. A 1-ml aqueous suspension, containing 1.50 mg of the dust, was instilled in the right eye of each animal; the left eye served as a control. Examination of the eyes at 1, 2, and 7 days showed no irritative effects of the conjunctiva or the cornea [108].

Cutaneous toxicity tests were conducted in three groups of eight rabbits each [108]. Antimony trioxide dust (2.6 g) was incorporated into an aqueous methyl cellulose paste and applied lightly to about two-thirds of the torso which had been carefully clipped 24 hours earlier. The treated area was covered, and the material held in contact with the skin for 1 week. Gross et al [108] reported no significant local reactions from the single application. Signs of systemic toxicity were not observed, indicating to the authors [108] that absorption through the skin had not taken place. No data on antimony in the blood or excretion of antimony were given.

The effect of antimony trioxide on wound-healing was also investigated [108], though the rationale for this type of experiment was not given. One gram of dry antimony trioxide powder was packed into a 2.5-cm incision on the shaved back of each of 10 rats. A duplicate incision made on the opposite

side that was left undisturbed served as a control. Although the dust-filled wounds tended to heal somewhat slowly, Gross et al believed that the delay was within the limits that could be expected with any nonspecific foreign body.

In another type of wound-healing experiment, Gross et al [108] excised circular areas 1 cm in diameter by electrocautery from the shaved backs of rabbits and rats. Five wounds were made on each animal. The wounds were dusted with 100 mg of antimony trioxide and then covered by a membrane that was cemented to the surrounding skin. The lesions were inspected periodically, and some were totally excised for microscopic examination after 1 week, 2 weeks, or 1 month. According to the authors [108], the wounds healed cleanly and rapidly.

(f) Carcinogenicity, Mutagenicity, Teratogenicity, and Reproductive Effects

Several reports suggestive of potential carcinogenic, mutagenic, or reproductive effects in animals following exposure to antimony have been published. The report of most concern in this section is the 1967 paper by Belyaeva [13], which is the only evidence of adverse effects on reproduction due to antimony exposure.

Animal studies were undertaken following Belyaeva's observations of reproductive disorders among women working at an antimony metallurgical plant (discussed under Epidemiologic Studies). Rats were given single and multiple exposures extending over 60 days to antimony, and their reproductive function, litter size, and weight of offspring were studied.

In the acute experiment, Belyaeva [13] injected antimony metal dust (diameters up to 5 μ m) in a single ip dose of 50 mg/kg to each of 30 female rats. The animals were mated while in estrus, 3-5 days after treatment. Fifteen became pregnant; 8 at the first mating, 5 at the second mating (1 month after treatment), and 2 only after the third mating. Of the 15 rats that failed to conceive, 6 were mated once, 7 twice, and 2 were mated three times. In the control group, only one rat failed to conceive after mating once. The experimental animals that became pregnant produced fewer offspring per animal than controls (5.7 vs 7.8) (see Table III-12).

In the second experiment [13], 24 female rats repeatedly inhaled antimony trioxide dust 4 hours daily for 1.5-2 months, at a concentration of 250 mg/cu m. Procedures for mating were like those used in the acute experiment except that dust exposure continued after mating until 3-5 days before delivery, when the rats were moved to individual cages. Sixteen of the 24 exposed rats conceived. The ten control females all became pregnant.

Table III-12 shows that the number of pups born to antimony-exposed dams was less than that of controls (6.2 vs 8.3). No other differences were noted.

Microscopic studies of 23 rats (from both the single and repeated exposure groups) showed uterine and ovarian changes which, Belyaeva suggested, would tend to interfere with the process of maturation and development of egg cells. The ovarian follicles either lacked ova or contained uncharacteristic ova. Cortical hyperemia of the ovaries and follicular cysts were common, as was metaplasia of the uterus. In some animals, the tubes also showed metaplasia. These effects on the reproductive organs were most clearly seen in the animals

treated ip with metallic antimony. In the rats exposed by inhalation to antimony trioxide, the most notable changes were in the lungs, liver, kidneys, and pancreas; changes in reproductive organs were not as clearly expressed [13].

TABLE III-12
EFFECTS OF ACUTE AND CHRONIC EXPOSURES TO ANTIMONY
ON THE LITTER SIZES AND WEIGHTS OF NEWBORN RATS

Exposure	No. of Females	Mean Weight of Dams (g)	Mean Litter Size	Weight of Infants at Birth (g)	Weight of Infants After 3 Weeks (g)
Single ip Metallic Antimony					
Exposed	30	190.0 \pm 5.2	5.4 \pm 0.2	5.5 \pm 1.1	32 \pm 9.2
Control	12	188.5 \pm 2.5	7.8 \pm 0.5	5.4 \pm 0.5	28.1 \pm 0.4
Repeated Inhalation Antimony Trioxide					
Exposed	24	195.5 \pm 7.2	6.2 \pm 1.0	5.6 \pm 1.2	25.2 \pm 2.8
Control	10	197.8 \pm 14.0	8.3 \pm 0.2	5.5 \pm 1.6	23.5 \pm 3.4

Modified from Belyaeva [13]

The reproductive organs of the treated rats that became pregnant were found to be normal except for some changes among the acutely treated rats. Uterine metaplasia and follicles without egg cells were observed in a few cases. Gross inspection of the placentas and newborns, and microscopic examination of several fetuses showed no morphological changes [13]. Belyaeva concluded from these findings that antimony may adversely influence the condition and function of the reproductive apparatus. The report cannot be regarded as conclusive, however. There was no discussion of vaginal smears; it is unclear how the author [13] determined that mating had occurred. Rates of resorption and fetal death among the experimental and control groups were likewise not discussed. A definitive interpretation of Belyaeva's [13] work is not possible without further evidence.

Casals [113], in a 1972 report, administered a solution of antimony dextran glycoside containing 125 or 250 mg Sb/kg to pregnant rats on five occasions between the 8th and 14th day of gestation. No fetal abnormalities were observed nor could the drug be detected in the six fetuses examined.

Andronikashvili et al [114] investigated the concentration of some heavy metals in nucleic acids in the process of neoplastic growth. In 1974, they [114] reported that RNA and DNA isolated from tumor tissues in rat livers (Sarcoma M-1 and Walker-256 carcinosarcoma) contained considerably greater

amounts of a number of trace elements including antimony than those found in DNA and RNA isolated from the livers of control rats. The role of metals in nucleic acids during normal and neoplastic growth has not been explained, making interpretation of these results difficult [114].

In 1972, Trifonova [115] reported on the distribution of antimony in tumorous rats. Ten rats received grafts of sarcoma-45 tumors; 10 others were controls. All animals received five ip injections of metallic antimony totaling 300 mg/kg suspended in peach oil [115]. Antimony was found to have accumulated in greater concentrations in the lungs of the tumorous rats than in controls. Antimony concentrations in muscles and skin of tumorous rats were also greater than in controls. The spleens and livers of both groups showed small concentrations of antimony. The author [115] did not speculate on the meaning of these results.

The carcinogen 3,4 benzo(a)pyrene, injected simultaneously with antimony into rats, was taken up by the lungs in greater amounts (21%) than in animals treated with benzo(a)pyrene alone, according to Erusalimski and Suspa [116].

Kanisawa and Schroeder [117] reported in 1969 that 76 mice given 5 μ g of antimony potassium tartrate/ml of drinking water throughout their lifetimes showed no increased incidence of tumors or other indications of carcinogenesis. There were 71 control mice.

Correlation of Exposure and Effect

Exposure to antimony and its compounds in the occupational setting has been associated with numerous health problems, including dermatitis and mucous membrane irritation, pneumoconiosis, ECG alterations, hepatic involvement, and hematologic changes. Many of these symptoms have also been described following occupational exposure to arsenic, a common contaminant of antimony ores and antimony compounds used in industry. Confounding exposures have made it difficult to evaluate cause-and-effect relationships. Studies of the effects of therapeutic administration of antimonial drugs are relevant because the antimony given has been considered responsible for heart, hematologic, hepatic, and renal abnormalities in the absence of arsenic contamination.

(a) Effects on the Heart

Two epidemiologic studies have implicated antimony in heart disease and ECG alterations among workers [11,15]. Brieger et al [15] noted eight deaths, attributed to heart disease, following occupational exposure to antimony trisulfide at relatively low airborne concentrations (0.58-5.5 mg/cu m). According to the report, most samples were over 3.0 mg/cu m; however, no information on frequency and duration of sampling was given. In the department where the deaths occurred, 37 of 75 workers showed ECG changes, primarily of the T wave. There was only one death in 16 years preceding the use of antimony trisulfide, and there were no further deaths reported after the use of antimony trisulfide was discontinued.

Following the deaths, Brieger et al [15] exposed rats, rabbits, and dogs to the same dust present in the work environment. Rats and rabbits exposed at 3.07 and 5.6 mg/cu m, respectively, 6 hours/day, 5 days/week for 6 weeks appeared to be normal but showed definite and consistent ECG changes. The T

waves were especially affected. Dogs were exposed at 5.5 mg/cu m 7 hours/day, 5 days/week for 10 weeks; their ECG's were reported to suggest some myocardial injury, but the changes were not specified.

Klucik and Ulrich [11] found abnormal ECG's in workers exposed to antimony trisulfide and trioxide in a metallurgical plant. The ECG changes consisted of T wave depression, borderline normal QT waves, prolongation of atrioventricular and QRS transmission, and changes in the ST segment. All workers with ECG alterations also had symptoms that the authors [11] considered to be indicative of heart problems. The concentrations reported (1.3-237 g Sb/cu m) could have been a result of editorial error, sampling error, or may actually have been accurate measurements of extremely high concentrations. There was also known arsenic contamination.

These two studies [11,15], implicating antimony trisulfide and a mixture of antimony trisulfide and trioxide, are the only evidence of adverse effects on the heart in workers. Cooper et al [9] found no ECG changes in seven workers exposed to antimony trisulfide ore and antimony trioxide, although one case of slight bradycardia was noted. Karajovic [6] did not find ECG alterations among workers exposed to antimony trioxide and pentoxide dust that contained 0.3-0.9% arsenic trioxide. Investigators of other antimony compounds have not reported the measurement of worker ECG's [5,7,10,12,13,16]. In rats, Bradley and Fredrick [17] reported myocardial damage following exposure to antimony metal, antimony potassium tartrate, antimony tri- and pentasulfide, and antimony tri- and pentoxide. Bromberger-Barnea and Stephens [106] reported a progressive decrease in myocardial contractile force in open-chest preparation dogs that ended in death following a single 10-15 mg/kg iv dose of antimony sodium or potassium tartrate.

The evidence needed to characterize the effects of various antimony compounds on the heart is far from complete. A primary problem in these determinations is identifying what, if any, influence is exerted by arsenic. Industrial antimony compounds are generally contaminated with small amounts of arsenic, a substance also associated with myocardial damage and ECG changes [89-93]; thus, it is difficult to ascribe observed ECG changes in antimony workers to antimony itself.

Pharmaceutical grades of antimony, however, contain no significant amounts of arsenic; therefore, effects due to arsenic should not occur following exposure to these compounds. Unfortunately, no data are available on antimony exposures in pharmaceutical workers. However, it is highly significant that patients who received arsenic-free antimony drugs in treatment against parasitic infections [36-45,49-50] showed essentially the same ECG changes as those observed among the antimony workers [11,15], and in animals exposed to antimony compounds [15,17]. The common denominator in all of these situations was antimony.

(b) Effects on the Lungs

Both Renes [5] and Karajovic [6] reported respiratory illnesses accompanying dermatitis and mucous membrane irritation in the worker populations they studied. Renes stated that pneumonitis and bronchitis occurred in workers exposed to antimony trioxide at 0.40-70.7 mg/cu m. Karajovic reported that of 101 men working at an antimony smelter exposed to concentrations of mixed dust totaling 16-248 mg/cu m that included silica with

antimony oxides, 4 had tuberculosis and 22 had emphysema with bronchitis. These symptoms were probably more related to silica than to antimony exposure.

Karajovic conducted X-ray examinations of 62 of the workers, which revealed 14 cases of pneumoconiosis, all without fibrosis. Ventilatory function was normal in three workers, slightly reduced in four, and not tested in the remaining individuals. Antimony oxides, representing the bulk of the dust load, most likely caused the pneumoconiosis, but the cause of the slightly reduced ventilatory function is not clear.

McCallum [12,79] reported 44 cases of pneumoconiosis in 262 workers exposed to antimony trioxide and metal dusts at concentrations reported to exceed 0.5 mg/cu m. The pneumoconiotic workers seemed to be free of symptoms. Microscopic examination of a lung section from a deceased antimony worker showed an accumulation of dust and dust-laden macrophages lying in alveolar septa and perivascular tissues, but there was no fibrosis or inflammation [79]. This finding might be expected in most work situations where large amounts of dust are generated and inhaled.

Cooper et al [9] reported 3 definite and 5 suspicious cases of pneumoconiosis from a group of 28 workers exposed to antimony ore and antimony trioxide in concentrations ranging from 0.08 to 138 mg/cu m, with most exposures under 10 mg/cu m. Unspecified decrements in pulmonary function were observed in 4 of 14 workers tested, which presumably included the workers with pneumoconiosis.

Le Gall [7] reported pneumoconiosis in 10 of 40 workers exposed to 0.3-14.7 mg/cu m containing antimony metal and trioxide. Airborne silica and sulfur dioxide were also present. X-ray examinations showed moderate, dense reticulo-nodular formations scattered throughout the pulmonary fields. Shortness of breath, coughing, some expectoration, prolonged expiration, and sparse adventitious sounds were noted. Antimony dust was probably responsible for the pneumoconioses, though silica cannot be disregarded. One affected employee had worked only at the oxide furnace, where antimony exposure could be assumed to be high and silica exposure low or nonexistent [7].

Animal experiments have resulted in lung changes similar to those described in workers. Dernehl et al [102] found pneumonitis in guinea pigs exposed to antimony trioxide at concentrations averaging 45 mg/cu m for 33-609 hours. In addition, subpleural hemorrhages were seen with the heavier exposures. Lipoid pneumonia and pulmonary fibrosis were reported by Gross et al [105] in rats repeatedly exposed to antimony trioxide at 100-125 mg/cu m. Fibrosis has not been reported in humans following levels of exposure common to the occupational environment.

In describing the effects of high (1,700 mg/cu m) intermittent exposure to antimony trioxide or antimony ore on the lungs of rats, Cooper et al [9] noted dust-laden phagocytes lying free within the alveolar spaces or intermingled with cells of the septa. In some rats, the phagocytes formed focalized deposits throughout the lungs. These observations are similar to those of McCallum [79], who described the lungs of a deceased antimony worker. Macrophage reaction in rats was also noted by Levina and Chekunova [103] following intratracheal administration of 20 mg of antimony trioxide, trisulfide, or pentasulfide. Animal studies have not addressed the issue of

pulmonary function impairment, but the decrements noted in humans by several investigators [6,7,9] may suggest functional impairment of the lungs as a result of antimony exposure.

(c) Skin and Mucous Membrane Effects

Dermatitis and mucous membrane irritation are two prevalent complaints of antimony workers; arsenic, however, produces the same effects [87-89]. One author [81] considered arsenic wholly responsible for the observed skin condition. Opinions have differed as to whether the dermatitis was an allergic response [77] or due to local irritation [78,81].

Renes [5] recorded the full range of skin and mucous membrane effects among smelter workers exposed to antimony (0.40-70.7 mg/cu m) with concomitant exposure to arsenic (0.02-4.66 mg/cu m). Twenty percent of the workers had dermatitis, which was usually found in sweaty, hairy, friction areas of the body. Most cases occurred during a 1-week period of heavy exposure (LE Renes, written communication, March 1978). Numerous cases of irritation of the conjunctival, nasal, and respiratory mucous membranes, and ulceration of the nasal septum and larynx were also seen. Renes noted that many common early signs of arsenic intoxication were not present in these workers [5].

Karajovic [6], like Renes, described respiratory tract irritation, conjunctivitis, ulcerated nasal septa, and dermatitis in antimony smelter workers. The dermatitis was more prevalent during the summer months. Of 16 workers with skin problems, 13 worked at the blast furnaces in hot temperatures with resulting perspiration.

Stevenson [78] also pointed out the importance of heat in the occurrence of the dermatitis. Two furnacemen who worked with one side of their bodies next to heat had lesions only on that side. The major site of irritation in other workers was the antecubital area of the forearms where rubbing and perspiration occurred. Patch tests using dry antimony trioxide or antimony trioxide suspended in water produced no positive reactions. These findings are compatible with those of Thivolet et al [81], who observed that dermatitis was produced in patch tests with scarification, but not without scarification. Skin tests on rats and rabbits by Gross et al [108] showed no effects.

Microscopic examination of the lesions studied by Stevenson [78] showed them to be adjacent to sweat ducts. Stevenson noted that antimony trioxide is slightly soluble in water, but soluble in lactic acid, which is present in sweat in increased amounts following heavy exercise. He believed the dermatitis resulted from antimony penetrating the sweat ducts and causing local irritation of the underlying dermal tissues.

Although Paschoud [77] regarded the dermatitides as allergic, the local irritant response appears to be a more reasonable conclusion. The observed irritant effects appear to be attributable to antimony, even though arsenic may have been a factor.

(d) Effects on Blood

Exposure to antimony has been associated with blood profile alterations. Gallina and Luvoni [16] found evidence of slightly abnormal leukopoiesis in all six workers they studied who were exposed to antimony pentasulfide.

Metamyelocytes were present as 2-6% of the differential white cell counts, and monocytes were also elevated.

Thrombocytopenia and lymphocytosis in type foundry workers were noted by Seitz [24], and one case of slight anisocytosis in a worker exposed to antimony trioxide was reported by Oliver [10]. These two reports are more than 40 years old and probably represent high exposures.

Lowered white cell counts, a decrease in polymorphonuclear leukocytes, and lymphocytosis were found in guinea pigs following very heavy exposure to antimony trioxide (such that at least 293 mg was retained in the lungs), according to Dernehl et al [102]. Bradley and Fredrick [17] reported eosinophilia in rats that had received the LD50 dose of antimony.

Severe hemolysis occurred in three metal refinery workers exposed to a gaseous mixture containing unspecified high concentrations of stibine, arsine, and hydrogen sulfide, according to Nau et al [97].

Antimony therapy for schistosomiasis, which has involved very high therapeutic doses of antimony, has been linked to hemolytic anemia, thrombocytopenic purpura, and eosinophilia [56-58]. These cases are rare. It is significant that all human and animal blood changes that have followed exposure to antimony have involved extreme levels of exposure that would be unusual in the workplace.

(e) Hepatic Effects

Gallina and Luvoni [16] reported hepatic involvement in six workers exposed to a coloring mixture containing 1.04-1.74% antimony pentasulfide. The livers were enlarged in all cases and painful upon palpation in some. Urobilinuria was present in all six workers. Karajovic [6], however, noted a lack of liver symptoms among smelter workers. Antimony has not been implicated in liver involvement by other authors.

In animals, fatty degeneration of the liver was demonstrated by Dernehl et al [102] in rats retaining 77 mg or more of antimony trioxide. Bradley and Fredrick [17] found that the livers of nearly all LD50 experimental rats showed moderate periportal congestion. There was functional hypertrophy, with many hepatic cells appearing cloudy with finely reticulated cytoplasm. Plasma cells were found in the liver.

Elevated liver enzymes, SGOT and SGPT, in patients receiving antimony drugs [44,57,61,62] indicate that antimony may adversely affect the liver at therapeutic doses. Elevated SGOT and SGPT, however, may also indicate damage to the heart. ECG alteration was not correlated with SGOT elevations by Waye et al, indicating to them [44] that SGOT was a measure only of hepatic damage during antimony treatment. It was noted, however, that more frequent SGOT determinations might have revealed a higher incidence of SGOT elevation in patients showing ECG alterations [44]. Consequently, the effect of antimony on the liver remains unclear.

(f) Gastrointestinal Effects

Gastrointestinal effects related to occupational antimony exposure have not received extensive investigation, but have been mentioned in several

studies. Brieger et al [15] recorded a higher incidence of gastrointestinal ulcers in workers exposed at 0.58-5.5 mg antimony trisulfide/cu m than in unexposed workers. Renes [5] considered abdominal cramps, diarrhea, vomiting, dizziness, nerve tingling, and severe headaches to be systemic effects resulting from heavy exposure to antimony smelter fumes.

Gallina and Luvoni [16] noted malaise, nausea, frequent vomiting, abundant salivation, a pasty metallic taste, and diarrhea in six workers exposed to a mixture containing 1.04-1.74% antimony pentasulfide. The disturbances began 15-20 days after the introduction of the mixture and were thought to be systemic [16].

Gastrointestinal symptoms noted by Taylor [96] were also considered to be of systemic origin. Five of seven men exposed to high concentrations of antimony metal (up to 73 mg/cu m) and hydrochloric acid (up to 146 mg/cu m) experienced nausea, vomiting, abdominal pain, and anorexia. Because antimony in urine of five workers exceeded 1.0 mg/liter, and because the symptoms persisted for up to 10 days, systemic action is more probable than local irritant effects arising from ingestion of the chemical. The same symptoms have been observed following parenteral administration of antimony drugs [35,37,43,47,56,58].

Carcinogenicity, Mutagenicity, Teratogenicity, and Effects on Reproduction

Firm conclusions cannot be drawn from the Davies [14] report suggesting an increased tendency to contract lung cancer in antimony workers. A retrospective survey was undertaken in 1962 following the lung cancer death of an antimony worker and the subsequent discovery of seven other lung cancer deaths among antimony workers in the preceding 8 years. Of 1,081 people formerly employed at the factory in question, 56 were known to be dead. Ten of these deaths were ascribed to lung cancer; 8 were to be expected from local mortality rates. Nine of the ten lung cancer deaths occurred among the factory subgroup engaged in smelting or related activities; 5.7 lung cancer deaths were to be expected in this group.

Recent followup information (KP Duncan, written communication, July 1978) again showed a disparity between observed and expected deaths due to lung cancer in the antimony factory population (21 vs 14.03), most of which occurred in the factory subgroup engaged in smelting and related activities (18 vs 10.25). The difference was especially prominent in workers 45-64 years old (13 vs 7.22). The absence of pertinent information, including community and factory population descriptions, data analysis, and environmental, blood, and urine antimony concentrations make it impossible to accept the findings without further scientific evaluation and confirmation.

Erusalimski and Suspa [116] reported that when the carcinogen 3,4 benzo(a)pyrene was injected simultaneously with antimony into rats, it was taken up by the lungs in greater amounts than in animals treated with benzo(a)pyrene alone.

Kanisawa and Schroeder [117] reported no increase in the incidence of tumors in mice given 5 µg antimony potassium tartrate/ml of drinking water throughout their lifetimes. Further animal studies to evaluate the cancer potential of antimony are in progress under a NIOSH contract.

Evidence of effects of antimony on reproduction is confined to a single report by Belyaeva [13]. A group of 318 antimony-exposed female workers was stated to have had higher incidences than controls of late-occurring spontaneous abortions (12.5% vs 4.1%), premature births (3.4% vs 1.2%), and gynecologic problems (77.5% vs 56%), which included menstrual cycle disorders, inflammatory disease, and other diseases of the reproductive apparatus. Inflammatory disease was the only category in which there were more cases among controls than exposed women, an unexplained finding. Exactly what constituted a menstrual cycle disorder was not stated.

The antimony workers studied by Belyaeva were exposed to mixed dusts of antimony metal, trioxide, and pentasulfide. Exposure duration and concentrations were not given, but concentrations of antimony in the blood of the exposed workers ranged from 0.5 to 20.0 mg/100 ml, and, in the urine, from 0.5 to 18.2 mg/100 ml [13]. These levels are probably common among antimony workers.

Antimony was also found in the breast milk, placental tissue, amniotic fluid, and umbilical cord blood of the exposed group, indicating the presence of antimony in the developing fetus, as well as in the mother [13]. Belyaeva noted that antimony affected the taste of breast milk, a possible explanation for differences in mean weight of babies in control and exposed groups at 1 year of age, assuming that breastfeeding was practiced. There was no followup of the children to ascertain trends in weight gain after the period of breastfeeding.

Belyaeva's [13] animal studies supported the findings of human reproductive effects due to antimony. Rats given metallic antimony in a single ip dose of 50 mg/kg showed decreased ability to conceive, produced fewer offspring, and showed microscopic uterine and ovarian changes that were believed to complicate normal development of ova. Rats repeatedly exposed by inhalation to antimony trioxide at 250 mg/cu m produced fewer offspring than controls, but no clearly expressed changes were seen in the reproductive organs. The offspring of treated rats were unaffected.

The high control figures reported by Belyaeva [13] for the category of gynecologic problems were unexplained. Reproductive effects ascribed to antimony have apparently not been studied by other investigators and need to be confirmed. Casals [113] reported that no antimony was detected in rat fetuses whose mothers had received im antimony dextran glycoside during gestation; these results tend to conflict with those of Belyaeva. However, Bradley and Fredrick [17] noted frequent abortions in rabbits given repeated high oral doses of metallic antimony.

Summary Tables of Exposure and Effect

The effects of short- and long-term exposures to antimony on humans and animals, presented in Chapter III, are summarized in Tables III-13, III-14, and III-15. Human data appear in Tables III-13 and III-14 and animal toxicity data are listed in Table III-15.

TABLE III-13

EFFECTS OF OCCUPATIONAL EXPOSURE TO ANTIMONY

Compound and Ref. No.	Concentration mg/cu m (particle size)	Duration	Sb in Urine, mg/l	Effects
<u>Inhalation</u>				
Antimony trisulfide [15]	0.58-5.5	8-24 mo	0.8-9.6	ECG changes, cardiac deaths, ulcers
Antimony pentasulfide [16]	NR*	15-20 d	.03-.24	GI upset, hepatic involvement, blood profile alterations
Antimony trisulfide and antimony trioxide [11]	1.3-237 g/cu m (sic)	NR	NR	ECG changes, hard breathing, weakness, sweating, cough, chest pain
Antimony trisulfide, metal, and trioxide [13]	NR	NR	5-182	Female reproductive problems, infant weight gain lower than normal
Antimony trioxide [5]	0.40-70.7 (most <1 μ m)	<6 mo	Trace- 600	Skin and mucous membrane irritation, respiratory illness, GI disturbance
Antimony trioxide and pentoxide, arsenic trioxide (also silicon) [6]	16-248 for antimony (most <0.5 μ m)	NR	.025	Skin and mucous membrane irritation, tuberculosis
Antimony trioxide and antimony metal [12]	<0.5 (<1 μ m)	NR	.425-.68	Pneumoconiosis, skin irritation

TABLE III-13 (CONTINUED)

EFFECTS OF OCCUPATIONAL EXPOSURE TO ANTIMONY

Compound and Ref. No.	Concentration mg/cu m (particle size)	Duration	Sb in Urine, mg/l	Effects
<u>Inhalation</u>				
Antimony trioxide, antimony ore [9]	0.081-138	1-15 yr	.007-1.02; most .07-.8	Pneumoconiosis
Antimony trioxide [8]	NR (<1 μ m)	.5-35 yr	NR	"
Antimony oxide (also silica, SO ₂) [7]	0.3-14.7 (most <3 μ m)	NR	Undetected	"
Antimony trioxide [14]	NR	NR	NR	Possible increased risk of lung cancer
" [10]	NR	2-13 yr	Undetected	Mild dermatitis, slight anisocytosis
" [82]	0.3-56 (0.57-1.46 μ m)	NR	.052-1.02	No effects
Antimony trichloride and HCl [96]	73 146	Several min-8 hr	>1	Respiratory tract irritation, gastro- intestinal symptoms
<u>Skin Contact With Liquid</u>				
Antimony pentachloride [95]	-	One-time	NR	2nd and 3rd degree burns, respiratory distress

*NR-Not reported

TABLE III-14

EXPERIMENTAL AND THERAPEUTIC EFFECTS OF ANTIMONY ON HUMANS

Compound and Ref. No.	Dose, mg	Duration	Effects
<u>Experimental Patch Tests</u>			
Antimony trioxide (arsenic contaminant) [77]	-	-	Dermatitis
" [81]	-	-	Dermatitis with scarification, none without
Antimony trioxide (0.29% arsenic) [82]	-	-	No effects
<u>Therapeutic</u>			
Antimony potassium tartrate [50]	Therapeutic dose	-	Death, liver damage
Antimony tartrate (K or Na) [37]	522-913	10-41 d	ECG changes
Antimony tartrate (K or Na) stibophen, or anthiolimine [64-66]	Therapeutic dose	-	Rise of Herpes zoster infections
Antimony sodium tartrate [56]	"	-	Hemolytic anemia
" [58]	"	-	Thrombocytopenic purpura
Antimony dimercaptosuccinate [57]	"	-	Eosinophilia, elevated SGOT, ECG alteration
n-Methyl glucamine antimonate [63]	"	-	Nephritis
Trivalent organic antimony [52]	214-510 iv	2-9 d	ECG changes
Pentavalent organic antimony [52]	4,950-19,350 iv	5-10 d	No ECG changes

TABLE III-15
EFFECTS OF ANTIMONY ON ANIMALS

Compound	Species	Dose or Exposure	Effects	Ref. No.
Antimony potassium tartrate	Rat	11 mg/kg	All LD50's, myocardial failure, liver damage, eosinophilia, splenic changes with metal and tartrate	[17]
Antimony metal		100 mg/kg		
Antimony trisulfide		1000 mg/kg		
Antimony pentasulfide		1500 mg/kg		
Antimony trioxide		3250 mg/kg		
Antimony pentoxide		4000 mg/kg		
Antimony potassium tartrate	"	Single sublethal ip dose	Chronic heart changes, liver damage with tartrate	[17]
Antimony metal				
Antimony trisulfide				
Antimony pentasulfide				
Antimony trioxide				
Antimony pentoxide				
Antimony sodium or potassium tartrate	Dog	10-15 mg/kg single iv dose	Progressive decrease in myocardial contractile force, then death	[106]
Antimony potassium tartrate	Mouse	5 µg/ml drinking water for lifetime	No increase in incidence of tumors	[117]
Antimony trisulfide	Rat, dog, rabbit	3.07-5.6 mg/cu m 7 hr/d, 5 d/wk, for 6 wk	Heart disorders in rats and rabbits	[15]
Metallic antimony	Rat	50 mg/kg single ip dose	Failure to conceive, fewer offspring, changes in reproductive organs in females	[13]
"	"	5 cc single intratracheal dose	Increased uptake of carcinogen 3,4 benzo-a-pyrene in lungs	[116]
"	"	5 ip injections totaling 300 mg/kg	Higher antimony levels in blood, lungs, muscles, and skin of tumorous rats than in controls	[115]

TABLE III-15 (CONTINUED)
EFFECTS OF ANTIMONY ON ANIMALS

Compound	Species	Dose or Exposure	Effects	Ref. No.
Metallic antimony	Rabbit	5-55 mg orally every other day for 30, 60, 90 d Larger doses	No effects Frequent abortions	[17]
Antimony trifluoride	Rat	2.5-20 mg single intratracheal dose	Labored breathing, convulsions, death	[103]
"	"	1.0-1.5 mg single intratracheal dose	Lung edema	[103]
"	"	15 mg/kg 25 sc doses over 1 mo	Liver, kidney damage	[103]
Antimony trioxide or trisulfide	Rat	20-mg single intratracheal dose	Weight reduction, macrophage reaction	[103]
Antimony trioxide	Guinea pig	av 45.4 mg/cu m 33-609 hr	Pneumonitis, sub-pleural hemorrhage	[102]
"	"	av 45.4 mg/cu m 138-609 hr	Liver degeneration, splenic damage, blood profile alterations	[102]
"	Rat	100-125 mg/cu m 25 hr/wk 14.5 mo	Lipoid pneumonia	[105]
Antimony ore	"	1,700 mg/cu m 1 hr/2 mo over 66-366 d	Acute pulmonary congestion, phagocytic response	[9]
Antimony trioxide	"	1,700 mg/cu m 1 hr/2 mo over 66-311 d	"	[9]
"	"	165 mg sc 5 times/wk over 3 mo	Habituating effect on adrenals and biologic amines, biochemical imbalance in liver and brain	[107]
"	"	250 mg/cu m 4 hr/d 7 d/wk, 1.5-2 mo	Fewer offspring, lung, liver, kidney and pancreatic changes	[13]

TABLE III-15 (CONTINUED)
EFFECTS OF ANTIMONY ON ANIMALS

Compound	Species	Dose or Exposure	Effects	Ref. No.
Antimony trioxide <2% arsenic	Rabbit	1.5 mg/d to eyes for 1, 2, or 7 d	No effects	[108]
"	"	25 g to skin for 1 wk	"	[108]
"	Rat	1 g into wound	Healed slowly	[108]
"	Rat, Rabbit	100 mg on wound for 1, 2, or 4 wk	No effects	[108]
Antimony dextran glycoside	Rat	125 or 250 mg/kg of mother's weight im 5 times between days 8 and 14 of gestation	No fetal abnormali- ties, no antimony detected in fetuses	[113]

IV. ENVIRONMENTAL DATA

Environmental Concentrations

In studying pneumoconiosis among smelter workers exposed to antimony trioxide, Cooper et al [9] found especially high concentrations at the bagging operations, where 138 mg antimony/cu m was measured. At ten other locations, concentrations ranged from 11 to 75 mg/cu m. At thirteen more locations, measurements ranged from 1.0 to 9.8 mg/cu m. A range of 0.081 to 0.95 was found at thirteen additional locations. No further specifications of these areas or the methods used in attaining the measurements were given.

McCallum [12] found the highest airborne antimony concentration in a smelter to occur during the tapping operation at the metal furnace. Duplicate samples of 1-2 cubic feet of air taken at breathing level on several days over 3 weeks revealed that the antimony concentration reached 36.70 mg/cu m during this brief operation. The workplace air concentrations of antimony at 19 other sample sites ranged from 0.53 to 5.34 mg/cu m. The analytical method and flowrate used were not given.

Renes [5] collected air samples in another smelter with an electrostatic precipitator except for the first 17 samples, which were obtained with the Greenberg-Smith impinger apparatus. Aliquots of each sample were analyzed chemically and spectroscopically. Results of these two methods did not vary by more than 2%. The average antimony concentration in the electric furnace zone was 10.1 mg/cu m before corrective measures had been instituted, and 4.7 mg/cu m after these improvements. The average antimony concentration in the cupel zone measured 11.8 mg/cu m before, and 8.2 mg/cu m after the changes. Before and after electric furnace zone average concentrations of arsenic were 1.10 mg/cu m and 0.8 mg/cu m, respectively. Cupel zone average arsenic levels were 0.4 mg/cu m both before and after changes. The zones had been established by what appeared to be a reasonable division after studying the smelting processes and the workers' medical situation. More of Renes's [5] sampling data are presented in Tables III-6, III-7, and III-8.

Okawa [118] evaluated health hazards due to lead and antimony exposure in a plant that rebuilt internal combustion engines of all types. Operations included all phases of rebuilding, from tearing down old engines to touchup painting of newly rebuilt engines. Worker exposures to lead and antimony were measured with personal air sampling equipment. All samples were taken with MSA Model G personal sampling pumps attached to Millipore cellulose membrane filters with 0.45- μ m pores. The sampling rate was 1.8 liters/minute, and the sampling times ranged from 1.5 to 2.75 hours per sample.

A total of six samples were collected on five workers: the lead pot assembler, two engine assemblers, a crankshaft grinder, and a valve grinder. Only two samples showed detectable concentrations of lead (above 0.006 mg/cu m); 0.18 mg/cu m was found in one of two samples taken on the lead pot assembler, and 0.10 mg/cu m was found in the valve grinder's sample. Antimony levels in all six samples were below the limits of detection (0.02 mg/cu m) for the method used.

Two other health hazard evaluations [119,120] demonstrated no detectable exposures to antimony. Gunter and Nelson [119] evaluated a plant that

prepared camouflage netting for use by the military. Before the netting was received at this plant, it was treated with antimildew agents containing lead, chromium, antimony, and tin. The process in question included unpacking the netting, cutting it to specification, sewing an edge on the netting, and folding, repacking, and shipping it out again. Eight-hour breathing zone samples taken on 25 workers were collected on AA filters using MSA Model G pumps operating at 1.5 liters/minute. Lead, chromium, antimony, and tin were analyzed by atomic absorption spectroscopy. All samples were below laboratory detection limits.

Moseley [120] evaluated the machinists' area/composing room of a large newspaper. The area was ventilated by a blower for air conditioning and heating with three ceiling exhaust vents. The source of antimony exposure was 8-9% antimony content of molten lead being cast into pigs used for spacing. Area samples were collected on 37-mm cellulose membrane filters with a Model G MSA vacuum pump operated at 2 liters/minute and analyzed by atomic absorption spectrometry. In all samples, antimony concentrations were below the limits of detection for the method used.

In an industry-wide study of the antimony industry, Donaldson and Cassady [121] monitored air levels of three major antimony producers. All three plants produced antimony oxide, but exposures were different in several respects. Two producers, Plants B and C, roasted antimony sulfide ore in rotary kiln-type furnaces to produce antimony oxide. Plant A oxidized antimony metal with air to form antimony oxide. Plant A was the only plant that produced antimony metal in addition to the oxide. Plant B manufactured several other chemicals besides antimony oxide. Plant B workers were exposed to soluble nickel, cadmium, and chromium as well as to antimony, arsenic, and sulfur dioxide, which were present in all the plants.

Personal samples were collected in the three plants [121]. The pumps worn by each worker during his shift (6-7 hours) operated at 2.0 liters/minute and collected dust on a 37-mm mixed cellulose ester membrane filters with 0.8- μ m pores. General area sampling was also done. Analyses for both antimony and arsenic were performed by atomic absorption. Sulfur dioxide concentrations were estimated with detector tubes.

Results indicated that antimony concentrations in general area samples from all three plants ranged from 0.01 to 5.6 mg/cu m; breathing zone concentrations of antimony were 0.05-8.7 mg/cu m [121]. Arsenic concentrations found in the general area samples from the three plants ranged from nondetectable to 3.4 μ g/cu m. Breathing zone concentrations of arsenic plants ranged from nondetectable to 87.0 μ g/cu m. Sampling data from all plants are given in Tables IV-1 to IV-5. Essentially no sulfur dioxide was found in the plants except during upset furnace conditions at Plant A.

TABLE IV-1

PLANT A
GENERAL AREA SAMPLE RESULTS, APRIL 1975

Location	Total Time (min)	Sb (mg/cu m)	As (mg/cu m)
Blast furnace	454	0.11	0.007
Slag tapping-blast furnace	454	0.26	0.0012
"	455	1.14	0.0024
Doubling furnace No. 2	451	1.13	0.0027
Starring furnace No. 1	458	1.12	0.0034
Starring furnace No. 2	457	0.52	0.0021
Casting area	453	2.02	0.0040
Warehouse	451	0.61	0.0018
Burner end of No. 1 starring furnace	437	1.24	0.0029
Oxide furnace	436	0.14	0.0011
Charge scale	417	0.36	0.0014
Change room	432	0.54	0.0006

Adapted from Donaldson and Cassady [121]

TABLE IV-2

PLANT A
SUMMARY OF RESULTS OF AREA SAMPLING FOR ANTIMONY AND ARSENIC
BY PLANT OPERATION, MARCH 1976

Operation	No. of Samples	Sb			As		
		Range mg/cu m	Mean mg/cu m	SD	Range mg/cu m	Mean mg/cu m	SD
Oxide manufacture	6	0.09-3.07	2.23	1.11	0.008-0.37*	0.022	0.011
Doubles furnace	4	0.89-2.10	1.45	0.50	0.002-0.010	0.006	0.004
Singles furnace	4	0.41-1.83	1.27	0.63	0.005-0.013	0.009	0.003
Maintenance	9	0.09-6.21	0.94	2.00	0.001-0.018	0.005	0.007
Laborers	22	0.09-4.91	1.26	1.08	0.001-0.041	0.009	0.010
Miscellaneous	6	0.05-3.74	1.11	1.35	0.001-0.047	0.010	0.020

*One arsenic value of 0.160 mg/cu m believed to be in error was dropped before calculating the mean.

Adapted from Donaldson and Cassady [121]

TABLE IV-3

PLANT A
PERSONAL AIR SAMPLE RESULTS, MARCH 1976

Operation/ Occupation	Total Time (min)	Sb (mg/cu m)	As (mg/cu m)
<u>Oxide</u>			
Furnace operator	455	0.090	0.008
"	464	2.980	0.022
"	460	3.070	0.037
"	471	2.010	0.017
Packer	457	2.590	0.160
"	470	2.610	0.024
<u>Singles Furnace</u>			
Tapper	505	1.62	0.005
"	480	1.22	0.008
"	466	0.41	0.010
Conveyor operator	460	1.83	0.013
<u>Doubles Furnace</u>			
Furnace operator	401	1.30	0.002
"	456	0.89	0.003
"	437	2.10	0.010
Furnace helper	455	1.52	0.007
<u>Maintenance</u>			
Blacksmith	431	0.15	0.001
Maint. man--shop	480	0.11	0.001
Mechanic	447	0.09	0.001
Mechanic shop	440	0.09	0.002
Maint. welder	447	0.09	0.002
Bricklayer	458	0.70	0.002
"	470	6.21	0.017
"	442	0.20	0.002
Laborer	440	0.09	0.001
"	448	1.63	0.013
"	451	1.92	0.009
"	477	0.94	0.002
"	485	1.34	0.041
"	482	0.38	0.004
"	457	1.61	0.013
"	466	0.67	0.005
"	487	1.07	0.005
"	454	1.600	0.009
"	456	0.230	0.003
"	468	0.980	0.007
"	461	0.120	0.001
"	427	0.140	0.001

TABLE IV-3 (CONTINUED)

PLANT A
PERSONAL AIR SAMPLE RESULTS, MARCH 1976

Operation/ Occupation	Total Time (min)	Sb (mg/cu m)	As (mg/cu m)
Laborer	453	1.240	0.008
"	454	1.880	0.010
"	458	2.100	0.029
"	443	0.470	0.002
"	439	1.640	0.011
"	441	4.910	0.025
"	459	1.530	0.009
"	450	1.230	0.004
Sweeper--yard	458	3.740	0.047
Fork lift operator	464	0.580	0.002
Gardener	443	0.050	0.001
Scale operator	459	1.210	0.009
Warehouse operator	455	0.460	0.003
"	452	0.500	0.003
Other	225	0.69	0.002
"	360	1.92	0.008
Oxide furnace operator	428	10.86	0.089
Laborer	456	10.24	0.044

Adapted from Donaldson and Cassady [121]

TABLE IV-4

PLANT B
AIR SAMPLING RESULTS, APRIL 1975

Job Description and Area	Type of Sample	Concentration		
		Antimony	Arsenic	Nickel
Furnace operator	Breathing zone	1.25	0.039	--
"	"	3.25	<0.035	--
"	"	0.21	<0.035	--
"	"	1.20	<0.035	--
"	"	0.78	<0.035	--
"	General air	0.28	<0.035	--
"	"	0.01	<0.035	0.018
"	"	0.43	<0.035	--
"	"	0.83	<0.035	--

Adapted from Donaldson and Cassady [121]

TABLE IV-5

PLANT C
GENERAL AIR AND PERSONAL SAMPLES, JUNE 1975

Location	Total Time (min)	Sb (mg/cu m)	As (mg/cu m)	Type of Sample
Operator--new system	420	2.7	0.0169	Personal
Operator--miscellaneous	420	5.0	0.0267	"
Bagging & No. 4 man	420	8.7	0.0560	"
Ore dumper (Wore air hood; Sampler not under hood)	420	4.5	0.0155	"
Top of coders	400	5.6	0.0061	General
At bagging station	405	2.3	0.0143	"
At ore hopper--operator wore air-supplied hood to dump ore	405	2.8	0.0092	"
Ore feed, second level outside	410	1.8	0.0017	"
On I-beam over bagging operation	390	2.6	0.0162	"
At control panel	390	1.9	0.0105	"
At operator's desk	400	2.9	0.0147	"
Feed oxide, out-of-doors, 2nd deck	405	5.3	0.0057	"

Adapted from Donaldson and Cassady [121]

Sampling and Analytical Methods for Antimony in Air

(a) Sampling Methods for Particulate Antimony

Although impinger and electrostatic precipitation methods have been used to sample antimony-containing aerosols [122,123], collection on filters is more appropriate for personal sampling [124]. Reasons for filter preference include ease and convenience of use, less interference with work operations, and less chance for spillage. The collection efficiency of Millipore Type AA 37-mm diameter filters for antimony potassium tartrate aerosol (1.08 mg Sb/cu m), sampled at 1.5 liters/minute, was found to be 99.7% [125].

The antimony content of blank filters has been reported by several authors. Some glass fiber filters have been found to contain relatively large amounts of antimony, up to 0.23 μg Sb/sq cm, or approximately 2.3 μg Sb on a 37-mm filter [126]. Such high blank values indicate that these filters are not acceptable for personal sampling, where as little as 1 μg Sb may be collected. Cellulose-mixed ester membrane filters were found by neutron activation analysis to have only 0.00024 μg Sb/sq cm (about 0.0024 μg on a 37-mm filter) [127]. Cellulose acetate membrane filters were reported to contain 0.000013 μg Sb/sq cm, or about 0.0013 μg on a 37-mm filter [128]. Polystyrene

filters used for area sampling were found to have blank values of 0.00018 μg Sb/sq cm, or about 0.0018 μg per filter [128], and less than 0.001 μg Sb/sq cm (0.01 μg per filter) [129,130].

(b) Sampling Methods for Vapors

Volatile antimony compounds include some of the halides, which either are soluble or decompose in water [131]. No reference to sampling methods for these compounds was found in the literature. The sampling method recommended for volatile antimony compounds uses a midget impinger containing 5% mercuric chloride in 6N hydrochloric acid. This will not distinguish individual volatile and particulate antimony compounds.

(c) Analytical Methods

Early analytical methods for antimony were based on reduction of antimony solutions by zinc, with evolution of stibine. The antimony deposited after pyrolysis of the stibine was determined gravimetrically [132] or colorimetrically [69]. The detection limits were 1-10 μg of antimony.

A number of wet chemical methods are available for the determination of milligram quantities of antimony in various alloys [133], but most are not sensitive enough for levels found in industrial hygiene work.

Fredrick described a sensitive colorimetric method for antimony based on rhodamine B in 1941 [99]. The detection limit demonstrated for standard solutions was 0.1- μg of antimony/5 ml of solution. Although Fredrick [99] realized the potential application of the method in industrial hygiene, sample handling procedures were not considered. In 1945, an improved method involving extraction of the metal-dye complex was described by Webster and Fairhall [134], and wet-ashing methods for determination of antimony in biologic samples were developed by Maren [101].

Results of a collaborative test on a rhodamine B method were reported in 1964 by the American Conference of Governmental Industrial Hygienists (ACGIH) [135]. Ten laboratories participated in the analysis of three sample solutions containing 3-8 μg antimony/ml. The overall coefficient of variation was 10.5%, and the average coefficient of variation within replicates for each analysis was 5%. Average recovery was 105.2%. As a result of this test, cooled reagents became required. The improved method was subsequently recommended by ACGIH for air and biological samples [122], by NIOSH for urine [136], and by Tabor et al for air samples [124]. The working range for a 50-liter air sample is 0.02-0.4 mg Sb/cu m.

Several other less thoroughly studied colorimetric methods have been published. These include procedures based on methyl fluorone [137], Brilliant Green [138-139], Malachite Green [140], iodine [141,142], and silver diethyldithiocarbamate [143]. A kinetic method with photometric end-point detection for microgram amounts of antimony was published in 1972 [144].

Spot tests have been used to detect traces of antimony compounds, including stibine. A ring-oven method for detection of particulate antimony compounds depends on conversion of the antimony to stibine, with detection by silver nitrate-impregnated paper [145,146]. Rapid detection of 10-20- μg amounts of antimony can be made with a modified Reinsch's test [147]. Feigl

and Chan [148,149] described spot tests using mercuric cyanide that are useful for 100- μ g quantities of elemental or bound antimony. Silver diethyldithiocarbamate can be used to detect as little as 60 pg of antimony in 60 nanoliters of solution [150]. To detect as little as 20 μ g of antimony in 20 ml of body fluids, a copper reduction was described [151].

Chromatography is one of the few analytical techniques specific for individual antimony compounds including different oxidation states of antimony. Applications of gas-liquid chromatography have been described for determination of antimony trichloride [152], antimony triiodide [153], antimony pentafluoride [154], and triphenyl antimony [155].

Electrochemical methods also have application in trace determination of antimony. Dubois and Monkman [156] described the use of polarography for determination of antimony in air samples taken on glass fiber filters. Minimal sample manipulation is required. Tri- and pentavalent antimony can be determined separately, and the method is useful for microgram quantities [156]. Other polarographic procedures describe the determination of antimony using thiocyanate electrolyte [157] and in organic compounds [158]. An ion-selective electrode sensitive to as little as 10 nanomoles/liter of either tri- or pentavalent antimony was reported in 1975 [138].

Spark source mass spectrometry has been used for determination of many elements, including antimony, in biological samples [159,160]. Detection limits were on the order of 0.1 ppm, but accuracy was probably not better than $\pm 25\%$.

In clinical investigations of antimony process workers, McCallum [79] and others [161] made estimates of the antimony burden in intact lungs by X-ray spectrophotometry. The minimum detection limit was approximately 2 mg/sq cm. This method was described in Epidemiologic Studies.

Bloch [162], in 1970, described a gamma-ray spectrometric method similar to that of McCallum [79] for determining antimony concentrations in the lungs of antimony workers. This technique also was reported to have a minimum sensitivity of approximately 2 mg/sq cm. Recent information indicates that antimony concentrations in intact lungs may be assayed by this method at levels as low as 50 ppm (P Bloch, written communication, March 1978), but the method for calculating ppm was not described.

Neutron activation analysis (NAA) has been used by several investigators to determine elements in atmospheric particulates [127-129,163,164]. Good sensitivity for many elements, minimal sample manipulation, and the ability to determine twenty or more elements simultaneously have been cited as advantages of NAA, which requires expensive equipment and extensive data processing [165]. An absolute detection limit of approximately 0.3 ng of antimony/filter has been reported with 57-mm cellulose ester filters [128], and another group that used polystyrene filters found the detection limit to be 0.03 μ g per 20 X 25-cm filter [163]. Photon activation analysis was also applied to determine antimony particulates in air but with much poorer sensitivity than NAA [130].

More than thirty elements, including antimony, have been determined in biologic materials by NAA [76,166-175]. Accuracy within 5% of the calculated value on samples containing 0.1-10 ng of antimony was reported in studies on

biologic materials [166]. Neutron activation analysis was also used for antimony in other matrices, including natural waters [176], pharmaceutical products [177], and laundry aids [178].

Analysis of airborne particulates by emission spectroscopy was demonstrated for 15 elements, including antimony [179], but no working range of concentrations was given. Another publication indicated that the detection limit in biologic materials is on the order of 15 μg of antimony per sample by conventional methods [180]. However, other analytical methods based on emission spectra may be modified to be more sensitive. For example, Braman et al [181] converted antimony to stibine with sodium borohydride and obtained a detection limit close to 0.5 ng per sample. Inductively coupled plasma emission spectroscopy has a detection limit of 0.2 ppm for antimony, about the same sensitivity as flame atomic absorption [182]. An emission spectrographic method of analysis for microsamples (less than 400 μg) was described by Svoboda and Kleinmann [183] in which the lower limit of detection for antimony was 4-10 ng.

Atomic absorption spectrophotometry (AAS) is one of the most widely used methods for the determination of antimony. Three major variations of the method have been developed: flame atomization, hydride generation, and flameless atomization.

A method evaluated and found acceptable by NIOSH [125] for determination of particulate antimony in air is based on flame AAS. The sensitivity of flame AAS is typically on the order of 0.3-0.5 ppm in the aspirated solution for 1% absorbance (5-10 μg total Sb in the sample), limiting the lower end of the working range to about 0.05-1.0 mg/cu m for a 360-liter air sample (approximately 18-36 μg /sample) [125,184,185]. Sensitivities about 50-100 times better than this may be obtained with either the hydride generation method or flameless atomization using a graphite furnace.

The graphite furnace (flameless) method has a sensitivity of about 120 pg/5-50- μm portion [186-189] or about 5-15 ng for an ashed air filter sample. A flameless method developed by NIOSH is presented in Appendix II. This method is recommended because a 50-liter air sample is adequate for analysis, as opposed to a 360-liter air sample required for equivalent sensitivity with flame AAS.

The first applications of hydride generation techniques to the determination of antimony used magnesium and titanium trichloride or zinc as reductants [190-192]. Subsequently, sodium borohydride showed advantages as a reductant because of its wide applicability and usefulness in both solid and solution forms [193-195]. Absolute sensitivity of 10 ng antimony was reported for an argon-hydrogen burner system [193]. With the use of a long path for the atomization of the hydride, a sensitivity of 0.6 ng was demonstrated [194]. Applications include the determination of antimony and other hydride-forming metals in steel [196], natural waters [197], and foods [198]. An automated procedure has been developed [199].

V. ENGINEERING CONTROLS, PERSONAL PROTECTION, AND WORK PRACTICES

General Control Principles

Occupational exposure to antimony and its compounds can be controlled by applying accepted industrial hygiene principles (1) at the point of generation, (2) in the general work environment, and (3) at the actual point of exposure to the worker. Although antimony and its compounds are associated with numerous processes, the control principles and methods can be applied to all.

Control methods applied at the point of generation include local exhaust ventilation, isolation, enclosure, process modification, and containment. These methods are generally the most effective means of control.

If control at the source cannot be made fully effective, methods must be used that minimize contamination of the work area. These include general dilution ventilation, good housekeeping, and good work practices.

In addition to control at the source and in the general work environment, personal protection must be afforded. Personal protective equipment (respirators, face shields, eyewear, hats) separates the worker from the contaminated environment. Individual protection involves some risks and problems, including the possibilities of equipment failure, improper fit or use, the discomfort of wearing the equipment, and increased risk of accidents due to restriction of vision or impairment of movement. Because of these drawbacks, the use of some personal protective equipment, such as respirators, should be relied upon only as a last resort, and not as an alternative to adequate engineering controls.

Appropriate application of source, work area, and personal protection control methods should provide effective worker protection under most conditions. A continuing health education program, environmental monitoring, and accurate and complete recordkeeping are also essential to a complete control system. Periodic inspection and quality checks of all aspects of the control system are necessary to ensure the system's continued effectiveness.

Engineering Controls

Guidance for specific design criteria for mechanical ventilation can be found in Industrial Ventilation--A Manual of Recommended Practice [200] and in Fundamentals Governing the Design and Operation of Local Exhaust Systems [201].

Complete enclosure or isolation of a process is a highly effective means of reducing worker exposure. The most effective method of control is a combination of local exhaust ventilation and enclosure. Because antimony ore is extremely brittle, certain operations (ie, reduction and screening) result in high workplace air concentrations of antimony dust. Local exhaust ventilation and enclosure should be used to control the dust. In addition, wetting the ore with a light water spray assists in reducing the amount of dust generated. Local exhaust ventilation and enclosure methods, as recommended by NIOSH for control of arsenic [89], are also recommended for the

control of antimony in smelting operations, where it is common for antimony trioxide fume to remain suspended in the air for an exceptionally long time [200].

In some operations, either local exhaust or enclosure may alone be sufficient. Local exhaust ventilation (exhaust hoods) can be located over pots containing molten metal for control of fumes, over crushing and packout operations for control of dust, and in areas where antimony trichloride or other halides may release irritating fumes. The toxic gas stibine can occur as a byproduct when storage batteries are overcharged [97]; therefore, appropriate ventilation controls should be used to control both hydrogen and stibine in battery charging areas.

A combination of isolation of the operation and process modification is another control possibility. In smelting, fettling, general furnace operation, and in battery charging, hazards can be minimized or eliminated through isolation and automation of processes.

Whenever mechanical ventilation is used to control antimony exposure, measurements that demonstrate the system's efficiency should be conducted frequently and recorded at least quarterly. Continuous airflow indicators, such as water or oil manometers, are recommended. Devices that measure air velocity (ie, anemometers) can also be used to determine the efficiency of the system. In addition to frequent checks, measurements should be conducted after any change in process, operation, or control method that might result in reduction of control efficiency. The employer should maintain a record of ventilation measurements, including the location of the test site, date, and results of tests. These records should be retained for 1 year.

Personal Protection

Working with antimony can lead to skin irritation and skin ulcers. To minimize or prevent skin contact, coveralls or long-sleeve shirts with trousers, gloves, and appropriate shoes and headwear should be worn.

Where antimony trichloride or other antimony halides may contact the skin, special care is necessary due to the very irritant properties of these compounds. Workers should wear gloves with gauntlets and aprons made of rubber or other material resistant to penetration by antimony halides, as well as chemical safety goggles or face shields (8-inch minimum) with goggles if spills or splashes are possible. Eye protection should follow the guidelines listed in 29 CFR 1910.133 to prevent damage to the eyes resulting from exposure to antimony.

The use of respirators should be limited to periods of installation and testing of engineering control equipment, nonroutine maintenance and repair, and during emergencies when concentrations of airborne antimony may exceed the recommended TWA. Requirements for a respiratory protection program are given in Chapter I, Section 4 of this document; the program should comply with the requirements of 29 CFR 1910.134. The selection of respiratory protective devices should comply with the provisions of 30 CFR 11.

Neither respiratory protective equipment nor personal protective clothing are to be regarded as substitutes for proper engineering controls.

Work Practices

Good work practices include recommended emergency procedures, proper use of facilities, careful sanitation practices and cleaning, and safe handling and storage. The importance of these practices should be continually emphasized.

(a) Emergency Procedures

For all work areas in which emergencies involving antimony may occur, employees should be properly trained to follow general specified procedures along with any others that may be appropriate for a specific operation or process.

Facilities for quick drenching of the body within the immediate work area should be provided whenever contact with antimony halides may occur. If halides contact the skin or mucous membranes, the involved area should be flushed with large quantities of water. The skin should then be washed with soap and water. Contaminated clothing should be removed promptly and not reworn until thoroughly washed.

If particulates or solutions of antimony halides have contacted the eyes, they should be washed out promptly with copious quantities of gently flowing water. The eyelids should be held open with the fingers during washing. The injured employee should receive medical attention at once.

Approved protective clothing and respirators should be ready for use by persons essential to emergency operations and should be stored in readily accessible locations. A worker who has received inhalation exposure to a halide should be moved immediately to fresh air and should receive medical attention.

Procedures should be prepared for maintenance or cleanup of areas where leaks or discharges of antimony have occurred. Employees not essential to emergency operations should be evacuated from the affected areas during emergencies, and perimeters of these areas should be delineated, posted, and secured.

Only personnel properly trained in emergency procedures and protected against the attendant hazards should clean up spills or control and repair leaks. After cleanup, protective clothing and equipment should be removed and decontaminated, and the cleanup personnel should shower.

Emergency telephone numbers should be prominently displayed.

(b) Handling and Storage

Procedures should be followed to avoid unintentional chemical reactions. Antimony and antimony compounds can generate highly toxic stibine gas under reducing conditions. Contact with various acids generates stibine; this potential must be recognized and avoided.

Three cases of accidental industrial poisoning by a mixture of arsine, stibine, and hydrogen sulfide have been documented [97]. Gases were liberated when water was added to a hot dross that contained metallic aluminum compounds

(arsenic, antimony, and free sulfur) to speed up the operation. Arsine, stibine, and hydrogen sulfide were formed from the reaction of the metals with the liberated nascent hydrogen. Workers became extremely ill as a result, but recovered.

Stibine has been generated when storage batteries were overcharged [202]. The amounts of stibine in battery room atmospheres have been reported to be generally less than 1 ppm (about 5.1 mg/cu m), although 5 ppm (about 25 mg/cu m) has been determined directly over large open battery cells. Under various experimental conditions, maximum stibine concentrations of 45 ppm (about 225 mg/cu m) were detected in undiluted battery gases. Other potential sources of stibine generation are welding and cutting with blow torches, soldering, zinc etching, preparation of antimony trichloride, steel burnishing, purification of type metal with caustic soda, and procedures in laboratories and industry where nascent hydrogen comes in contact with metallic antimony or soluble antimony compounds [203]. Workers should be made aware of such possibilities at their workplace.

Antimony oxides, antimony sulfides, and antimony metal do not present storage problems, though the corrosive halides do. Drums and pails are adequate for some grades of antimony trichloride, but glass carboys are necessary for pharmaceutical-grade trichloride and for all other halides. Carboys should be protected by wooden frames. Liquid halides can be poured from the carboys, but the solid antimony trichloride must be removed by breaking the glass container. Procedures for breaking the glass have been outlined by the Manufacturing Chemists Association [204]. Storage containers should be kept tightly closed. Storage areas should be cool, dry, well-ventilated, protected from sunlight, and away from manufacturing areas.

Information on antimony and its compounds should be recorded on the "Material Safety Data Sheet" shown in Appendix III or on a similar form approved by the Occupational Safety and Health Administration, US Department of Labor. Workers should be made familiar with this information as part of the continuing education program outlined in Chapter 1.

(c) Sanitation Practices

Employers should provide rest areas, smoking areas, and facilities for food preparation, storage, dispensing, and eating that are physically separated from work areas to prevent ingestion of antimony.

Employees should not eat or smoke in areas where antimony is present. Signs should be posted that prohibit eating and smoking in work areas. Workers should wash their hands before putting anything in their mouths and before and after using toilet facilities.

A daily change of work clothing should be provided for workers. Separate lockers for work clothing and street clothing should be available. Workers should not wear their work clothing away from the workplace, but should shower and change into street clothing before leaving. Contaminated clothing should be put in closed containers until it is washed.

Washing and shower facilities, including eyewash fountains and quick-drench units for emergencies, should be provided by the employer and should be easily accessible to employees. The portions of 29 CFR 1910.141 pertaining to

facilities that are especially relevant to antimony are subsections (a) General, (c) Toilet Facilities, (d) Washing Facilities, (e) Change Rooms, and (g) Consumption of Food and Beverages on the Premises.

(d) Laundering

Used work clothing should be laundered frequently, preferably daily. Clothing should be washed with soap or other detergent and water. Precautions should be taken to protect personnel who handle and launder soiled clothing. These employees should be advised of the hazards of, and means of preventing, exposure to antimony. If an outside laundry facility is used, the launderers should be advised of the hazards and proper procedures involved in handling contaminated work clothing. Contaminated clothing that is to be transported to an outside laundry facility should be placed in containers and sealed.

(e) Decontamination

To reduce antimony dust exposures in the work area, cleaning by vacuuming, wet mopping, or hosing is advised. No dry sweeping or blowing should be permitted. Liquid spills should be copiously flushed with water and channeled to a treatment system or a holding tank for reclamation or proper disposal. Tanks that have contained antimony trichloride may be cleaned according to guidelines offered by the Manufacturing Chemists Association [204].

(f) Disposal

Waste materials contaminated with antimony should be disposed of in a manner not hazardous to employees. The disposal method should conform to applicable local, state, and Federal regulations.

VI. DEVELOPMENT OF STANDARD

Basis for Previous Standards

The first maximum allowable concentration (MAC) for antimony dusts, fumes, and mists was recommended in 1947 by the American Conference of Governmental Industrial Hygienists (ACGIH) [205]. The recommended value was 0.1 mg/cu m of air. No basis for the recommendation was given.

In 1948, the ACGIH adopted the term "Threshold Limit Value" (TLV) to replace maximum allowable concentration. Both terms were imprecise, implying to some a ceiling, and to others a time-weighted average (TWA). Antimony was one of five substances that had values raised from 1947 values. The TLV for antimony became 0.5 mg/cu m [206].

In his 1950 text on industrial toxicology, Elkins [207] proposed a MAC of 1 mg/cu m, citing the animal experiments by Dernehl et al [102]. However, Elkins [207] wrote that his MAC proposal of 1 mg/cu m was based on insufficient information. That same year, the ACGIH [208] continued to recommend a TLV of 0.5 mg/cu m for antimony dusts, fumes, and mists.

TLV's adopted in 1953 by the ACGIH were, for the first time, defined as maximum average concentrations over an 8-hour workshift that should not be exceeded rather than as ceilings not to be exceeded even momentarily [209]. The recommended value for antimony, however, remained at 0.5 mg/cu m.

In his 1956 review of TLV's, Smyth [210] cited the studies by Bradley and Fredrick [17] and Dernehl et al [102] and suggested that the TLV of 0.5 mg/cu m was low enough to prevent injury.

The ACGIH published documentation for the TLV of 0.5 mg/cu m in 1962 [211]. The value was based on the industrial studies of Brieger et al [15] in 1954 and Renes [5] in 1953. A later ACGIH documentation, published in 1966, stated that the recommended level of 0.5 mg/cu m would prevent accumulation of antimony in the body [212]. The 1971 documentation [213] cited industrial studies by Klucik et al [11,214,215] and continued to recommend 0.5 mg/cu m.

Notices of intent to change the TLV for antimony and its compounds were published by ACGIH in 1975 and 1976 [216,217]. The changes proposed separate TLV's for the handling and use of antimony trioxide, and for the production of antimony trioxide. A TLV of 0.5 mg/cu m was proposed for handling and use, and a TLV of 0.05 mg/cu m was proposed for production. The 0.05 mg/cu m value for antimony trioxide production was most likely based on the epidemiologic report of Davies [14] that suggested an increased incidence of lung cancer among antimony production workers.

In 1976, the term "Short-Term Exposure Limit" (STEL) was instituted by the ACGIH. It was defined as the maximal concentration to which workers could be exposed for up to 15 minutes continuously without suffering from intolerable irritation, chronic or irreversible tissue change, or narcosis of sufficient degree to increase accident proneness, impair self-rescue, or materially reduce work efficiency, provided that no more than four excursions per day were permitted, with at least 60 minutes between exposure periods, and

provided that the daily TLV-TWA was also not exceeded [217]. The STEL for antimony and compounds was tentatively set at 0.75 mg/cu m but did not appear in the 1976 documentation [218].

In 1977, the ACGIH [219] again listed the TLV for antimony as 0.5 mg/cu m with notice of intended changes. The tentative STEL value of 0.75 mg/cu m proposed the year before was not adopted and did not appear in the 1977 list.

The most recent intended change, appearing in 1977, was a TLV of 2 mg/cu m proposed for soluble salts of antimony. This value was based on the reports of Taylor [96] and Cordasco [95], who studied accidental poisoning by antimony trichloride and pentachloride, respectively. The proposed TLV's of 0.5 mg/cu m for handling and use of antimony trioxide, and 0.05 mg/cu m for antimony trioxide production remained in the notice of intended changes.

Tables in Occupational Exposure Limits for Airborne Toxic Substances--A Tabular Compilation of Values from Selected Countries were published by the International Labour Office in 1977 [220]. The environmental limits for antimony in other countries are presented in Table VI-1.

The Occupational Safety and Health Administration, US Department of Labor, has adopted the 1968 ACGIH TLV for antimony of 0.5 mg/cu m determined as a TWA concentration limit [221] as the Federal standard (29 CFR 1910.1000).

TABLE VI-I
HYGIENIC STANDARDS OF SEVERAL COUNTRIES
FOR ANTIMONY AND COMPOUNDS IN THE WORKING ENVIRONMENT

Country	Standard (mg/cu m)	Qualifications
Finland	0.5	Not stated
Federal Republic of Germany	0.5	8-hour TWA
Democratic Republic of Germany	0.5	Not stated
Rumania	0.5	"
USSR	0.5	For antimony dust
	0.3	For flourides and chlorides (tri- and pentavalent); obligatory control of HF and HCl
	1.0	For trivalent oxides and sulfides
Sweden	1.0	For pentavalent oxides and sulfides
	0.5	Not stated
USA	0.5	8-hour TWA
Yugoslavia	0.5	Not stated

Modified from references 220 and 222

Basis for the Recommended Standard

(a) Permissible Exposure Limit

Adverse health effects reported for antimony and its compounds in occupational settings include effects on the heart, respiratory system, skin and mucous membranes, and a suggestion of reproductive problems.

Many nonoccupational reports have implicated antimony in adverse heart effects manifested by ECG alterations, primarily a flattening or inversion of the T wave. These effects have followed iv or im administration of antimony salts in high multiple doses (about 0.5-6.0 mg/kg per dose) for the treatment of parasitic infections [36-50].

Brieger et al [15] noted seven deaths of antimony workers attributed to cardiac disease. Of 75 workers in the department where the deaths occurred, 37 had altered ECG's, primarily of the T wave. Concentrations of antimony trisulfide in the department ranged from 0.58 to 5.5 mg/cu m, with most samples over 3.0 mg/cu m, according to Brieger et al. According to Bradley and Fredrick [17], rats had myocardial damage after LD50 administration of antimony. T wave alterations were also found in rats and rabbits given inhalation exposures of 3.07 and 5.6 mg antimony/cu m, respectively, for 6 hours/day, 5 days/week for 6 weeks [15]. Similar abnormal ECG's in workers exposed to antimony trisulfide and trioxide were described by Klucik and Ulrich [11] at concentrations that were reported to range from 1.3 to 237 g Sb/cu m (sic); however, these stated concentrations may be in error, since they are inordinately high. It may be questioned whether arsenic, present as a contaminant in industrial antimony compounds, caused the observed ECG changes because arsenic has produced the same effects [89-93]. Although some reports have failed to note ECG changes in antimony workers [9,10], ECG alterations in animals [15,17], in patients receiving arsenic-free antimony drugs [36-50], and in workers exposed at concentrations generally above 3 mg/cu m are judged to be due to antimony.

Simple pneumoconiosis, manifested as moderate, dense reticulo-nodular formations scattered throughout pulmonary fields on X-rays [7], is a frequent finding among antimony workers [6,7,9,12,79]. Fibrosis appears to be absent [6,79]. According to some reports, workers seem to be free of symptoms [12,79], but decrements in pulmonary function have been reported occasionally [6,7,9]. Quantitative information was lacking in these reports, as were specifics on the procedures used. Environmental levels were reported to exceed 0.5 mg/cu m for antimony trioxide and antimony metal dust [12,79], to be mostly less than 10 mg/cu m (range, 0.08-138 mg/cu m) for antimony ore and trioxide [9], to measure 16-248 mg/cu m for a mixed dust that included antimony oxides and silica [6], and to be 0.3-14.7 mg/cu m for antimony metal and trioxide [7]. Airborne exposures to antimony workers generally involved materials other than antimony. Contaminants have included silica and arsenic as well as other particulates and gases characteristic of smelter operations.

Reported environmental concentrations frequently lack detail, such as whether they constituted breathing zone or area measurements and what specific operations were evaluated; however, most environmental levels appear to be greater than 0.5 mg/cu m and less than 10 mg/cu m. The bulk of the dust loads consisted of antimony or antimony compounds in these cases and it is reasonable to conclude that simple pneumoconiosis was attributable to the

antimony dusts. It is unknown whether the effects were due to worker exposures at 10 mg/cu m or less or whether they were the result of higher concentrations.

A question was raised in 1973 concerning increased mortality due to lung cancer in a group of antimony smelter workers in England that originally numbered 1,081 people [14]. Of 56 deaths recorded from 1961 to the end of 1971, 10 were due to lung cancer; 68 individuals in the cohort remained untraced. Eight deaths from lung cancer occurred among individuals 45-64 years old who were engaged in antimony smelting or related activities. The eight deaths represented a two-fold excess over the number expected from a comparison with local death rates. Because of the small group, the excess deaths were not necessarily considered by the author [14] to be due to antimony. In the factory and office as a whole, the number of deaths from all causes was less than expected. Because of the lack of knowledge of smoking habits and the small size of the study group, the findings were considered by the author [14] to be equivocal. The study was to be continued to include a detailed investigation of smoking habits.

A recent update of the figures reflected essentially the same two-fold ratio, 13 deaths observed vs 7.2 deaths expected (KP Duncan, written communication, July 1978). With the exception of observed vs expected figures, further data have not been forthcoming. Many questions remain such as smoking habits of the workers, the makeup of the local (control) group used to generate the expected estimate, work locations and worker histories, other smelter contaminants, environmental levels of antimony and contaminants, and changes that have taken place in processes or procedures. Therefore, the question raised in 1973 on lung cancer in antimony workers in England remains equivocal. Because of the lack of definitive data, lung cancer is not judged to be a factor at this time in consideration of a recommended occupational exposure limit for antimony and its compounds.

Dermatitis and mucous membrane irritation are common complaints of antimony workers [5,6,77,78]. Renes [5] correlated most incidents of dermatitis with a 1-week period of heavy exposure when concentrations reached 70.7 mg/cu m, but some cases of dermatitis and mucous membrane irritation occurred at exposures in the range of 0.4-70.7 mg/cu m. The occurrence of dermatitis seems to be related at least as much to conditions of heat, perspiration, and friction, as to actual exposure level.

Of concern is the single report of Belyaeva [13] in which 318 antimony-exposed female workers were stated to have higher incidences than controls of late-occurring spontaneous abortions (12.5% vs 4.1%), premature births (3.4% vs 1.2%), and gynecologic problems (77.5% vs 56%). Although subsequent animal findings in female rats by the same author [13] were reported to support the findings of human reproductive effects due to antimony, the dose (50 mg/kg ip) and the concentration (250 mg/cu m) given to rats were high and of questionable relevance to the occupational setting. Many procedural points were not discussed and a definitive interpretation of the work is not possible without further evidence. The percentage of gynecologic problems reported in the control group (56%) seems abnormally high. It is unclear whether the overall working conditions in this smelter were representative of smelter conditions in the US.

Blood and urine levels of antimony were reported to be about the same in dusty operations as in less dusty operations, such as the chemical laboratory or in quality control [13]. Average urine levels of antimony for exposed workers ranged from 2.1 to 2.9 mg/100 ml. The highest value found was 18.2 mg/100 ml and the lowest was 0.5 mg/100 ml. These levels would appear to be reasonable when compared with the statement by Renes [5] that one heavily exposed worker had a urinary antimony level of 60 mg/100 ml. Clearly, further work is needed on the effects of antimony on reproduction. At this time, the available information on reproductive effects is insufficient to make recommendations pertaining to an occupational exposure limit for antimony.

The present Federal limit for occupational exposure to antimony and its compounds is 0.5 mg/cu m (as Sb) as a time-weighted average concentration limit. Stibine is excluded from this recommended standard because it is a transitory byproduct of operations involving other sources of antimony, and decomposes rapidly in the air. From a review of the data and all available information, it is believed that a TWA limit of 0.5 mg/cu m will afford worker protection from the health effects associated with exposure to antimony including dermatitis, mucous membrane irritation, pneumoconiosis, and ECG alterations. Therefore, NIOSH recommends that the current Federal limit of 0.5 mg/cu m as a TWA concentration limit be retained.

(b) Medical Surveillance and Recordkeeping

Medical surveillance should include preplacement and periodic examinations with attention directed to the skin, lungs, and heart. Chest X-rays should be taken annually to screen for possible pulmonary problems including pneumoconiosis that may be attributed to antimony exposure. Several authors [6,7,9] have suggested that pulmonary functional impairment may be a feature of antimony pneumoconiosis; therefore, tests of ventilatory function should also be required on an annual basis. Because of the findings of ECG alterations in workers exposed to antimony trisulfide [15] and also in rats and rabbits [15], annual ECG's of antimony-exposed workers should also be mandatory.

The uncertain nature of the evidence of liver dysfunction makes a requirement for liver function tests difficult to justify. However, liver function tests are encouraged because of their possible relationship to antimony exposure as well as their relevance to an evaluation of general health.

The research is inconclusive with regard to possible adverse effects of antimony exposure on reproduction. Belyaeva [13] reported that women working with antimony experienced more late spontaneous abortions, premature births, and gynecologic problems than did women not exposed to antimony. Animal experiments [13] suggested that antimony may interfere with the normal development of ova. No investigation of the fertility of male antimony workers or further animal experiments involving either sex has been reported. Until Belyaeva's findings are confirmed or refuted, NIOSH recommends workers be advised that a single report indicates that there may be an increased risk of reproductive disorders resulting from occupational exposure to antimony.

Because of the possibility of chronic lung changes and cardiac alterations as a result of antimony exposure, medical records of antimony workers should be kept for 30 years after termination of employment.

(c) Sampling and Analysis

Personal sampling with a membrane filter is the primary recommended technique, since most antimony compounds in the industrial environment exist as particulates. A Millipore type AA or equivalent cellulose ester membrane filter with 0.8- μ m pores provides optimum sampling efficiency. The residue obtained from digesting the collected particulate matter in a mixture of nitric, perchloric, and sulfuric acids is diluted with distilled water; aliquots are analyzed for antimony at 217.6 nm by flameless atomic absorption. If lead is present in the sample, the 231.2-nm resonance line should be used.

The recommended sampling method for volatile antimony compounds uses a midget impinger containing 5% mercuric chloride in 6N hydrochloric acid. The sample solutions are diluted with distilled water and analyzed directly by flameless atomic absorption.

Analysis by atomic absorption spectrophotometry has been successfully used to monitor air for antimony and antimony compounds. The flameless method is relatively simple and quick, and is highly sensitive. Recommended procedures for sampling and analysis are discussed in Chapter IV and are presented in greater detail in Appendices I and II.

(d) Personal Protective Equipment and Clothing

The irritant properties of antimony make it necessary to protect the skin and eyes from contact with antimony materials. Coveralls with long sleeves, head and neck protection, and gloves should be worn during exposure to antimony dusts. When antimony halides may contact the skin, gloves with gauntlets and aprons made of rubber or other material resistant to antimony halides should also be worn to prevent burns. Because of the occurrence of conjunctivitis following antimony exposure [5,6], it is important to protect the eyes from antimony by wearing chemical safety goggles in work situations where antimony could contact the eyes. Respirators should be worn when airborne concentrations of antimony exceed 0.5 mg/cu m, but this should occur only during unusual circumstances, ie, during installation and testing of engineering controls, during nonroutine maintenance or repair, or during emergencies. For initial selection of a respirator to be assigned to an individual worker, a quantitative fit test of facepiece to face seal is recommended for negative pressure respirators. This method provides a numerical index of respirator fit, does not rely solely on the subjective response of the wearer, and therefore provides more reliable protection than qualitative fit testing. Procedures and allowable leakages as specified in A Guide to Industrial Respiratory Protection [223] should be followed. All protective clothing and equipment should be provided by the employer and be cleaned, maintained in good condition, and replaced as necessary by the employer.

(e) Informing Employees of Hazards

Continuing education is important in a preventive hygiene program for employees exposed to hazardous materials such as antimony. Workers should be periodically informed by properly trained persons of the possible sources of antimony exposure, the adverse health effects associated with excessive exposure to antimony, the engineering and work practice controls in use and being planned to limit exposure to acceptable concentrations, and good

personal hygiene and housekeeping practices. The procedures used in environmental and medical monitoring should also be explained, and the benefits to workers of participating in these environmental and medical monitoring procedures should be stressed.

(f) Work Practices

To prevent the intake of antimony, NIOSH recommends that storage, handling, dispensing, and eating of food be prohibited in antimony exposure areas. While antimony does not pose a fire hazard, its deposition on smoking materials may result in inhalation or ingestion of antimony during smoking; therefore, smoking as well as carrying uncovered smoking materials in the workplace should be prohibited. Workers should shower and change clothes before leaving work so as to minimize their exposure to antimony and to prevent contamination outside the workplace.

(g) Monitoring and Recordkeeping Requirements

In workplaces where antimony is present, an annual industrial hygiene survey is recommended to determine if exposure exceeds the action level. If there is occupational exposure to antimony, ie, if the action level is exceeded, personal sampling representative of the worker's exposure should be instituted on at least a semiannual basis. Records of sampling and analysis should be preserved for at least 30 years after the last work-related exposure to antimony to enable correlations between air levels of antimony in the workplace and any health effects on workers. Medical records should be kept for the same period. The Toxic Substances Control Act of 1976 requires that "Records of...adverse reactions to the health of employees shall be retained for thirty years from the date such reactions were first reported to or known by the person maintaining such records."

(h) Action Level

Many workers handle small amounts of antimony or work in situations in which, regardless of the amount used, there is only negligible contact with the substance. Under these conditions, it should not be necessary to comply with some provisions of this recommended standard that were prepared primarily to protect workers' health under more hazardous conditions. Concern for worker health requires that protective measures and emergency procedures be instituted below the enforceable limit to ensure that exposures stay below that limit. For these reasons, the action level has been defined as one-half the recommended TWA environmental limit, thereby delineating those work situations that do not require the expenditure of health resources for environmental and medical monitoring and for associated recordkeeping. However, because of nonrespiratory hazards such as those resulting from eye contact or skin contact, NIOSH recommends that the appropriate work practices and protective measures be required regardless of airborne concentration.

VII. RESEARCH NEEDS

The most serious research needs in connection with occupational exposure to antimony are resolution of the questions of reproductive hazard and carcinogenic potential. The available literature does not supply conclusive evidence for an evaluation of these issues. The only epidemiologic survey [14] that suggested an increased risk of lung cancer was merely a statement issued to workers engaged in antimony oxide manufacture; it cannot be considered scientific or complete. Research is in progress under a NIOSH contract to determine the carcinogenicity of antimony trioxide. Research is also needed to determine if antimony acts synergistically to promote carcinogenic properties of other substances.

Belyaeva [13] reported increased incidences of late spontaneous abortions, premature births, and gynecologic problems in women antimony workers, as well as less-than-normal weight gain in their infants. With animal experiments, the same author [13] substantiated the findings of reproductive disorders. More animal research should be undertaken to confirm Belyaeva's results. Possible behavioral consequences of exposure to antimony in utero should also be investigated.

Epidemiologic studies of worker populations exposed to antimony at or near the recommended environmental limit would serve to evaluate the adequacy of the limit. These studies should attempt to distinguish exposures to antimony from mixed exposures to antimony and arsenic. As a minimum, these studies should include environmental air measurements, identification of jobs, description of work practices and overall plant conditions, work, medical, and exposure histories, and carefully derived control rates for morbidity and mortality comparisons.

VIII. REFERENCES

1. Wyche C: Antimony, in Mineral Facts and Problems--1975 Edition, Bulletin No. 667. US Dept of the Interior, Bureau of Mines, 1975, pp 79-91
2. Rathjen JA: Antimony--Preprint from the 1976 Bureau of Mines Minerals Yearbook. US Dept of the Interior, Bureau of Mines, 1978, 9 pp
3. Windholz M, Budavari S, Stroumtsos LY, Fertig MN (eds.): The Merck Index--An Encyclopedia of Chemicals and Drugs, ed 9. Rahway, NJ, Merck and Co, Inc, 1976, pp 95-97
4. Selisky AB: [Occupational skin injuries by antimony salts in the textile industry.] Dermatol Wochenschr 86:723-27, 1928 (Ger)
5. Renes LE: Antimony poisoning in industry. AMA Arch Ind Hyg Occup Med 7:99-108, 1953
6. Karajovic D: [Pneumoconiosis in workers at an antimony smelting plant], in Proceedings of the 12th International Congress on Occupational Health, Helsinki, 1958, vol 3, pp 370-74 (Ger)
7. Le Gall: [Pneumoconiosis and antimony.] Arch Mal Prof 30:361-62, 1969 (Fre)
8. McCallum RI, Day MJ, Underhill J, Aird EGA: Measurement of antimony oxide dust in human lungs in vivo by X-ray spectrophotometry, in Walton WH (ed.): Inhaled Particles--III. Proceedings of an International Symposium Organized by the British Occupational Hygiene Society, London, September 14-23, 1970. Old Woking, Surrey, England, Gresham Press, Unwin Brothers Ltd, 1971, vol 2, pp 611-19
9. Cooper DA, Pendergrass EP, Vorwald AJ, Mayock RL, Brieger H: Pneumoconiosis among workers in an antimony industry. Am J Roentgenol Radium Ther Nucl Med 103:495-508, 1968
10. Oliver T: The health of antimony oxide workers. Br Med J 1:1094-95, 1933
11. Klucik I, Ulrich L: [Electrocardiographic examination of workers in an antimony metallurgical plant.] Prac Lek 12:236-43, 1960 (Cze)
12. McCallum RI: The work of an occupational hygiene service in environmental control. Ann Occup Hyg 6:55-64, 1963
13. Belyaeva AP: [The effect of antimony on reproductive function.] Gig Tr Prof Zabol 11(1):32-37, 1967 (Rus)
14. Davies TAL: The health of workers engaged in antimony oxide manufacture--A statement. London, Department of Employment, Employment Medical Advisory Service, 1973, 2 pp

15. Brieger H, Semisch CW III, Stasney J, Piatnek DA: Industrial antimony poisoning. *Ind Med Surg* 23:521-23, 1954
16. Gallina R, Luvoni R: [Occupational poisoning from antimony--Clinical observations.] *Rass Med Ind* 27:28-37, 1958 (Ita)
17. Bradley WR, Fredrick WG: The toxicity of antimony--Animal studies. *Ind Med (Industr Hyg Sec)* 2:15-22, 1941
18. Harvey SC: Antimony, in Goodman LS, Gilman A, Gilman AG, Koelle GB (eds.): *The Pharmacological Basis of Therapeutics*, ed 5. New York, MacMillan Publishing Co, Inc, 1975, pp 928-30
19. Browning E: Antimony (Sb), in *Toxicity of Industrial Metals*, ed 2. New York, Appleton-Century-Crofts, 1969, pp 23-38
20. Ramazzini B: *Diseases of Workers--The Latin Text of 1713* (Wright WC, transl). Chicago, University of Chicago Press, 1940, pp 49,63,65
21. McWalter JC: Printers' palsy (chronic antimonial poisoning). *Med Press Circ* 141:160-62, 1910
22. Schruppf F, Zabel B: [Clinical and experimental studies on antimony intoxication in typesetters--A contribution to occupational hygiene.] *Arch Exp Pathol Pharmacol* 63:242-54, 1910 (Ger)
23. Rambousek J: Antimony, in *Industrial Poisoning* (Legge TM, transl). London, Edward Arnold, 1913, pp 146,342
24. Seitz A: [Studies on type foundries.] *Munchener Med Wochenschr* 70:1501-03, 1923 (Ger)
25. Seitz A: [Hygiene in type-casting industry and experimental antimony intoxication.] *Arch Hyg* 94:284-97, 1924 (Ger)
26. Shirley JN: Rubber compounding ingredients and their health hazards. *Rubber Age (NY)* 22(2):71-76, 1927
27. Shirk DA: Disagrees with speaker's statement on antimony poisoning. *Rubber Age (NY)* 22(3):130, 1927 (Lett)
28. Feil A: [The role of antimony in occupational pathology. Results of an investigation in an antimony foundry.] *Presse Med* 47:1133-34, 1939 (Fre)
29. Fairhall LT, Hyslop F: The toxicology of antimony. *Public Health Rep Suppl No.* 195, 1947, 41 pp
30. Markell EK, Voge M (eds.): *Medical Parasitology*, ed 3. Philadelphia, WB Saunders Co, 1971, pp 128-39,166-80
31. Monier-Williams GW: Antimony in enamelled hollow-ware. *Reports on Public Health and Medical Subjects*, No. 73. London, Ministry of Health, His Majesty's Stationery Office, 1934, 18 pp

32. Werrin M: Chemical food poisoning. Assoc Food Drug Off US Q Bull 27:38-45, 1963
33. Dunn JT: A curious case of antimony poisoning. Analyst 53:532-33, 1928
34. Polson CJ, Tattersall RN: Antimony, in Clinical Toxicology, ed 2. London, Pitman Medical & Scientific Publishing Co Ltd, 1969, pp 211-16
35. Khalil MB: The specific treatment of human schistosomiasis (Bilharzias) with special reference to its application on a large scale. Arch Schiffs Trop Hyg 35(Supp 2):1-128, 1931
36. Mainzer F, Krause M: Changes of the electrocardiogram appearing during antimony treatment. Trans Roy Soc Trop Med Hyg 33:405-18, 1940
37. Honey M: The effects of sodium antimony tartrate on the myocardium. Br Heart J 22:601-16, 1960
38. Schroeder EF, Rose FA, Most H: Effect of antimony on the electrocardiogram. Am J Med Sci 212:697-706, 1946
39. Tarr L: Effect of the antimony compounds, fuadin and tartar emetic on the electrocardiogram of man--A study of the changes encountered in 141 patients treated for schistosomiasis. Ann Intern Med 27:970-88, 1947
40. Abdalla A, Badran A: Effect on the electrocardiogram of potassium antimony tartrate (tartar emetic) in patients treated for schistosomiasis. J Egypt Med Assoc 44:767-71, 1961
41. Germiniani H, da Mota CCS, de Lacerda FS Jr, Baranski MC: [Electrocardiographic changes observed in patients treated with antimony compounds.] Arq Bras Cardiol 16:299-310, Oct 1963 (Por)
42. Dancaster CP, Duckworth WC, Matthews REP: Stokes-Adams attacks following sodium antimonylgluconate (Triostam). S Afr Med J 40:1029-30, 1966
43. Sapiro DW, Silverman NH: Myocardial involvement in antimonial therapy--A case report of acute antimony poisoning with serial ECG changes. S Afr Med J 44:948-50, 1970
44. Waye JD, Donoso E, Spingarn CL, Edelman MH: Cardiotoxic effects of antimony dimercaptosuccinate in schistosomiasis with special reference to coexistent hepatic dysfunction. Am J Cardiol 10:829-35, 1962
45. Hsu JK, Wu YS, Lu CP, Ch'en MK, Lu CS: Sodium antimony dimercaptosuccinate (Sb-58) in treatment of Schistosomiasis japonica. Chinese Med J 80:530-37, 1960
46. Abdalla A, Badran A: Effect of antimony dimercaptosuccinate on the electrocardiogram in patients treated for schistosomiasis. Am J Trop Med Hyg 12:188-92, 1963

47. Somers K, Rosanelli JD: Electrocardiographic effects of antimony dimercapto-succinate ("astiban"). Br Heart J 24:187-91, 1962
48. Awwaad S, Attia M, Reda M: The effect of TWSb on the electrocardiogram of children suffering from urinary bilharziasis. Am J Trop Med Hyg 10:365-69, 1961
49. Badran AM, Abdalla A: Treatment of schistosomiasis in cardiac patients by weekly injections of sodium antimony dimercaptosuccinate. J Egypt Med Assoc 50:360-68, 1967
50. O'Brien W: The effects of antimony on the heart. Trans Roy Soc Trop Med Hyg 53:482-86, 1959
51. Toxic and Hazardous Industrial Chemicals Safety Manual for Handling and Disposal with Toxicity and Hazard Data. Tokyo, International Technical Information Institute, 1976, pp 47-49
52. Lopez M, DaCunha AS: [Electrocardiographic course in patients treated with trivalent and pentavalent antimonials.] Hospital (Rio de Janeiro) 63:919-27, 1963 (Por)
53. Huang MH, Chiang SC, Yu KJ, Lu CW, Hsu CY: Cardiac arrhythmias in tartar emetic intoxication. Chinese Med J 80:319-23, 1960
54. Lu ST, Liu H: A survey of short-course antimony tartrate therapy for schistosomiasis japonica in China. Chinese Med J 82:46-54, 1963
55. Khalil MB: Individual variation in the excretion of drugs as an important factor in their therapeutic results. A practical method for detecting the schistosomiasis cases with so-called idiosyncrasy to antimony to avoid fatalities and complication. J Egypt Med Assoc 19:285-305, 1936
56. de Torregrosa MVV, Rosado ALR, Montilla E: Hemolytic anemia secondary to stibophen therapy. J Am Med Assoc 186:598-99, 1963
57. Spingarn CL, Edelman MH, Waye JD, Donoso E, Gregory C: Observations on the treatment of Schistosomiasis mansoni with antimony dimercaptosuccinate (TWSb). Am J Med 34:477-82, 1963
58. Kahn HR, Brod RC: Thrombocytopenia due to stibophen. Arch Intern Med 108:496-501, 1961
59. Rivera JV, Rodriguez HF, Perez-Santiago E: Thrombocytopenic purpura due to fuadin (stibophen). Am J Trop Med Hyg 5:863-68, 1956
60. Archer RK: The Eosinophil Leucocytes. Oxford, Blackwell Scientific Publications, 1963, pp 170-79
61. Abdalla A, Shakir M, Hamamsy A, Ali IM, Tawfik J: Changes in serum transaminase levels during treatment of bilharziasis with tartar emetic. J Egypt Med Assoc 47:52-56, 1964

62. Asshauer E: [On the problem of the toxic effect of trivalent antimony compounds.] *Arzneim Forsch* 16:1546-49, 1966 (Ger)
63. Charlas R, Benabadji A: [Azotemic nephritis during antimony therapy of a case of infantile visceral leishmaniasis.] *Maroc Med* 41:1180-82, 1962 (Fre)
64. Rollier R, Rollier M, Garzon J: [Lupus erythematosus aggravated by anthiomaline.] *Bull Soc Franc Derm Syph* 69:414-18, 1962 (Fre)
65. Aslamazov EG, Metelskaya OA, Tumolskaya NI: [Herpes zoster as a result of the toxic effect of antimonous compounds on the organism.] *Med Parazitol Parazit Bolezni* 35:600-01, 1966 (Rus)
66. Most H, Kane CA, Lavietes PH, Schroeder EF, Behm A, Blum L, Katzin B, Hayman JM Jr: *Schistosomiasis japonica* in American military personnel--Clinical studies of 600 cases during the first year after infection. *Am J Trop Med* 30:239-99, 1950
67. Otto GF, Maren TH, Brown HW: Blood levels and excretion rates of antimony in persons receiving trivalent and pentavalent antimonials. *Am J Hyg* 46:193-211, 1947
68. Boyd TC, Roy AC: Observations on the excretion of antimony in the urine. *Indian J Med Res* 17:94-108, 1929
69. Sanger CR, Riegel ER: The quantitative determination of antimony by the Gutzeit method. *Proc Am Acad Arts Sci* 45(2):21-28, 1909
70. Bartter FC, Cowie DB, Most H, Ness AT, Forbush S: The fate of radioactive tartar emetic administered to human subjects--I. Blood concentration and excretion following single and multiple intravenous injections. *Am J Trop Med* 27: 403-16, 1947
71. Schulert AR, Browne HG, Salem HH: Human disposition of antimony administered as antimony sodium dimercapto-succinate. *Trans Roy Soc Trop Med Hyg* 58:48-52, 1964
72. Brahmachari UN, Chaudhury SC, Das J, Sen PB: Chemotherapy of antimonial compounds in Kala-azar infection--VIII. Quantitative studies in excretion of antimony (tartar emetic and urea stibamine). *Ind J Med Res* 11:829-38, 1924
73. Hirayama A: [Studies on the normal limits of antimony in blood, urine, and feces among healthy Japanese urban inhabitants.] *J Osaka City Med Cen* 8(5):609-17, 1959 (Jap)
74. McChesney EW: Colorimetric micromethod for determination of antimony in biological materials with concomitant determination of bismuth. *Ind Eng Chem Anal Ed* 18:146-49, 1946
75. Elkind A, Gayer KH, Boltz DF: Ultraviolet spectrophotometric determination of antimony as iodoantimonous acid. *Anal Chem* 25:1744-45, 1953

76. Molokhia MM, Smith H: Trace elements in the lung. Arch Environ Health 15:745-50, 1967
77. Paschoud JM: [Clinical notes on eczemas from occupational contact with arsenic and antimony.] Dermatologica 129:410-15, 1964 (Fre)
78. Stevenson CJ: Antimony spots. Trans St Johns Hosp Dermatol Soc 51:40-45, 1965
79. McCallum RI: Detection of antimony in process workers' lungs by X-radiation. Trans Soc Occup Med 17:134-38, 1967
80. Gocher TEP: Antimony intoxication. Northwest Med 44:92-93, 1945
81. Thivolet J, Melinat M, Pellerat J, Perrot H, Francou M: [Occupational dermatitis attributed to antimony.] Arch Mal Prof 32:571-73, 1971 (Fre)
82. Lynch AL, Sigmund JM: Antimony trioxide--Industrial hygiene evaluation of a manufacturing operation. Presented before the 16th Annual American Industrial Hygiene Conference, Atlanta, May 16-21, 1976
83. Hamilton A, Hardy HL (ed.): Antimony, in Industrial Toxicology, ed 3. Littleton, Mass, PSG Publishing Co Inc, 1974, pp 27-29
84. Nebergall WH, Schmidt FC: Antimony, in General Chemistry. Boston, DC Heath and Company, 1959, pp 617-19
85. Paton GR, Allison AC: Chromosome damage in human cell cultures induced by metal salts. Mutat Res 16:332-36, 1972
86. Stock A, Guttman O: [On stibine and yellow antimony.] Ber Dtsch Chem Ges 37:885-900, 1904
87. Birmingham DJ, Key MM, Holaday DA, Perone VB: An outbreak of arsenical dermatoses in a mining community. Arch Dermatol 91:457-64, 1965
88. Pinto SS, McGill CM: Arsenic trioxide exposure in industry. Ind Med Surg 22:281-87, 1953
89. Criteria for a Recommended Standard....Occupational Exposure to Inorganic Arsenic--New Criteria-1975, DHEW Publication No. (NIOSH) 75-149. Cincinnati, US Dept of Health, Education and Welfare, Public Health Service, Center for Disease Control, National Institute for Occupational Safety and Health 1975, 127 pp
90. Glazener FS, Ellis JG, Johnson PK: Electrocardiographic findings with arsenic poisoning. Calif Med 109:158-62, 1968
91. Barry KG, Herndon EG: Electrocardiographic changes associated with acute arsenic poisoning. Med Anal D C 31:25-27, 65-66, 1962
92. Zettel H: [The effect of chronic arsenic damage on heart and blood vessels.] Z Klin Med 142:689-703, 1943 (Ger)

93. Butzengeiger KH: [Chronic arsenic poisoning--I. EKG alterations and other cardiovascular manifestations--II. Mucosal symptoms and pathogenesis.] Dtsch Arch Klin Med 194:1-16, 1949 (Ger)
94. Rothman S: The principles of percutaneous absorption. J Lab Clin Med 28:1305-21, 1943
95. Cordasco EM: Newer concepts in the management of environmental pulmonary edema. Angiology 25:590-601, 1974
96. Taylor PJ: Acute intoxication from antimony trichloride. Br J Ind Med 23:318-21, 1966
97. Nau CA, Anderson W, Cone RE: Arsine, stibine, and hydrogen sulfide--Accidental industrial poisoning by a mixture. Ind Med 13:308-10, 1944
98. Nishioka H: Mutagenic activities of metal compounds in bacteria. Mutat Res 31:185-89, 1975
99. Fredrick WG: Estimation of small amounts of antimony with rhodamine B. Ind Eng Chem Anal Ed 13:922-24, 1941
100. Meeting of experts on the international classification of radiographs of the pneumoconioses, Geneva, 27 October to 7 November 1958. Occup Safety Health 9:63-69, 1959
101. Maren TH: The microdetermination of antimony. Bull Johns Hopkins Hosp 77:338-44, 1945
102. Dernehl CU, Nau CA, Sweets HH: Animal studies on the toxicity of inhaled antimony trioxide. J Ind Hyg Toxicol 27:256-62, 1945
103. Levina EN, Chekunova MP: Toxicity of antimony halides. Fed Proc 24(4, Part II):T608-10, 1965
104. Gross P, Westrick ML, Brown JHU, Srsic RP, Schrenk HH, Hatch TF: Toxicologic study of calcium halophosphate phosphors and antimony trioxide--II. Pulmonary studies. AMA Arch Ind Health 11:479-86, 1955
105. Gross P, Brown JHU, Hatch TF: Experimental endogenous lipoid pneumonia. Am J Pathol 28:211-21, 1952
106. Bromberger-Barnea B, Stephens NL: Effects of antimony on myocardial performance in isolated and intact canine hearts. Am Ind Hyg Assoc J 26:404-08, 1965
107. Minkina NA, Chekunova MP, Levina EN: [State of adrenals and biogenic amines under the effect of antimony and lead.] Gig Tr Prof Zabol 17(3): 21-24, 1973 (Rus)
108. Gross P, Brown JHU, Westrick ML, Srsic RP, Butler NL, Hatch TF: Toxicologic study of calcium halophosphate phosphors and antimony trioxide--I. Acute and chronic toxicity and some pharmacologic aspects. AMA Arch Ind Health 11:473-78, 1955

109. Felicetti SA, Thomas RG, McClellan RO: Metabolism of two valence states of inhaled antimony in hamsters. *Am Ind Hyg Assoc J* 35:292-300, 1974
110. Task Group on Lung Dynamics: Deposition and retention models for internal dosimetry of the human respiratory tract. *Health Phys* 12:173-207, 1966
111. Thomas RG, Felicetti SW, Lucchino RV, McClellan RO: Retention patterns of antimony in mice following inhalation of particles formed at different temperatures. *Proc Soc Exp Biol Med* 144:544-50, 1973
112. Carpenter CP, Smyth HF Jr: Chemical burns of the rabbit cornea. *Am J Ophthalmol* 29:1363-72, 1946
113. Casals JB: Pharmacokinetic and toxicological studies of antimony dextran glycoside (RL-712). *Br J Pharmacol* 46:281-88, 1972
114. Andronikashvili EL, Mosulishvili LM, Belokobilski AI, Kharabadze NE, Tevzieva TK, Efremova EY: Content of some trace elements in sarcoma M-1 DNA in dynamics of malignant growth. *Cancer Res* 34:271-74, 1974
115. Trifonova NF: [The problem of accumulation of antimony in the blood and certain organs of rats with a grafted sarcoma-45 tumor.] *Vop Klin Eksp Onkol* 8:283-85, 1972 (Rus)
116. Erusalimski EI, Suspa GA: [On the question of depositing 3,4-benzpyrene in the lungs of rats under the influence of metallic antimony.] *Vop Klin Eksp Onkol* 8:239-42, 1972 (Rus)
117. Kanisawa M, Schroeder HA: Life term studies on the effect of trace elements of spontaneous tumors in mice and rats. *Cancer Res* 29:892-95, 1969
118. Okawa MT: Health Hazard Evaluation Determination Report No. 75-82-224--Bokan Brothers Corp, Sacramento, California. Cincinnati, US Dept of Health, Education, and Welfare, Public Health Service, Center for Disease Control, National Institute for Occupational Safety and Health, October 1975, 6 pp
119. Gunter BJ, Nelson B: Health Hazard Evaluation Determination Report No. 77-4-402--A & S Tribal Industries, Poplar, Montana. Cincinnati, US Dept of Health, Education, and Welfare, Public Health Service, Center for Disease Control, National Institute for Occupational Safety and Health, June 1977, 13 pp
120. Moseley CL: Health Hazard Evaluation Determination Report No. 77-68-417--The Washington Post Company, Washington, D.C. Cincinnati, US Dept of Health, Education, and Welfare, Public Health Service, Center for Disease Control, National Institute for Occupational Safety and Health, August 1977, 14 pp
121. Donaldson HM, Cassady M: Industry-Wide Study of the Antimony Industry--April 1975-March 1976. Cincinnati, US Dept of Health, Education and Welfare, Public Health Service, Center for Disease Control, National Institute for Occupational Safety and Health, November 1977, 22 pp

122. Determination of Antimony in Air and Biological Materials, in Manual of Analytical Methods--Recommended for Sampling and Analysis of Atmospheric Contaminants. Cincinnati, American Conference of Governmental Industrial Hygienists, Committee on Recommended Analytical Methods, 1958, 7 pp
123. Goldman FH, Jacobs MB (eds.): Antimony, in Chemical Methods in Industrial Hygiene. New York, Interscience Publishers Inc, 1953, pp 111-13
124. Tabor EC, Braverman MM, Bumstead HE, Carotti A, Donaldson HM, Dubois L, Kupel RE: Tentative method of analysis for antimony content of the atmosphere. Health Lab Sci 7(Supp):92-95, 1970
125. Antimony and Compounds (as Sb), in NIOSH Manual of Analytical Methods, ed 2, DHEW (NIOSH) Publication No. 77-157-B. Cincinnati, US Dept of Health, Education and Welfare, Public Health Service, Center for Disease Control, National Institute for Occupational Safety and Health, 1977, vol 2, pp S2-1 to S2-7
126. Pate JB, Tabor EC: Analytical aspects of the use of glass fiber filters for the collection and analysis of atmospheric particulate matter. Am Ind Hyg Assoc J 23:145-50, 1962
127. Gray D, McKown DM, Kay M, Eichor M, Vogt JR: Determination of the trace element levels in atmospheric pollutants by instrumental neutron activation analysis. IEEE Trans Nucl Sci 19(1):194-98, 1972
128. Zoller WH, Gordon GE: Instrumental neutron activation analysis of atmospheric pollutants utilizing Ge(Li) gamma-ray detectors. Anal Chem 42:257-65, 1970
129. Bogen J: Trace elements in atmospheric aerosol in the Heidelberg Area, measured by instrumental neutron activation analysis. Atmos Environ 7:1117-25, 1973
130. Aras NK, Zoller WH, Gordon GE, Lutz GJ: Instrumental photon activation analysis of atmospheric particulate material. Anal Chem 45:1481-90, 1973
131. Weast RC (ed): CRC Handbook of Chemistry and Physics--A Ready-Reference Book of Chemical and Physical Data, ed 58. Cleveland, CRC Press, Inc, 1977, pp B90-B91
132. Sanger CR, Gibson JA: The determination of small amounts of antimony by the Berzelius-Marsh process. Proc Am Acad Arts Sci 42:719-34, 1907
133. 1975 Annual Book of ASTM Standards--Chemical Analysis of Metals; Sampling and Analysis of Metal Bearing Ores. Philadelphia, American Society for Testing and Materials, 1975, Part 12, pp 51,73,146,155-57,162-64,198-200
134. Webster SH, Fairhall LT: The microdetermination of stibine. J Ind Hyg Toxicol 27:183-92, 1945

135. Bartlett JC, Monkman JL: Summary of results of the collaborative tests on the rhodamine B colorimetric method for antimony. J Assoc Off Agric Chem 47:630-32, 1964
136. Antimony in Urine, in NIOSH Manual of Analytical Methods, ed 2, DHEW (NIOSH) Publication No. 77-157-A. Cincinnati, US Dept of Health, Education and Welfare, Public Health Service, Center for Disease Control, National Institute for Occupational Safety and Health, 1977, vol 1, pp 107-1 to 107-6
137. Short DWE, Wheatley KH: The determination of stibine in air. Ann Occup Hyg 5:15-25, 1962
138. Fogg AG, Al-Sibaai AA, Burgess C: Ion-selective electrodes for the determination of antimony and thallium based on water-insoluble basic dye salts. Anal Lett 8:129-37, 1975
139. Yadav AA, Khopkar SM: Rapid extraction of antimony with tributyl phosphate. Direct photometric determination with brilliant green. Bull Chem Soc Jap 44:693-96, 1971
140. Palalau L, Mihailescu E: The photolorimetric determination of antimony and its compounds in the atmosphere. Rev Chim (Bucharest) 18:562-64, 1967
141. Holland R: The determination of stibine. Analyst 87:385-87, 1962
142. Golacka J: [Application of the iodide method in determining antimony in air.] Med Pracy 22:91-96, 1971 (Pol)
143. Dal Cortivo LA, Cefola M, Umberger CJ: The determination of arsenic and antimony in biologic material. Anal Biochem 1:491-97, 1960
144. Burgess AE, Ottaway JM: A kinetic method for the determination of arsenic(III), antimony(III) and ascorbic acid. Analyst 97:357-62, 1972
145. West PW, Mukherji AK: Separation and microidentification of metallic ions by solvent extraction and ring oven techniques. Anal Chem 31:947-50, 1959
146. West PW: The identification and determination of airborne particulates by means of the ring oven technique. J Air Pollut Control Assoc 16:601-03, 1966
147. Clarke EGC, Hawkins AE, Barratt FJ: A modified apparatus for Reinsch's test. J Pharm Pharmacol 15:73-75, 1963
148. Feigl F, Chan FL: Spot tests for the detection of elemental arsenic, antimony, and tin. Chemist-Analyst 56:13-14, 1967
149. Feigl F, Chan FL: Spot tests for the detection of bound arsenic and antimony. Chemist-Analyst 56:14, 1967

150. Luis P, Sa A, Mascaro A: Capillary apparatus for nascent hydrogen production--Application to the detection of nitrate, nitrite, sulfur anions, antimony, and arsenic. *Mikrochim Acta* 5:1-6, 1969
151. Kaye S: Rapid, simple, reliable tests for poisons. *Lab Med* 3(5):28-41, 1972
152. Parissakis G, Iatridis B: A rapid quantitative determination of antimony and arsenic in their sulfides, minerals and concentrates by gas liquid chromatography. *J Chromatogr Sci* 12:737-41, 1974
153. Chesler SN, Juvet RS Jr: Anion exchange gas chromatography and the elution characteristics of metal bromides and iodides. *J Chromatogr Sci* 11:320-26, 1973
154. Juvet RS Jr, Fisher RL: Gas-Liquid chromatography of volatile metal fluorides. *Anal Chem* 37:1752-55, 1965
155. Schwedt G, Ruessel HA: [Gas chromatography of Tl, Se, Te, Hg, As, Sb, Bi, Sn as phenyl compounds.] *Fresenius Z Anal Chem* 264:301-03, 1973 (Ger)
156. Dubois L, Monkman JL: Polarographic determination of heavy metals in air samples. *Am Ind Hyg Assoc J* 25:485-91, 1964
157. Jacobsen E, Rojahn T: The polarographic determination of antimony. *Anal Chim Acta* 54:261-69, 1971
158. Bishara SW, Gawargious YA, Faltaoos BN: Polarographic microdetermination of cobalt, nickel, and antimony in organic compounds. *Anal Chem* 46:1103-05, 1974
159. Wolstenholme WA: Analysis of dried blood plasma by spark source mass spectrometry. *Nature* 203:1284-85, 1964
160. Harrison WW, Clemena GG: Survey analysis of trace elements in human fingernails by spark source mass spectrometry. *Clin Chim Acta* 36:485-92, 1972
161. Day MJ, Hickling SM: The measurement of antimony deposits in the lung. *Phys Med Biol* 12:455-67, 1967
162. Bloch P: Gamma-ray spectrometric method using a lithium-drifted silicon detector to determine the antimony deposits in the lung in vivo. *Radiology* 96:657-58, 1970
163. Dams R, Robbins JA, Rahn KA, Winchester JW: Nondestructive neutron activation analysis of air pollution particulates. *Anal Chem* 42:861-67, 1970
164. Peirson DH, Cawse PA, Salmon L, Cambray RS: Trace elements in the atmospheric environment. *Nature* 241:252-56, 1973

165. Linch AL, Hendrickson ER, Katz M, Martin RJ, Nelson GO, Pattison JN, Vander Kolk AL, Weidner RB, Harman JN: Nondestructive neutron activation analysis of air pollution particulates. *Health Lab Sci* 10:251-62, 1973
166. Howie RA, Molokhia MM, Smith H: Estimation of antimony in biological materials by neutron activation analysis. *Anal Chem* 37:1059-61, 1965
167. Brune D, Frykberg B, Samsahl K, Wester PO: Determination of elements in normal and leukemic human whole blood by neutron activation analysis, Facsimile Report, AE-60. Oak Ridge, Tenn, US Atomic Energy Commission, Technical Information Center, 1961, 16 pp
168. Brune D, Samsahl K, Wester PO: Determination of elements in milli-, micro-, and submicrogram quantities in human whole blood by neutron activation analysis. *Atompraxis* 9:368-73, 1963
169. Wester PO, Brune D, Samsahl K: Radiochemical recovery studies of a separation scheme for 23 elements in biological material. *Int J Appl Radiat Isot* 15:59-67, 1964
170. Wester PO: Concentration of 24 trace elements in human heart tissue determined by neutron activation analysis. *Scand J Clin Lab Invest* 17:357-70, 1965
171. Samsahl K, Brune D, Wester PO: Simultaneous determination of 30 trace elements in cancerous and non-cancerous human tissue samples by neutron activation analysis. *Int J Appl Radiat Isot* 16:273-81, 1965
172. Samsahl K: Radiochemical method for determination of arsenic, bromine, mercury, antimony, and selenium in neutron-irradiated biological material. *Anal Chem* 39:1480-83, 1967
173. Eckhoff ND, Clack RW, Anthony HD, Gray AP: Measurement of toxic heavy metals by neutron activation analysis. *Toxicol Appl Pharmacol* 24:178-81, 1973
174. Nadkarni RA, Morrison GH: Multielement instrumental neutron activation analysis of biological materials. *Anal Chem* 45:1957-60, 1973
175. Kennedy JH: Analysis of diseased and normal lung tissue for trace antimony content by neutron activation analysis. *Am J Med Sci* 251:37-39, 1966
176. Tanner TM, Rancitelli LA, Haller WA: Multielement analysis of natural waters by neutron activation, group chemical separations, and gamma-ray spectrometric techniques. *Water Air Soil Pollut* 1:132-43, 1972
177. Kaiser DG, Christian JE: Activation analysis of certain arsenic and antimony-containing pharmaceuticals and the effect of beta-emitting isotopes. *J Am Pharm Assoc (Sci Ed)* 48:650-52, 1959
178. Tanner JT, Friedman MH, Holloway GE: Arsenic and antimony in laundry aids by instrumental neutron activation analysis. *Anal Chim Acta* 59, 1973

179. Braverman MM, Masciello FA, Marsh V: Spectrographic trace analysis of air-borne particulates. J Air Pollut Control Assoc 11:408-09,427, 1961
180. Geldmacher M, Mallinckrodt V, Pooth M: [Simultaneous spectrochemical testing for 25 metals and metalloids in biological materials.] Arch Toxikol 25:5-18, 1969 (Ger)
181. Braman RS, Justen LL, Foreback CC: Direct volatilization-spectral emission type detection system for nanogram amounts of arsenic and antimony. Anal Chem 44:2195-99, 1972
182. Fassel VA, Kniseley RN: Inductively coupled plasma--Optical emission spectroscopy. Anal Chem 46:1110A-1111A,1116A-1120A, 1974
183. Svoboda V, Kleinmann I: High-current impulse argon arc method for the spectrographic analysis of microsamples. Anal Chem 40:1534-40, 1968
184. Stresko V, Martiny E: Determination of antimony in geological materials by atomic absorption spectrometry. At Absorpt Newsl 11:4-6, 1972
185. Supp GR: Determination of antimony in petroleum additives using atomic absorption spectrophotometry. At Absorpt Newsl 11:122-23, 1972
186. Schreiber BE, Frei RW: Determination of trace amounts of antimony by flameless atomic absorption spectroscopy. Int J Environ Anal Chem 2:149-56, 1972
187. Renshaw GD, Pounds CA, Pearson EF: The quantitative estimation of lead, antimony and barium in gunshot residues by non-flame atomic absorption spectrophotometry. At Absorpt Newsl 12:55-56, 1973
188. Hwang JY, Mokeler CJ, Ullucci PA: Maximization of sensitivities in tantalum ribbon flameless atomic absorption spectrometry. Anal Chem 44:2018-21, 1972
189. Kunselman GC, Huff EA: The determination of arsenic, antimony, selenium, and tellurium in environmental water samples by flameless atomic absorption. At Absorpt Newsl 15:29-32, 1976
190. Pollock EN, West SJ: The determination of antimony at submicrogram levels by atomic absorption spectrophotometry. At Absorpt Newsl 11:104-06, 1972
191. Pollock EN, West SJ: The generation and determination of covalent hydrides by atomic absorption. At Absorpt Newsl 12:6-8, 1973
192. Yamamoto Y, Kumamaru T, Hayashi Y: Enhancement of sensitivity for antimony determination in atomic absorption spectrophotometry by introducing stibine into an argon-hydrogen flame. Anal Lett 5:419-24, 1972
193. Fernandez FJ: Atomic absorption determination of gaseous hydrides utilizing sodium borohydride reduction. At Absorpt Newsl 12:93-97, 1973

194. Thompson KC, Thomerson DR: Atomic-absorption studies on the determination of antimony, arsenic, bismuth, germanium, lead, selenium, tellurium and tin by utilizing the generation of covalent hydrides. *Analyst* 99:595-601, 1974
195. Schmidt FJ, Royer JL: Submicrogram determination of arsenic, selenium, antimony and bismuth by atomic absorption utilizing sodium borohydride reduction. *Anal Lett* 6:17-23, 1973
196. Fleming HD, Ide RG: Determination of volatile hydride-forming metals in steel by atomic absorption spectrometry. *Anal Chim Acta* 83:67-82, 1976
197. Goulden PD, Brooksbank P: Automated atomic absorption determination of arsenic, antimony, and selenium in natural waters. *Anal Chem* 46:1431-36, 1974
198. Fiorino JA, Jones JW, Capar SG: Sequential determination of arsenic, selenium, antimony, and tellurium in foods via rapid hydride evolution and atomic absorption spectrometry. *Anal Chem* 48:120-25, 1976
199. Schmidt FJ, Royer JL, Muir SM: Automated determination of arsenic, selenium, antimony, bismuth and tin by atomic absorption utilizing sodium borohydride reduction. *Anal Lett* 8:123-28, 1975
200. Industrial Ventilation Manual--A Manual of Recommended Practice, ed 15. Cincinnati, American Conference of Governmental Industrial Hygienists, 1978, pp 1-1 to 14-8
201. American National Standard--Fundamentals Governing the Design and Operation of Local Exhaust Systems, ANSI Z9.2-1971. New York, American National Standards Institute, 1972, 65 pp
202. Haring HE, Compton KG: The generation of stibine by storage batteries. *Trans Electrochem Soc* 68:283-92, 1936
203. Stokinger HE: Antimony, Sb, in Patty FA (ed.): *Industrial Hygiene and Toxicology*, ed 2 rev; *Toxicology* (Fassett DW, Irish DD, eds.). New York, Interscience Publishers, 1963, vol 2, pp 993-98
204. Antimony Trichloride (Anhydrous), Chemical Safety Data Sheet SD-66. Washington, DC, Manufacturing Chemists Association Inc, 1957, 13 pp
205. Proceedings of the Ninth Annual Meeting, American Conference of Governmental Industrial Hygienists, Committee on Threshold Limits, Buffalo, April 26-29, 1947, pp 43-45
206. Transactions of the Tenth Annual Meeting, American Conference of Governmental Industrial Hygienists, Committee on Threshold Limits, Boston, March 27-30, 1948, pp 29-32
207. Elkins HB: *The Chemistry of Industrial Toxicology*. New York, John Wiley and Sons, Inc, 1950, pp 67-68, 225

208. Threshold limit values adopted at the meeting of the American Conference of Governmental Industrial Hygienists, Chicago, April 1950. AMA Arch Ind Hyg Occup Med 2:98-100, 1950
209. Threshold limit values for 1953 adopted at the meeting of the American Conference of Governmental Industrial Hygienists, Los Angeles, April 1953. AMA Arch Ind Hyg Occup Med 8:296-98, 1953
210. Smyth HF Jr: Improved communication--Hygienic standards for daily inhalation. Am Ind Hyg Assoc Q 17:129-85, 1956
211. Documentation of Threshold Limit Values. Cincinnati, American Conference of Governmental Industrial Hygienists, 1962, pp 9-10,95
212. Documentation of Threshold Limit Values, rev ed. Cincinnati, American Conference of Governmental Industrial Hygienists, Committee on Threshold Limits, 1966, pp 13,176
213. Documentation of Threshold Limit Values for Substances in Workroom Air, ed 3. Cincinnati, American Conference of Governmental Industrial Hygienists, 1971, pp 14-15,223
214. Klucik I, Juck A, Gruberova J: [Lesions of the respiratory tract and the lungs caused by pulverulent antimony trioxide.] Prac Lek 14:363-68, 1962 (Cze)
215. Klucik I, Kemka R: [Antimony excretion among workers in an antimony plant.] Prac Lek 12:133-38, 1960 (Cze)
216. TLVs--Threshold Limit Values for Chemical Substances in Workroom Air Adopted by ACGIH for 1975. Cincinnati, American Conference of Governmental Industrial Hygienists, 1975, pp 11,37,42
217. TLVs--Threshold Limit Values for Chemical Substances in Workroom Air Adopted by ACGIH for 1976. Cincinnati, American Conference of Governmental of Industrial Hygienists, 1976, pp 2,3,9,34,38
218. Supplements for those substances added or changed--Year 1976, in Documentation of the Threshold Limit Values for Substances in Workroom Air, ed 3. Cincinnati, American Conference of Governmental Industrial Hygienists, 3rd Printing 1976, pp 14-15,409-31
219. TLVs--Threshold Limit Values for Chemical Substances in Workroom Air Adopted by ACGIH for 1977. Cincinnati, American Conference of Governmental Industrial Hygienists, 1977, pp 9,35
220. Occupational Exposure Limits for Airborne Toxic Substances--A Tabular Compilation of Values from Selected Countries, Occupational Safety and Health Series No. 37. Geneva, International Labour Office, 1977, pp 44-45
221. Threshold Limit Values of Air-borne Contaminants for 1968--Recommended and Intended Values, Adopted by the 30th Annual Meeting, ACGIH, St Louis, May 13, 1968. Cincinnati, American Conference of Governmental Industrial Hygienists, 1968, pp 1-5

- 222. Winell MA: An international comparison of hygienic standards for chemicals in the work environment. *Ambio* 4:34-36, 1975
- 223. Pritchard JA: A Guide to Industrial Respiratory Protection, HEW Publication No. (NIOSH) 76-189. Cincinnati, US Dept of Health, Education, and Welfare, Public Health Service, Center for Disease Control, National Institute for Occupational Safety and Health, 1976, 150 pp
- 224. Gordon J, Kornreich M, Ouellette R, Thomas L, Walker P: Preliminary Assessment of Antimony in the Atmosphere, MTR-7158. McLean, Va, Mitre Corp, 1976, 58 pp
- 225. Sax NI: Dangerous Properties of Industrial Materials, ed 4. New York, Van Nostrand Reinhold Co, 1975, pp 412-16
- 226. Kusnetz S, Hutchison MK (eds.): Antimony, in A Guide to Work-Relatedness of Disease, ed 2. To be published by US Dept of Health, Education, and Welfare, Public Health Service, Center for Disease Control, National Institute for Occupational Safety and Health, 1978

IX. APPENDIX I

METHODS FOR SAMPLING ANTIMONY IN AIR

General Requirements

(a) Collect air samples representative of the breathing zones of individual workers to characterize the exposure from each job or specific operation in each work area.

(1) Collect samples as near as practicable to the face of workers without interfering with freedom of movement.

(2) Collect samples to permit determination of exposures for every job involving antimony in sufficient numbers to express the variability of the exposures for the work situation.

(b) Suggested records:

- (1) Date and time of sample collection;
- (2) Sampling rate and duration;
- (3) Total sample volume;
- (4) Location of sampling;
- (5) Temperature, pressure, and relative humidity at time of sampling; and
- (6) Other pertinent information regarding worker and work setting.

Sampling for Particulate Antimony and Compounds

(a) The sampling equipment consists of:

(1) A portable, battery-operated personal sampling pump calibrated to $\pm 5\%$ of the required flowrate.

(2) A 2-or 3-piece filter cassette containing an $0.8\text{-}\mu\text{m}$ cellulose ester membrane filter (Millipore type AA, or equivalent) supported by a cellulose backup pad for collecting the sample.

(b) The sampling rate must be accurately ($\pm 5\%$) maintained at the target value, which should lie within the range of 1.5–2.5 liters/minute. Samples should be taken for a time period that will provide at least $2.5\text{ }\mu\text{g}$ Sb in the sample.

(c) Upon completion of sampling, plastic plugs are replaced on the inlet and outlet openings of the cassette and an appropriate identification is attached. A minimum of four samples are taken for each operation and averaged

on a time-weighted basis. Note the suspected identities of all substances present in the air sample.

(d) To determine background correction, a field blank and a laboratory blank are analyzed along with the samples. The field blank is a filter that is handled in exactly the same manner as the samples (ie, placed in a cassette) except that no air is drawn through it. The laboratory blank is a clean, unused filter which has not been handled.

Sampling for Volatile Antimony Compounds

(a) The sampling equipment consists of:

(1) A prefilter unit (if needed), consisting of an 0.8- μ m membrane filter in a cassette filter holder. Possible interactions between reactive, volatile antimony compounds and the prefilter may cause erroneously low readings in the impinger sample.

(2) A midget impinger containing 10 ml of absorbing solution. The absorbing solution is made by dissolving 50 g mercuric chloride in 1 liter of 6N hydrochloric acid.

(3) A personal sampling pump capable of calibration to $\pm 5\%$ of the required flowrate, which should be 1.5-2.5 liters per minute.

(4) The sampling pump is protected from splashover or water condensation by an absorption tube loosely packed with glass wool and inserted between the exit arm of the impinger and the pump. Connect the impinger via the absorption tube to the pump and the prefilter assembly (if needed) with a short piece of nonrubber, flexible tubing. The air being sampled should not be passed through any other tubing or other equipment before entering the impinger.

(b) After sampling, remove the impinger stem and rinse it with 2 or 3 ml of distilled-deionized water, collecting the rinsings in the impinger. The impinger is then sealed with a nonreactive stopper, such as Teflon. Do not use a rubber stopper. If it is preferred to store or ship the impinger with the stem in, the openings should be sealed with an inert film or other nonrubber cover, and the ground glass joint should be taped securely. Care should be taken to minimize spillage or loss by evaporation at all times.

(c) A "blank" impinger should be handled in the same manner as the samples (ie, fill, seal, transport, and analyze) except that no air is sampled through it.

(d) Where a prefilter has been used, the filter cassettes are capped and appropriately identified. The prefilter, along with blank filters, is analyzed for particulate antimony and antimony compounds.

(e) Samples should be collected so as to contain at least 2.5 μ g Sb if analysis is to be by the flameless method. If the flame method is used, at least 50 μ g Sb should be collected.

Calibration of Equipment

Since the accuracy of an analysis can be no greater than the accuracy with which the volume of air is measured, the accurate calibration of the sampling pump is essential. The frequency of calibration required depends on the use, care, and handling to which the pump is subjected. Pumps should be calibrated initially and recalibrated if they have been abused or repaired. Regardless of use, maintenance and calibration should be performed on a routine schedule, and records of these should be kept.

The accuracy of calibration depends on the type of instrument used for calibration. The choice of instrument will depend largely on where the calibration is to be performed. For laboratory testing, a spirometer or soapbubble meter is recommended, although other calibration instruments, such as a wet test meter, dry gas meter, or rotameter can be used. For field testing, calibration as necessary using a rotameter is recommended. Since the flowrate given by a pump depends on the pressure drop across the sampling device, the pump must be calibrated while operating with a representative filter in line.

X. APPENDIX II

ANALYTICAL METHODS FOR ANTIMONY

Method for Particulates

A known volume of air is drawn through a membrane filter to collect particulate matter. The residue obtained from digesting the collected particulate matter in a mixture of nitric, perchloric, and sulfuric acids is diluted with distilled water; aliquots are analyzed for antimony at 217.6 nm by flameless atomic absorption. If lead is present in the sample, the 231.2-nm resonance line is used.

Method for Volatile Antimony Compounds

Air samples collected in impinger solutions are analyzed directly by flameless atomic absorption.

Range and Sensitivity

The analytical range is 0.05-1.0 mg of antimony/cu m for a 50-liter air sample diluted to 50 ml for particulates and 25 ml for volatile compounds; a 25- μ l aliquot is used for analysis. This range corresponds to 2.5-50 μ g Sb in the collected sample. The analytical range may be extended by altering the dilution volume or the size of the analytical aliquot.

Sensitivity varies with different instruments, graphite tubes, and sample matrices. NIOSH has found a sensitivity of 125 pg Sb/1% absorbance in ashed filter solutions and 250 pg Sb/1% absorbance in 5% HgCl₂/6N HCl. Sensitivity may be increased 5-fold over these values by using the purge-gas interrupt mode.

Interferences

(a) Lead in the sample will absorb at 217.0 nm and may interfere at 217.6 nm if the reading power of the instrument is not adequate.

(b) Flameless atomic absorption is prone to matrix effects; standard addition methods can be used to evaluate such interferences.

Precision and Accuracy

The performance characteristics of the method as found by NIOSH are discussed in subsections (a) and (b).

(a) The pooled coefficient of variation for the analysis of five calibration solutions (10 determinations each) covering the range (0.05-1.0 μ g/ml) was 0.038.

(b) The recoveries of antimony from filters spiked with 5.0, 12.5, and 25.0 μg Sb/filter were $100 \pm 3.9\%$, $99.3 \pm 2.9\%$, and $98.7 \pm 3.2\%$, respectively. The pooled coefficient of variation was 0.034.

Advantages of the Flameless Method

(a) It is approximately 50-100 times more sensitive than conventional flame atomic absorption.

(b) It requires fewer operations on the sample and has a lower coefficient of variation than hydride generation techniques.

Disadvantages of the Flameless Method

Matrix effects are more prevalent than with conventional flame atomic absorption.

Apparatus

(a) Atomic absorption spectrophotometer with graphite atomizer and deuterium or hydrogen continuum correction.

(b) Hollow cathode or electrodeless discharge lamp for antimony (wavelength, 217.6 nm).

(c) Argon, high purity, in a cylinder equipped with a two-stage pressure regulator and appropriate hose connections.

(d) Variable temperature hotplate capable of reaching 350 C.

(e) Perchloric acid fume hood.

(f) Borosilicate glassware, including:

(1) Phillips beakers with watchglass covers (125 ml);

(2) Volumetric flasks, (50 and 100 ml);

(3) Volumetric pipets, (1, 5, and 10 ml);

(4) Micro-pipets, (10, 25, 50 and 100 μl);

(5) Small test tubes (10 ml).

Reagents

(a) Double distilled or deionized water.

(b) Nitric acid, concentrated, analytic reagent grade, redistilled in glass.

- (c) Perchloric acid, 70%, analytic reagent grade.
- (d) Sulfuric acid, 98%, analytic reagent grade.
- (e) Ashing acid, (3:1:1, nitric:perchloric:sulfuric).
- (f) Antimony stock solution containing antimony at 1,000 $\mu\text{g/ml}$.
- (g) Mercuric chloride (HgCl_2).
- (h) Hydrochloric acid, 6N, redistilled (constant-boiling HCl is approximately 6N).

Procedure

(a) Cleaning of Equipment

(1) Before first use, clean all glassware with a detergent solution, followed in order by rinsing with water, rinsing with distilled water, soaking 30 minutes in concentrated nitric acid, and thorough rinsing in distilled water.

(2) Glassware used exclusively for antimony analysis may be cleaned by soaking for 30 minutes in dilute nitric acid followed by thorough rinsing in distilled water.

(b) Analysis of Samples

(1) Place sample filters and blank filters in 125-ml Phillips beakers, add 5 ml of ashing acid, cover with a watchglass and heat at 140 C on a hotplate for 2 hours. Increase the temperature to 200 C and reduce the volume of solution to approximately 2 ml. Complete digestion is indicated by a nearly colorless residual solution. Additional small amounts (1 ml) of nitric acid may be added and evaporated to complete digestion. Remove the watchglass and raise the temperature to 350 C until the evolution of sulfur trioxide is complete and the residual volume is reduced to 0.5 ml. Do not allow the solution to evaporate to dryness. Cool, then add 1 ml of H_2SO_4 , transfer quantitatively to a volumetric flask, and dilute to volume with distilled water.

(2) For impinger samples, quantitatively transfer the contents of the impinger to a 25-ml volumetric flask. Dilute to volume with distilled water.

(3) Analyze triplicate aliquots of sample solution for antimony by flameless atomic absorption using the manufacturer's recommended operating conditions except for drying, charring, and atomizing times and temperatures. For these, use the following:

- (A) Dry for 30 seconds at 110 C;
- (B) Char for 20 seconds at 700 C; and
- (C) Atomize for 8 seconds at 2,700 C.

(4) Analyze triplicate aliquots of standard solutions, at least one standard analysis for three sample analyses.

(c) Determine the concentration of antimony present in the sample from a standard curve or by standard addition, as indicated below.

(1) Standard Curve

(A) For analysis of particulate samples, prepare at least five standard solutions containing a series of concentrations of antimony within the analytical range of the method. Prepare the final dilutions by transferring the required aliquot to 3 ml of sulfuric acid and diluting to 100 ml with distilled water.

(B) For analysis of volatile compounds, prepare at least five standard solutions containing a series of concentrations of antimony within the analytical range of the method. The concentration of the Cl_2 and HCl in the standards should be made identical to those in the samples by diluting 10 ml of 5% HgCl_2 in 6N HCl to 25 ml with distilled water after adding an appropriate amount of antimony stock solution. Prepare a blank solution by diluting 10 ml of 5% $\text{HgCl}_2/6\text{N}$ HCl to 25 ml with distilled water.

(C) Determine absorbance of the standard solutions and subtract the absorbance of the blank solution from each.

(D) Prepare a calibration curve by plotting absorbance vs concentration of antimony in $\mu\text{g}/\text{ml}$.

(E) From the peak absorbance of the samples, subtract the absorbance of the filter blank to determine the corrected sample absorbance. Compare the corrected sample absorbance with the calibration curve to determine the amount of antimony, in $\mu\text{g}/\text{ml}$, in the sample solution.

The concentration of antimony in air is calculated as follows:

$$C = \mu\text{g Sb/ml} \times \frac{V}{V_s}$$

where:

C = Concentration of antimony (mg Sb/cu m)

$\mu\text{g Sb/ml}$ = Concentration determined from the calibration curve

V = Volume of diluted solution (ml)

V_s = Volume of air samples (liters)

(2) Standard Addition

(A) To a series of at least three test tubes containing equal aliquots (5 ml) of the sample solution, add, to all but one, aliquots of a standard antimony solution graded to contain multiples, such as 0.5, 1, 2, and 3, of the amount of antimony estimated to be present in the sample aliquots. Make the final volume in all test tubes equal by adding distilled water. Prepare a similar set of test tubes starting with equal aliquots (5 ml) of the

filter blank solution. All concentrations of antimony must fall within the linear portion of the standard curve; otherwise the standard addition is invalid.

(B) Analyze triplicate aliquots of each of these sample and blank solutions.

(C) Plot the absorbance values for the sample solutions and the spiked sample solutions against an abscissa labeled " μg of Sb added/ N ml." Draw the best straight line through the points. The intercept of this line on the negative abscissa (0.0 absorbance units) is read as the concentration in $\mu\text{g}/N$ ml of antimony in the sample solution. The concentration is converted to $\mu\text{g}/\text{ml}$ by multiplying by N . Subtract the concentration, if any, in $\mu\text{g}/\text{ml}$ for the blank from the samples. Convert to $\text{mg Sb}/\text{cu m}$.

If the result of this determination is not within 10% of the values obtained from the standard curve, an interference is indicated and standard addition techniques should be utilized for sample analysis.

XI. APPENDIX III

MATERIAL SAFETY DATA SHEET

General instructions for preparing a Material Safety Data Sheet (MSDS) are presented in this appendix. The examples used in the text are for illustrative purposes and are not intended to apply to any specific compound or product. Applicable information about a specific product or material shall be supplied in the appropriate block of the MSDS.

The product designation is inserted in the block in the upper left corner of the first page to facilitate filing and retrieval. Print in upper case letters as large as possible. It should be printed to read upright with the sheet turned sideways. The product designation is that name or code designation which appears on the label, or by which the product is sold or known by employees. The relative numerical hazard ratings and key statements are those determined by the guidelines in Chapter V, Part B, of the NIOSH publication, An Identification System for Occupationally Hazardous Materials. The company identification may be printed in the upper right corner if desired.

(a) Section I. Product Identification

The manufacturer's name, address, and regular and emergency telephone numbers (including area code) are inserted in the appropriate blocks of Section I. The company listed should be a source of detailed backup information on the hazards of the material(s) covered by the MSDS. The listing of suppliers or wholesale distributors is discouraged. The trade name should be the product designation or common name associated with the material. The synonyms are those commonly used for the product, especially formal chemical nomenclature. Every known chemical designation or competitor's trade name need not be listed.

(b) Section II. Hazardous Ingredients

The "materials" listed in Section II shall be those substances which are part of the hazardous product covered by the MSDS and individually meet any of the criteria defining a hazardous material. Thus, one component of a multicomponent product might be listed because of its toxicity, another component because of its flammability, while a third component could be included both for its toxicity and its reactivity. Note that a MSDS for a single component product must have the name of the material repeated in this section to avoid giving the impression that there are no hazardous ingredients.

Chemical substances should be listed according to their complete name derived from a recognized system of nomenclature. Where possible, avoid using common names and general class names such as "aromatic amine," "safety solvent," or "aliphatic hydrocarbon" when the specific name is known.

The "%" may be the approximate percentage by weight or volume (indicate basis) which each hazardous ingredient of the mixture bears to the whole

mixture. This may be indicated as a range or maximum amount, ie, "10-40% vol" or "10% max wt" to avoid disclosure of trade secrets.

Toxic hazard data shall be stated in terms of concentration, mode of exposure or test, and animal used, eg, "100 ppm LC50-rat," "25 mg/kg LD50-skin-rabbit," "75 ppm LC man," or "permissible exposure from 29 CFR 1910.1000," or, if not available, from other sources of publications such as the American Conference of Governmental Industrial Hygienists or the American National Standards Institute Inc. Flashpoint, shock sensitivity or similar descriptive data may be used to indicate flammability, reactivity, or similar hazardous properties of the material.

(c) Section III. Physical Data

The data in Section III should be for the total mixture and should include the boiling point and melting point in degrees Fahrenheit (Celsius in parentheses); vapor pressure, in conventional millimeters of mercury (mmHg); vapor density of gas or vapor (air = 1); solubility in water, in parts/hundred parts of water by weight; specific gravity (water = 1); percent volatiles (indicate if by weight or volume) at 70 F (21.1 C); evaporation rate for liquids or sublimable solids, relative to butyl acetate; and appearance and odor. These data are useful for the control of toxic substances. Boiling point, vapor density, percent volatiles, vapor pressure, and evaporation are useful for designing proper ventilation equipment. This information is also useful for design and deployment of adequate fire and spill containment equipment. The appearance and odor may facilitate identification of substances stored in improperly marked containers, or when spilled.

(d) Section IV. Fire and Explosion Data

Section IV should contain complete fire and explosion data for the product, including flashpoint and autoignition temperature in degrees Fahrenheit (Celsius in parentheses); flammable limits, in percent by volume in air; suitable extinguishing media or materials; special firefighting procedures; and unusual fire and explosion hazard information. If the product presents no fire hazard, insert "NO FIRE HAZARD" on the line labeled "Extinguishing Media."

(e) Section V. Health Hazard Information

The "Health Hazard Data" should be a combined estimate of the hazard of the total product. This can be expressed as a TWA concentration, as a permissible exposure, or by some other indication of an acceptable limit. Other data are acceptable, such as lowest LD50, if multiple components are involved.

Under "Routes of Exposure," comments in each category should reflect the potential hazard from absorption by the route in question. Comments should indicate the severity of the effect and the basis for the statement, if possible. The basis might be animal studies, analogy with similar products, or human experiences. Comments such as "yes" or "possible" are not helpful. Typical comments might be:

Skin Contact--single short contact, no adverse effects likely; prolonged or repeated contact, irritation, and cracking.

Eye Contact--some pain and mild transient irritation; no corneal scarring.

"Emergency and First Aid Procedures" should be written in lay language and should primarily represent first-aid treatment that could be provided by paramedical personnel or individuals trained in first aid.

Information in the "Notes to Physician" section should include any special medical information which would be of assistance to an attending physician including required or recommended preplacement and periodic medical examinations, diagnostic procedures, and medical management of overexposed workers.

(f) Section VI. Reactivity Data

The comments in Section VI relate to safe storage and handling of hazardous, unstable substances. It is particularly important to highlight instability or incompatibility to common substances or circumstances such as water, direct sunlight, steel or copper piping, acids, alkalies, etc. "Hazardous Decomposition Products" shall include those products released under fire conditions. It must also include dangerous products produced by aging, such as peroxides in the case of some ethers. Where applicable, shelf life should also be indicated.

(g) Section VII. Spill or Leak Procedures

Detailed procedures for cleanup and disposal should be listed with emphasis on precautions to be taken to protect workers assigned to cleanup detail. Specific neutralizing chemicals or procedures should be described in detail. Disposal methods should be explicit including proper labeling of containers holding residues and ultimate disposal methods such as "sanitary landfill," or "incineration." Warnings such as "comply with local, state, and Federal antipollution ordinances" are proper but not sufficient. Specific procedures should be identified.

(h) Section VIII. Special Protection Information

Section VIII requires specific information. Statements such as "Yes," "No," or "If Necessary" are not informative. Ventilation requirements should be specific as to type and preferred methods. Specify respirators as to type and NIOSH or US Mine Safety and Health Administration approval class, ie, "Supplied air," "Organic vapor canister," "Suitable for dusts not more toxic than lead," etc. Protective equipment must be specified as to type and materials of construction.

(i) Section IX. Special Precautions

"Precautionary Statements" shall consist of the label statements selected for use on the container or placard. Additional information on any aspect of safety or health not covered in other sections should be inserted in Section

IX. The lower block can contain references to published guides or in-house procedures for handling and storage. Department of Transportation markings and classifications and other freight, handling, or storage requirements and environmental controls can be noted.

(j) Signature and Filing

Finally, the name and address of the responsible person who completed the MSDS and the date of completion are entered. This will facilitate correction of errors and identify a source of additional information.

The MSDS shall be filed in a location readily accessible to workers potentially exposed to the hazardous material. The MSDS can be used as a training aid and basis for discussion during safety meetings and training of new employees. It should assist management by directing attention to the need for specific control engineering, work practices, and protective measures to ensure safe handling and use of the material. It will aid the safety and health staff in planning a safe and healthful work environment and in suggesting appropriate emergency procedures and sources of help in the event of harmful exposure of employees.

MATERIAL SAFETY DATA SHEET

I PRODUCT IDENTIFICATION		
MANUFACTURER'S NAME		REGULAR TELEPHONE NO EMERGENCY TELEPHONE NO
ADDRESS		
TRADE NAME		
SYNONYMS		
II HAZARDOUS INGREDIENTS		
MATERIAL OR COMPONENT	%	HAZARD DATA
III PHYSICAL DATA		
BOILING POINT, 760 MM HG		MELTING POINT
SPECIFIC GRAVITY (H ₂ O = 1)		VAPOR PRESSURE
VAPOR DENSITY (AIR = 1)		SOLUBILITY IN H ₂ O, % BY WT
% VOLATILES BY VOL		EVAPORATION RATE (BUTYL ACETATE = 1)
APPEARANCE AND ODOR		

IV FIRE AND EXPLOSION DATA				
FLASH POINT (TEST METHOD)			AUTOIGNITION TEMPERATURE	
FLAMMABLE LIMITS IN AIR, % BY VOL.		LOWER		UPPER
EXTINGUISHING MEDIA				
SPECIAL FIRE FIGHTING PROCEDURES				
UNUSUAL FIRE AND EXPLOSION HAZARD				
V HEALTH HAZARD INFORMATION				
HEALTH HAZARD DATA				
ROUTES OF EXPOSURE				
INHALATION				
SKIN CONTACT				
SKIN ABSORPTION				
EYE CONTACT				
INGESTION				
EFFECTS OF OVEREXPOSURE				
ACUTE OVEREXPOSURE				
CHRONIC OVEREXPOSURE				
EMERGENCY AND FIRST AID PROCEDURES				
EYES				
SKIN				
INHALATION				
INGESTION				
NOTES TO PHYSICIAN				

VI REACTIVITY DATA
CONDITIONS CONTRIBUTING TO INSTABILITY
INCOMPATIBILITY
HAZARDOUS DECOMPOSITION PRODUCTS
CONDITIONS CONTRIBUTING TO HAZARDOUS POLYMERIZATION
VII SPILL OR LEAK PROCEDURES
STEPS TO BE TAKEN IF MATERIAL IS RELEASED OR SPILLED
NEUTRALIZING CHEMICALS
WASTE DISPOSAL METHOD
VIII SPECIAL PROTECTION INFORMATION
VENTILATION REQUIREMENTS
SPECIFIC PERSONAL PROTECTIVE EQUIPMENT
RESPIRATORY (SPECIFY IN DETAIL)
EYE
GLOVES
OTHER CLOTHING AND EQUIPMENT

IX SPECIAL PRECAUTIONS

PRECAUTIONARY
STATEMENTS

OTHER HANDLING AND
STORAGE REQUIREMENTS

PREPARED BY _____

ADDRESS _____

DATE _____

XII. TABLES

TABLE XII-1

PHYSICAL AND CHEMICAL PROPERTIES OF ANTIMONY AND SOME OF ITS INORGANIC COMPOUNDS

Substance	Formula Weight	SG*	Melting Point C	Boiling Point C	Temperature for 1 mm Hg Vapor Pressure	Solubility Data, Solvent and Degree**
<u>Solids at STP</u>						
Antimony (Sb)	121.76	6.68	630	1,380	886 C	Hot conc. H ₂ SO ₄ s Aqua regia s Dilute acids i
Antimony trioxide (Sb ₂ O ₃)	291.52	5.2	656	1,550	574 C	Hot water sl s Conc. HCl s Conc. H ₂ SO ₄ s KOH
Antimony pentoxide (Sb ₂ O ₅)	323.5	3.78	loses O at 380 C loses O ₂ at 930 C			Hot water i Cold water i Conc. HCl s KOH s
Antimony trisulfide (Sb ₂ S ₃)	339.7	4.64	550	1,150		Water i Hot water d Alkali s Conc. HCl s Sulfide solns s
Antimony pentasulfide (Sb ₂ S ₅)	403.82	4.12	75 d**			Hot water i Alkali s

TABLE XII-1 (CONTINUED)

PHYSICAL AND CHEMICAL PROPERTIES OF ANTIMONY AND SOME OF ITS INORGANIC COMPOUNDS

Substance	Formula Weight	SG*	Melting Point C	Boiling Point C	Temperature for 1 mm Hg Vapor Pressure	Solubility Data, Solvent and Degree**	
Antimony trichloride (SbCl ₃)	228.13	3.14	73.4	283	49.2 C (sublimes)	Alcohol	i
						Acetone	s
						Acids	s
Antimony trifluoride (SbF ₃)	178.8	4.38	292	319 (Sublimes)		Cold water	385
						Hot water	5.6
						NH ₃	i
<u>Liquids at STP</u>							
Antimony pentachloride (SbCl ₅)	299.05	2.34	2.8	79 (at 22 mm Hg)	22.7 C	Excess water	d
						HCl	s
						Chloroform	s
Antimony pentafluoride (SbF ₅)	216.76	2.99	7	149.5		Cold water	s
						KF	s
<u>Gas at STP</u>							
Antimony hydride (SbH ₃)	124.78	4.34 (15 C, air=1)	-88	-17		Cold water	500
						Water 100 C	250

*SG-specific gravity

**s-soluble, sl s-slightly soluble, i-insoluble, d-decomposes; numerical values in g/100 ml

Adapted from references 131,224-26

TABLE XII-2

US INDUSTRIAL CONSUMPTION OF PRIMARY ANTIMONY IN 1976
BY CLASS OF MATERIAL PRODUCED

Product	Antimony Content (Short Tons)
Metal products	
Ammunition	63
Antimonial lead	3,861
Bearing metal and bearings	405
Cable covering	19
Castings	24
Collapsible tubes and foil	23
Sheet and pipe	74
Solder	188
Type metal	79
Other	164
Subtotal	4,900
Nonmetal products (excluding flame retardants)	
Ammunition primers	13
Fireworks	12
Ceramics and glass	1,260
Pigments	415
Plastics	1,277
Rubber products	578
Other	1,330
Subtotal	4,885
Flame retardants	
Plastics	3,777
Pigments	183
Rubber	199
Adhesives	141
Textiles	1,055
Paper	197
Subtotal	5,552
Total	15,337

Adapted from reference 2

TABLE XII-3

US INDUSTRIAL CONSUMPTION OF ANTIMONY IN 1976
BY CLASS OF MATERIAL CONSUMED

Material Consumed	Antimony Content (Short Tons)	End Use
Primary Antimony:		
Metal	3,375	Solder, type metal, ammunition, storage batteries, power transmission and communication equipment
Ore and concentrate	640	
Oxide	10,397	Glass products, rubber and plastics, textiles, chemicals, metalware
Sulfide	37	Pigments, plastics, ammunition, visual signaling, vulcanizing agent
Byproduct antimonial lead	697	Storage batteries, cable covering, printing and publishing, communications, ammunition
Residues	191	
Secondary Antimony:		
Antimonial lead and other alloys	19,799	Storage batteries, cable covering, printing and publishing, communications, ammunition

Adapted from references 1 and 2

TABLE XII-4

POTENTIALLY HAZARDOUS ANTIMONY COMPOUNDS

Chemical Name	Synonym
Antimony	Regulus of antimony, antimony regulus, stibium
Antimony arsenate	
Antimony arsenite	
Antimony dioxysulfate	
Antimony ethoxide	Triethyl antimonite
Antimony hydride	Stibine, antimonous hydride hydrogen antimonide
Antimony lactate	Antimonine, antimony salt of lactic acid
Antimony a-mercaptoacetamide	Antimony thioglycolamide
Antimony pyrogallol	
Antimony oxychloride	Algaroth powder, antimonyl chloride, antimony chloride oxide, basic antimony chloride, mercurius vitae
Antimony oxysulfide	Cathusian powder, kermes mineral, kermesite, pyrostibonite antimony blend, sulfurated antimony
Antimony pentachloride	Antimony perchloride, butter of antimony, antimonie chloride
Antimony pentafluoride	Antimony fluoride
Antimony pentaiodide	Antimony iodide
Antimony pentasulfide	Antimony red, antimony sulfide, antimonial saffron, antimony persulfide, golden antimony sulfide
Antimony pentoxide	Antimonie anhydride, antimonie oxide, antimonie acid, antimonie pentoxide, stibic anhydride
Antimony potassium dimethylcysteine tartrate	
Antimony potassium oxalate	Potassium-antimony oxalate, potassium oxalatoantimonate
Antimony sodium dimethylcysteine tartrate	
Antimony sodium gluconate	Antimony gluconate complex sodium salt, antimony gluconate sodium, gluconic acid, antimony sodium derivative, sodium antimony gluconate, sodium stibogluconate, triostam, T.S.A.G.
Antimony sodium tartrate	Antimony sodium oxide L-tartrate, Emeto-Na, sodium antimonyl tartrate, stibunal
Antimony sodium thioglycollate	Antimony sodium thioacetate, mercaptoacetic acid
Antimony sulfate	Antimony salt of sulfuric acid, antimonous sulfate, antimony trisulfate
Antimony tetroxide	Antimony oxide

TABLE XII-4 (CONTINUED)

POTENTIALLY HAZARDOUS ANTIMONY COMPOUNDS

Chemical Name	Synonym
Antimony tribromide	Antimonous bromide, antimony bromide
Antimony trichloride	Antimonous chloride, butter of antimony, caustic antimony, mineral butter
Antimony trichloride solution	Antimony chloride solution, liquid butter of antimony
Antimony trifluoride	Antimonous fluoride, antimony fluoride
Antimony trioxide	Antimony white, flowers of antimony, antimony bloom, antimony oxide, black antimony, weisspiess-glanz
Antimony triiodide	Antimonous iodide, antimony iodide
Antimony triselenide	
Antimony trisulfide	Sulfuret of antimony, antimony orange, black antimony, antimony needles, antimonous sulfide, antimony glance, crimson antimony, gray antimony
Antimony tritelluride	Antimony telluride
Emetine antimony iodide	Antimony emetine iodide
Lead antimonate	Antimony yellow, Naples yellow
Oxo(tartrato)antimonate (1-)aniline	Aniline antimonyl tartrate, antimonyl aniline tartrate
Sodium antimonate	Antimony sodiate
Sodium antimonyl adonitol	
Sodium antimonyl D-arabitol	
Sodium antimonyl biscatechol	
Sodium antimonyl tert-butyl catechol	
Sodium antimonyl catechol thiosalicylate	Sodium antimonous-3-catechol thiosalicylate, stibsol
Sodium antimonyl citrate	
Sodium antimonyl erythritol	
Sodium antimonyl D-funcitol	
Sodium antimonyl gluco-guloheptitol	
Sodium antimonyl glycerol	
Sodium antimonyl 2,5-methylene D-mannitol	
Sodium antimonyl 2,4-methylene D-sorbitol	
Sodium antimonyl xylitol	

Adapted from reference 226

TABLE XII-5

OCCUPATIONS WITH POTENTIAL EXPOSURE TO ANTIMONY

Antimony ore smelters	Metal bronzers
Antimony workers	Miners
Babbitt metal workers	Monotypers
Battery workers, storage	Mordanters
Brass founders	Organic chemical synthesizers
Britannia metal workers	Paint makers
Bronzers	Painters
Burnishers	Perfume makers
Cable splicers	Pewter workers
Ceramic makers	Pharmaceutical workers
Compositors	Phosphor makers
Copper refiners	Pigment makers
Dye makers	Plaster cast bronzers
Electroplaters	Porcelain workers
Explosives makers	Pottery workers
Fireworks makers	Printers
Flame retardant workers	Pyrotechnics workers
Foundry workers	Rubber makers
Glass makers	Semiconductor workers
Glaze dippers, pottery	Solder makers
Gold refiners	Stereotypers
Insecticide makers	Stibnite miners
Insulators, wire	Textile dryers
Lake color makers	Textile flame-retardant workers
Lead burners	Textile printers
Lead hardeners	Type metal workers
Lead shot workers	Typesetters
Linotypers	Vulcanizers
Match makers	Zinc refiners

Adapted from reference 226

DEPARTMENT OF
HEALTH, EDUCATION, AND WELFARE
PUBLIC HEALTH SERVICE
CENTER FOR DISEASE CONTROL
NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH
ROBERT A. TAFT LABORATORIES
4676 COLUMBIA PARKWAY, CINCINNATI, OHIO 45226

OFFICIAL BUSINESS
PENALTY FOR PRIVATE USE: \$300



POSTAGE AND FEES PAID
U.S. DEPARTMENT OF H.E.W.
HEW 396